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 General introduction 13
1 Clinical Problem of Skeletal Metastasis
Cancers account for over 20% of deaths in Western countries and these are primarily due to 
the spread of cancer to distant organs 1. It has long been recognized that primary cancers 
spread to distant organs with characteristic preference 2, and the skeleton is one of the 
most common organs to be affected by metastatic cancer 3-6. Breast and prostate cancer are 
osteotropic tumors, i.e., carcinomas that have a special predilection to form bone metas-
tases. At postmortem examination ~70% of patients dying of these cancers have evidence 
of metastatic bone disease (Table 1) 5,7. Carcinomas of thyroid, kidney and bronchus also 
commonly give rise to bone metastases, with an incidence of 30% to 40%, but tumors of the 
gastrointestinal tract rarely (<10%) produce bone metastases. In these routine autopsies, 
the true incidence of metastases in the skeleton is most likely underestimated, and more 
accurate assessments may be determined by scintigrams. Together, breast and prostate 
cancer probably account for more than 80% of cases of metastatic bone disease 6.
Table 1 Incidence of skeletal metastases at autopsy 
Based on all autopsy studies listed by Galasko 5 + study from Walther 7
  Incidence (%) of bone metastases
Primary tumor site Number of studies Median Range
Breast 13 67 47– 85
Prostate 8 66 33 – 85
Thyroid 5 38 28 – 60
Lung 6 36 30 – 55
Kidney 4 34 33 – 40
Esophagus 3 6 5 – 7
Gastro-intestinal tract 5 7  3 – 11
Rectum 3 11  8 – 13
Uterine/ cervix 1 50 x
Ovaries 1 9 x
Liver 1 16 x
 Breast and prostate cancer are the most commonly diagnosed malignancies 1 and the 
second leading cause of cancer death in the western world in women and men, respec-
tively 1. At time of diagnosis, most patients with breast 3 and prostate 8 cancer do not have 
clinicopathologic signs of overt distant metastases. Thus, after resection of the primary 
tumor and all positive lymph nodes, these patients are in complete clinical remission. How-
ever, disseminated tumor cells (DTCs) can already be present in bone marrow (BM) 9-13, a 
clinical situation called minimal residual disease (MRD). The DTCs that are still present in 
BM are frequently resistant to current treatment (chemo-/hormone therapy), and can stay 








dormant for many years 10,14,15. So, only the very small subfraction of the DTCs that have 
acquired the abilities of metastasizing to, surviving in, and colonizing the bone/BM microen-
vironment, can eventually result in the development of an overt bone metastasis. Only this 
subpopulation of DTCs can, therefore, be regarded as true metastasis-initiating cells (MICs). 
Even though, the general presence of DTCs in BM at time of diagnosis is significantly associ-
ated with the formation of distant metastases, particularly to bone 9,10.
 The clinical courses of patients with breast and prostate cancer with a first recurrence 
in bone are relatively long, with a median survival of 24 and 40 months 4. This is in marked 
contrast to those with first recurrence of breast cancer in the liver (3 months)3. Moreover, 
patients with disease that remains confined to the skeleton have a better prognosis than 
those with subsequent visceral involvement 16. In these patients, the decline in quality of life 
and eventual death is due almost entirely to skeletal complications and their subsequent 
treatment 17,18. The prognostic indicators that metastatic breast cancer remains confined 
to skeleton are low histological grade (well-differentiated), lobular subtype (vs. ductal), 
postmenopausal state and a low number of positive lymph nodes at time of surgery. For 
patients with breast cancer, good prognostic factors for survival after the development of 
bone metastases are low histological grade (well-differentiated), positive estrogen recep-
tor status, a long disease free interval, and increasing age 16.
 Bone pain is the most common complication of metastatic bone disease, resulting from 
structural damage, periosteal irritation, and nerve entrapment 19. In addition, hypercalce-
mia occurs in 5–10% of all patients with advanced cancer but is most common in patients 
with breast cancer, multiple myeloma, and squamous carcinomas of the lung 20,21. Patho-
logic fractures are a relatively late complication of bone involvement.
 Bone metastases in prostate cancer patients are predominantly osteoblastic (osteoscle-
rotic), characterized by increased bone formation due to exaggerated osteoblastic activity. 
In contrast, patients with breast, lung, and kidney cancers have predominantly osteolytic 
bone metastases, characterized by increased bone degradation resulting from enhanced 
osteoclastic activity 18,21,22. However, patients can have both osteolytic and osteoblastic bone 
metastases, or mixed lesions containing both elements (see paragraph 5.2, ‘Bone Meta-
static Phenotype’).
 In this chapter, a brief introduction into the multistep process of metastasis will be 
given. Subsequently, this chapter will give an overview of our current understanding of the 
molecular and biological mechanisms involved in the process of bone metastasis forma-
tion, including a summary of normal bone physiology and therapeutic opportunities. Finally, 
the outline of this thesis will be presented. But first, to set the scene, the next paragraph will 
describe the well-established ‘seed and soil’ hypothesis as postulated by Stephen Paget in 
1889.
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2 Paget’s ‘Seed and Soil’ Hypothesis
Over a century ago Stephen Paget was the one of the first who observed a non-random pat-
tern of metastasis to certain organs by analyzing autopsy records of 735 women who had 
died of breast cancer 2. He proposed the ‘seed and soil’ hypothesis in which he compared 
the seeding of cancer cells to the dispersal of the seeds of plants. Accordingly, circulating 
cancer cells (‘seeds’) disperse in all directions, but can accomplish metastases only in the 
organs where the microenvironment (‘soil’) is permissive for their growth, i.e., osteotropic 
cancer cells posses certain properties that enable them to grow in bone, and the bone/bone 
marrow microenvironment provides a fertile soil on which to grow. Ever since, the hypoth-
esis holds forth. Based on this hypothesis, the ‘seed’ (see paragraph ‘The Seed: Tumor Pro-
gression and Metastasis’), the ‘soil (‘The Soil: Bone/Bone Marrow’) and their interactions 
(‘Seed–Soil Interactions’) will be specifically addressed in this chapter.
3 ‘ The Seed’: Tumor Progression and Metastasis
Since Paget postulated the ‘seed and soil’ hypothesis, our understanding of the metastatic 
process has increased tremendously. It has now been well-established that tumor progres-
sion and metastasis is a multistep process characterized sequentially by carcinogenesis 
and growth of the primary tumor, angiogenesis, cell invasion, access to the systemic blood 
circulation (intravasation), survival in circulation, arrest in microvasculature and subse-
quent extravasation, and growth at distant organs, (reviewed in 23) (Fig. 1). These processes 
will be discussed in more detail in the next paragraphs.
3.1  Carcinogenesis
The great majority of cancers (>80%) occur in epithelial tissues, yielding carcinomas 1,24. 
Epithelial tissues are generally built according to a common set of architectural principles; 
relatively thin sheets of epithelial cells are separated from complex layers of stroma by a 
basement membrane. By definition, carcinomas begin on the epithelial side of the base-
ment membrane as hyperplastic and dysplastic growth progressing to a carcinoma in situ, 
and are considered to be benign. Nevertheless, carcinoma in situ may develop into an inva-
sive malignancy as it breaks through the basement membrane and, by then, is classified as 
malignant, and commonly called a cancer 24.
 In the normal, healthy situation tissue fibroblasts regulate the proliferation and differ-
entiation of epithelial tissues 25. Likewise, tumor–stroma interactions also play a critical 
role in development and progression of carcinomas 26,27. For example, transformed stroma 
can induce malignancy in lung 28 and mammary epithelia 29, and conversely, normal fibro-
blasts have been reported to convert malignant epithelia to morphologically benign lesions 








30. Cancer-associated fibroblasts (CAFs) could also induce tumorigenesis in non-malignant 
prostatic epithelial cells, mediated via CAF-secreted stromal-derived factor (SDF-1) and 
transforming growth factor-β (TGF-β) 31. This is in line with the dual role that is implicated 
for TGF-β in carcinogenesis. In normal and non-malignant epithelial cells TGF-β actc as a 
potent growth inhibitor 32,33. However, different types of carcinomas (e.g., Ras-transformed 
cells) can become refractory to growth inhibition. In fact, TGF-β can potentiate tumorigen-
esis and contribute to invasiveness by stimulating an epithelial-to-mesenchymal transition 

























Figure 1 Main steps in tumor progression and metastasis. Cellular transformation due to genomic instability 
and changes can result in dysplasia, which may eventually result in a carcinoma in situ. At the same time, 
new blood vessel are formed (angiogenesis). This will facilitate cancer cells to enter into the systemic 
circulation (intravasation), after they have undergone an epithelial-to-mesenchymal transition (EMT). 
The EMT confers an invasive phenotype to the cancer cells, including loss of cell-cell adhesion, increased 
motility and matrix degradation. Aggregates of cancer cells with platelets and leukocytes may form cell 
embolis that may consequently be protected from the immune reaction. Arrest in the capillaries may be 
facilitated by mechanical mechanism and by adhesion to endothelium-specific cell adhesion molecules. 
Eventually some of the micrometastases may acquire the ability to colonize the tissue in which they have 
landed, enabling them to form a macrometastasis. The small probability of successfully completing all 
steps of this cascade explains the low likelihood that any single cancer cell leaving a primary tumor will 
succeed in becoming the founder of a distant, macroscopic metastasis.
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Many other tumor–stroma interactions are also mediated by members of the TGF-β super-
family 39, e.g., the involvement of TGF-β signaling in fibroblasts was determined by condi-
tional inactivation of the TGF-β type II receptor (TβRII) gene in mouse fibroblasts (TβRIIfspKO) 
40. The loss of TGF-β responsiveness in fibroblasts resulted in intra-epithelial neoplasia in 
prostate and invasive squamous cell carcinoma of the forestomach, both associated with an 
increased abundance of stromal cells. TGF-β and other members of the TGF-β superfamily 
will be discussed in greater detail in the section ‘TGF-β superfamily members’.
 For over 150 years, it has been anticipated that only a minority of cells within a tumor 
are responsible for tumor growth and development (reviewed in 41). Over the past few years 
it has become possible to isolate and characterize these tumor-initiating cells, first from 
hematological malignancies 42,43 and recently also from many solid tumors, including breast 
44 and prostate cancer 45,46. Cell fractions of as few as 100 to 200 sorted cells with a par-
ticular phenotype from human primary breast 44 and prostate cancer 46 could successfully 
be orthotopically transplanted in immune-deficient mice, whereas much larger numbers 
(104–105) of the rest of the cells depleted of that particular phenotype could not. Many of 
these isolated tumor-initiating cells share (surface) markers with somatic stem cells and 
both share the characteristics of 1) self-renewal, 2) an indefinite proliferative potential, 3) 
differentiation along one or several diverse lineages, and 4) homing to allow cells to migrate 
and seek their niche. For these reasons, tumor-initiating cells have been given the popular 
name ‘cancer stem cells (CSCs)’ 47,48. The concept of CSCs underscores the importance of 
targeting the correct cells for cancer therapy. Eliminating only the more differentiated, rap-
idly dividing cells by chemo- or radiotherapy is not likely to result in successful long term 
remission if the less differentiated and slower proliferating CSCs remain to repopulate the 
tumor. At present, much remains to be learned about the identification, molecular signature 
and functional plasticity of the CSCs 49.
3.2  Angiogenesis
Angiogenesis, also referred to as neovascularization, is the process of new capillary for-
mation from pre-existing vessels 50,51. Angiogenesis is a complex multistep process that 
involves dissolution of the basement membrane of the vessel, extracellular matrix degra-
dation, migration and proliferation of endothelial cells, capillary differentiation, stabiliza-
tion and anastomosis. These processes are tightly regulated by inducers and inhibitors of 
endothelial proliferation, migration and differentiation 52.
 In malignancy, tumor cells can switch from an angiogenesis-inhibiting phenotype to an 
angiogenesis-stimulating phenotype, the so-called ‘angiogenic switch’ 53. This angiogenic 
switch is essential for tumor growth beyond 1–2 mm3 without neovascularization 54. In 
breast cancer, tumor-induced angiogenesis is already evident at the pre-invasive stage of 
ductal carcinoma in situ, characterized by a rim of microvessels formed around the ducts 
that are filled with proliferative epithelial cells. So before carcinoma cells breach the base-








ment membrane, they often succeed in stimulating angiogenesis on the stromal side of the 
membrane, by dispatching angiogenic factors through this porous barrier to endothelial 
cells within the stroma 55. Angiogenesis is not only required to meet the growing metabolic 
demands of the tumor by supplying nutrients and oxygen, but also provides routes for tumor 
dissemination and metastasis 54,56. Not surprisingly, high blood vessel counts or produc-
tion of factors that stimulate angiogenesis are independent predictors of poor prognosis in 
many primary solid cancers 57-61. A variety of factors, including hypoxia and genetic changes 
in the tumor cells, contribute to the increase in production of angiogenic factors. Further-
more, cells within the activated tumor stroma also play an important role in increasing the 
production of vascular endothelial growth factors (VEGFs) and other angiogenic factors, 
including basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) 
26,62.
 VEGF-A is a specific endothelial cell mitogen and regarded as the most important inducer 
of angiogenesis. It is constitutively expressed in many cancers 62,63. Its importance was 
underlined when it was demonstrated that monoclonal antibodies against VEGF-A inhibited 
the growth of various tumors in animal models 64. Angiogenesis is not only essential for the 
primary tumor to grow and metastasize, but is required for the outgrowth of a micrometas-
tasis into an overt (bone) metastasis as well 65,66.
 Besides weakly stimulating angiogenesis, VEGF-C and VEGF-D are the main inducers of 
tumor lymphangiogenesis, and are overexpressed in breast and prostate cancers as well 67. 
Accordingly, VEGF-C and VEGF-D expression levels have been correlated with increased 
number of lymph vessels in cancer patients, and have been shown to promote metastatic 
spread via the lymphatics 68,69.
 In addition to (lymph)angiogenesis, evidence is accumulating that malignant tumors are 
often capable of inducing other structures that may contribute to (invasive) growth and dis-
semination (reviewed in 70). Networks that stain positive with periodic acid-Schiff (PAS) have 
been observed in different types of cancers 62,71-73. In both uveal and cutaneous melanoma, 
these structures have been shown to be of prognostic significance 73-75.
The PAS reaction is a non-specific indicator for polysaccharides, which are present in base-
ment membranes, including those of blood vessels. The PAS-positive patterns may rep-
resent (a mixture of): blood vessels/vascular network 72,74, fibrovascular tissue 76,77, tumor 
cells 78, or a fluid conducting meshwork 71. Maniotis and co-workers have shown that highly 
aggressive, but not non-aggressive, melanoma cells are capable of forming highly patterned 
vascular channels in vitro that are composed of a PAS-positive basement membrane in the 
absence of endothelial cells and fibroblasts 78. These channels formed in vitro are morpho-
logically identical to PAS-positive channels in histological preparations of highly aggressive 
primary and metastatic uveal and cutaneous melanomas. The generation of microvascular 
channels by aggressive tumor cells was termed “vasculogenic mimicry” (VM) to emphasize 
their de novo generation without participation by endothelial cells 78-80. Since then, VM has 
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been identified in several cancers, including prostate 81 and inflammatory breast cancer 82. 
However, the and co-workers remains a debatable subject, and 
Although some investigators state that the original findings of VM by Maniotis are not con-
vincing 83,84, or lack novelty 85, VM is becoming increasingly accepted as a concept for tumor 
cell plasticity
3.3 Acquisition of an Invasive Phenotype: Epithelial-to-Mesenchymal Transition
In the pre-invasive stage of carcinoma in situ, with or without increased neovascularization 
in the underlying stroma, the first step leading to dissemination is the acquisition of local 
invasiveness 23. The organization of the epithelial cell layers in normal tissue is incompat-
ible with the motility and invasiveness displayed by malignant cancer cells. Therefore, in 
order to acquire motility and invasiveness, cancer cells must shed many of their epithelial 
characteristics, detach from epithelial sheets, and undergo a drastic alteration, which is 
referred to as the epithelial-to-mesenchymal transition (EMT) 37,86.
In order to invade adjacent cell layers carcinoma cells are required to remodel the nearby 
tissue environment by excavating passageways through the extracellular matrix (ECM) and 
pushing aside any cells that stand in their path 87. The most important effectors to create 
space in the ECM are matrix metalloproteinases (MMPs)(reviewed in 88). In carcinomas, the 
great bulk of these proteases are secreted by recruited stromal cells, notably macrophages, 
mast cells and fibroblasts, rather than neoplastic cells 26,89. During the course of degrading 
ECM components (e.g., fibronectin, tenascin, laminin, collagens, and proteoglycans), MMPs 
can also activate certain growth factors that have been tethered in inactive form to the ECM 
or to cell-surfaces 88.
 The EMT displayed by cancer cells is reminiscent of the highly conserved and funda-
mental process of EMT that occurs during early embryonic development 90-93. During gas-
trulation, embryonic epithelial cells need to undergo an EMT in order to migrate to a new 
environment. Eventually these embryonic cells may regain a fully differentiated epithelial 
phenotype via a mesenchymal-to-epithelial transition (MET) (Fig. 2) 94-98. The transition 
to a more mesenchymal, motile cellular phenotype is the result of a complex physiologi-
cal process that includes dissolution of adherens junctions, loss of cell polarity, a change 
to spindle-like cell morphology, cytoskeletal reorganization, increased cell motility, loss 
of epithelial markers and induction of mesenchymal markers 90-93,99. Increased vimentin 
expression and perturbation of E-cadherin-mediated cell adhesion appear as hallmarks 
of this process 37,100-102. Accordingly, it has been shown that once E-cadherin expression is 
suppressed, other cell-physiologic changes associated with the EMT seem to follow suit. 
Additionally, re-expression of E-cadherin in different types of cancer strongly suppressed 
the invasiveness and metastatic dissemination 103,104.
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Figure 2 The cycle of epithelial-cell plasticity as observed in embryonic development during gastrulation. The 
diagram shows the cycle of events during which epithelial cells are transformed into mesenchymal cells 
and vice versa. The different stages during EMT (epithelial–to-mesenchymal transition) and the reverse 
process MET (mesenchymal–to-epithelial transition) are regulated by effectors of EMT and MET, which 
influence each other. Important events during the progression of EMT and MET, including the regulation 
of the tight junctions and the adherens junctions, are indicated. ECM, extracellular matrix; ZO-1, zona 
occludens 1; SMA, smooth muscle actin; FSP-1, fibroblast-specific protein-1; adapted from 97.
 Under non-pathological conditions, EMT and MET are both non cell-autonomous pro-
cesses, and thus require an external stimulus to be initiated 92,93,105. In malignancy, both 
genetic alterations and tumor environment may be able to induce EMT in tumor cells. 
Transformed mammary epithelial cells that are in direct contact with the surrounding 
stromal cells can undergo an EMT, indicated by expression of vimentin and an elongated, 
fibroblastic shape 105. However, established metastases of most cancers recapitulate the 
differentiated phenotype of their primary tumors including re-expression of E-cadherin 
106,107. Therefore, the important steps that enable metastasis can be reversible, and are not 
explained solely by irreversible genetic alterations, indicating the existence of a dynamic 
component to human tumor progression 108,109.
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 TGF-β is one of the main inducers of EMT as was demonstrated in Ras-transformed mam-
mary and other epithelial cells 110-112 (Fig. 3). These mammary epithelial cells were even able 
to maintain the mesenchymal, fibroblast-like state through autocrine TGF-β signaling 110,111. 
However, when TGF-β was removed (by adding fresh medium or neutralizing antibodies) 
they reverted back to their epithelial appearance 110, indicating that they had undergone an 
MET. Another example of a self-sustaining positive feedback loop for EMT is the expression 
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Figure 3 Overview of the molecular networks that regulate EMT. A small selection of EMT regulators, and a limited 
representation of their crosstalks are illustrated. TGF-β is one of the main inducers of EMT. However, several 
normal and transformed epithelial cell lines need co-activation of Ras-signaling, to overcome transforming 
growth factor-β (TGF-β)-induced apoptosis. It is likely that the EMT is normally triggered in response to a 
mixture of signals that carcinoma cells receive from the stroma together with intracellular signals, e.g. the 
signal released by the Ras oncogene. FGF, fibroblast growth factor; HGF, hepatocyte growth factor; EGF, 
epidermal growth factor; RTK, receptor tyrosine kinase; FAK, focal adhesion kinase; GSK3β, glycogen-
synthase kinase-3β; MAPK, mitogen-activated protein kinase; NF-kB, nuclear factor-kB; TAK1, TGF-β-
activated kinase-1.








 Additional microenvironmental signals that can induce EMT are ECM components and 
soluble factors, including other members of the TGF-β superfamily, fibroblast growth fac-
tor (FGF) family, epidermal growth factor (EGF), hepatocyte growth factor (HGF, alias scat-
ter factor) 114, insulin-like growth factor (IGF)-II 115 and proteins of the wingless (Wnt) and 
Hedgehog (Hh) families (Fig. 3) (reviewed in 86,97). It is important to take into account that 
besides the tumor–stroma interactions at the edge of tumor, infiltrating cells (e.g., lympho-
cytes, macrophages) might also be able to induce EMT in tumor cells. Moreover, accumu-
lation of irreversible mutations could also trigger invasive behavior, particularly resulting 
in poorly differentiated anaplastic cancers, in which no re-differentiation is detectable in 
primary cancers and metastases 116,117.
 Both the EMT concept and the CSC concept cover distinct aspects of tumor progression 
and metastasis, but can be converged into a single concept, which subdivides CSCs in the 
stationary cancer stem cell (SCS cell) and the migrating cancer stem cell (MCS cell) 109. SCS 
cells, which are still embedded in the epithelial tissue, are already active in benign precur-
sor lesions, such as carcinoma in situ, and persist in differentiated areas throughout all 
steps of tumor progression; however SCS cells cannot disseminate. MCS cells, which are 
located predominantly at the tumor–stroma interface, are derived from SCS cells through 
the acquisition of a (transient) EMT in addition to stemness. This concept takes into account 
two important requirements — CSCs that have undergone EMT can disseminate, and DTCs 
that retain stem-cell functionality can form metastatic colonies. So, the MCS cell concept 
combines the important current tumor initiation and progression concepts — the cancer 
stem cell and EMT concept — and it integrates both genetic alterations and the tumor envi-
ronment as combined driving forces of malignant progression. However, the concept still 
awaits verification in different models of tumor progression for various types of cancer.
3.4 Intravasation, Circulation and Extravasation
Once tumor cells detach from the primary tumor via EMT, they can intravasate into the 
blood or lymphatic system. Via the lymphatic system, tumor cells can form lymph node 
metastases in close proximity of the primary tumor, or eventually enter the blood circula-
tion in the left and right subclavian veins. Tumor cells that directly, or indirectly, enter the 
blood vessels can spread via the pulmonary circulation throughout the whole body, where 
they may found new colonies. However, the event of a successful development of a distant 
metastasis is very rare, and most cancer cells are not able to by-pass the capillary bed of 
the lungs. This is substantiated by the fact that in animal models, it has been estimated that 
3–4 106 cancer cells/g of tumor can reach the bloodstream per day 118, but that only a very 
small minority of cancer cells reaching the blood will survive and grow at the distant sites.
 In the blood circulation, cancer cells may interact with platelets 119,120 and leucocytes, 
to create aggregates or emboli. These may increase resistance to shear stress and pro-
tect from immune-cell–mediated tumor cell clearance 23,121. These aggregates may also 
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facilitate mechanical trapping in the capillaries of different organs, and promote extravasa-
tion 122. Once the tumor cells have exited the circulation, the activated platelets are a source 
of factors that are able to induce angiogenesis 123, stimulate tumor cell proliferation, and 
indirectly enhance osteoclastic activity in the bone environment 119,120.
3.4.1 Vertebral Venous System
As first demonstrated by Batson, there exists a vertebral venous system, which is composed 
of three freely communicating thin-walled valveless networks: intraosseous vertebral veins, 
epidural and paravertebral venous complexus 124,125. The pressure in the intraosseous veins 
is always 35–50% higher than on the caval side of the venous circulatory system, enabling 
blood to flow along this pressure gradient from the vertebrae to the inferior vena cava. 
However, the absence of valves makes it possible that an increase of abdominal pressure, 
such as caused by coughing, lifting or palpation, could cause retrograde flow. Moreover, 
Batson showed in human cadaver and animal experiments that venous blood from both the 
pelvis and the breast flowed not only into the vena cava, but also directly into the vertebral 
venous system 124,125. This system, in which blood is thus continuously subjected to arrest 
and reversal of the direction of the flow, could enable cancer cells from the pelvic region and 
breast to by-pass the pulmonary circulation, providing an explanation for the predilection 
of breast and prostate cancer to produce metastases in the axial skeleton. This hypothesis 
was tested by Coman and De Long, who performed an inoculation with cancer cells in the 
femoral veins during a moderate temporarily increase in intra-abdominal pressure in 
experimental animals. Indeed, an increased abdominal pressure enabled cancer cells to 
directly enter, and form metastases within the vertebral venous system 124,126.
 Although the system of blood flow in the vertebral venous system can, at least in part, 
explain the high incidence of bone metastases in the vertebrae, it cannot explain that human 
cancers, particularly breast and prostate cancer, metastasize with high frequency to other 
bones 5. For this explanation, we may need to have a closer look at the interactions between 
the ‘seed’ and the ‘soil’. But before these interactions will be discussed, the next paragraph 
will first comprehensively describe the properties of the soil.
4 ‘ The Soil’: Bone/Bone Marrow Microenvironment
In addition to anatomy, the pathophysiology of bone metastasis is determined by multiple 
direct and indirect interactions between metastatic cancer cells and the bone/BM 
microenvironment (including BM cells, bone cells, and bone matrix). First, the normal 
physiology of the bone/BM microenvironment will first be dilineated below.









Bone is a highly mineralized tissue that provides mechanical support and metabolic functions 
to the skeleton. It can be formed by either intramembraneous ossification or endochondral 
ossification. Intramembranous ossification occurs when mesenchymal precursor cells dif-
ferentiate directly into bone-forming osteoblasts, a process employed in generating the flat 
bones of the skull as well as in adding new bone to the outer surfaces of long bones. In con-
trast, endochondral bone formation entails the conversion ofan initialcartilage template into 
bone and is responsible for generating most bones of the skeleton (reviewed in 127).
4.1.1 Bone Cells
The formation and degradationof bone matrix is regulated by normal bone cells, namely 
the osteoblast and osteoclast, respectively. In normal bone, there is a balanced remodeling 
sequence: first, osteoclasts resorb bone matrix, and then osteoblasts form bone matrix at 
the same site (reviewed in 127).
4.1.1.1 Osteoclasts
Osteoclasts are specialized cells derived from the monocyte–macrophage hematopoietic 
lineage that adhere to and, once activated, degrade bone matrix (reviewed in 128,129). Acti-
vated osteoclasts resorb bone by secreting the protease cathepsin K that dissolves the 
matrix, and produce acid that releases bone mineral into the extracellular space under 
the ruffled border of the plasma membrane of osteoclasts, which faces bone (reviewed 
in 129). The adherence of osteoclasts to the bone surface is critical for the bone resorp-
tive process, since agents that interfere with osteoclast attachment block bone resorp-
tion 130. Although osteoclasts can be influenced by various locally produced cytokines as 
well as systemic hormones, two specific hematopoietic factors — macrophage colony 
stimulating factor (M-CSF, alias CSF1) and receptor activator of nuclear factor κB ligand 
(RANKL) — are both necessary and sufficient for the formation and activation of osteo-
clasts. M-CSF is produced by stromal cells and osteoblasts and interacts with its receptor 
c-fms expressed on macrophage precursors to stimulate proliferation. Accordingly, op/op 
mice that lack expression of M-CSF due to a gene mutation are deficient in osteoclasts (and 
macrophages), resulting in enhanced bone formation 131-133. Substitution of M-CSF reversed 
the osteopetrotic phenotype in op/op mice 134. While M-CSF is crucially important in the 
early steps of osteoclastogenesis, RANKL — expressed on osteoblasts and stromal cells — 
is critically involved in maturation and activation of the osteoclasts. Interaction of RANKL 
with the membrane receptor RANK on osteoclast precursors induce — by signaling through 
the nuclear factor-κB (NF-κB) and Jun N-terminal kinase (JNK) pathways — commitment 
of the monocyte–macrophage precursor to the osteoclast lineage 135-139. The importance 
of RANK–RANKL binding in the formation of osteoclasts has been demonstrated clearly 
by RANKL 140,141 and RANK 142 knock-out mice. Both knock-out mice lack osteoclasts, and 
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as a result, severe osteopetrosis develops. In addition, the development of B cells and T 
cells is defective in these animals. Likewise, mice bearing mutations or deletions in intra-
cellular signal molecules critically involved in RANK signaling, such as c-Fos 143, c-Jun 144 
and NFATc 145, also develop osteopetrosis. Various locally produced cytokines as well as 
systemic calcitropic hormones — including parathyroid hormone (PTH), 1,25-dihydroxyvi-
tamin D3, and prostaglandins — indirectly stimulate osteoclastogenesis by upregulation 
of RANKL expression on marrow stromal cells and osteoblasts 139,146,147. In addition, many 
cytokines, such as interleukin (IL)-1 and tumor necrosis factor-α, are also able to directly 
affect osteoclasts 128.
 Osteoprotegerin (OPG) was identified as the decoy receptor for RANKL, and is normally 
present in the BM 139,148. OPG is a member of the superfamily of tumor necrosis factor recep-
tors and inhibits the differentiation and resorption of osteoclasts in vitro and in vivo 136,148,149. 
The ratio of RANKL to OPG regulates the formation and activity of osteoclasts 150. Accord-
ingly, OPG-deficient mice display marked osteoporosis 151,152, whereas overproduction of 
OPG in these mice causes severe osteopetrosis 153.
4.1.1.2 Osteoblasts and Osteocytes
Osteoblasts are the bone-forming cells, responsible for the production of the matrix con-
stituents. They are always found lining the layer of bone matrix that they are producing 
before it is calcified, referred to as osteoid tissue. Osteoid tissue exists because of a time 
lag between matrix formation and its subsequent calcification (the osteoid maturation 
period), which is approximately 10 days 127,154. Osteoblasts never appear to function indi-
vidually, and are always found in clusters of cuboidal cells along the bone surface (~100 
to 400 cells per bone-forming site). Osteoblasts arise from local mesenchymal stem cells 
(MSCs), which are precursor cells for many cell types involved in bone formation, such as 
osteoblasts, osteocytes and chondrocytes, and for other mesenchymal cell lineages, such 
as fibroblasts, myoblasts, adipocytes, and neuronal cells 155. For differentiation towards 
an osteoblast, MSCs first undergo proliferation, become committed and then differenti-
ate into a pre-osteoblast — producing alkaline phosphatase — and subsequently into a 
mature osteoblast, producing increasing amounts of osteocalcin and calcified matrix 156. 
Runt-related transcription factor 2 (Runx2; alias core-binding factor α1) and Osterix are 
crucial transcription factors that drive the expression of most genes associated with osteo-
blast differentiation 157,158. Accordingly, bone does not develop in mice that lack the Runx2 
gene 159,160. The commitment of MSCs to the osteoblast lineage is regulated by at least three 
major morphogenetic pathways, the BMP 161,162, the Hh 163, and the Wnt 164 signaling path-
way. These pathways can still be influenced and fine-tuned by factors, such as PTH, PTH-
related protein (PTHrP), platelet-derived growth factor (PDGF), fibroblast growth factors 
(FGFs), TGF-β, sex steroids and other hormones (reviewed in 154). When osteoblasts become 
embedded in the bone matrix, they differentiate into osteocytes, the most abundant cells in 








mature bone. Because they can function as mechanosensors, osteocytes are considered to 
modulate bone remodeling in response to bone loading (reviewed in 127,165).
4.1.2 Bone Matrix
Bone is composed of an organic matrix that is strengthened by deposits of calcium salts. 
Type I collagen constitutes approximately 90-95% of the organic bone matrix, whereas 
noncollagenous proteins comprise the remaining 5-10%. Crystalline salts deposited in 
the matrix are primarily calcium and phosphate in the form of hydroxyapatite 127. Noncol-
lagenous proteins can be subdiveded in 1) cell attachment proteins, 2) proteoglycans, 3) 
γ-carboxylated (gla) proteins, and 4) growth factors (e.g., IGFs, TGF-βs, FGFs, PDGFs, and 
BMPs) (reviewed in 166). Any of the attachment proteins, e.g., osteopontin (OPN), bone sialo-
protein (BSP), and vitronectin and collagen type I facilitate interactions with integrins that 
are expressed by specialized bone and HSC cells as well as osteotropic cancer cells 167,168. 
The mineralized bone also stores a variety growth factors, including IGFs, TGF-βs, FGFs, 
PDGFs, and BMPs. Since bone continuously remodels, bone-stored growth factors, such 
as IGFs, TGF-βs, FGFs, PDGFs, and BMPs 169,170, are constantly released in the BM cavity 
by osteoclastic bone resorption, affecting growth of bone metastatic cells as will be dis-
cussed in detail in paragraph 5: ‘Seed-Soil Interactions’. IGF-I is the growth factor that is 
stored most abundantly in the bone matrix, and upon release, it can play an important role 
in stimulation of (cancer) cell proliferation and chemotaxis, and inhibition of apoptosis 171. 
TGF-βs and BMPs will be discussed in detail in paragraph 4.4.
4.1.3 Bone Turnover
Adult bone is continuously remodeled by bone resorption and subsequent bone formation 
in temporary anatomic structures, called the basic multicellular units (BMUs), described by 
Frost more than forty–years ago 172 (Fig. 4). These two phases are in a balanced sequence 
and the net result is replacement of old bone with new bone, thus maintaining structural 
integrity of the skeleton throughout adult life 172-174. The actual number and activity of 
these BMUs determine the bone turnover rate (or status) and they are under the control 
of mechanical stress, cytokines and hormones. Upon resorption, local mitogenic factors, 
such as TGF-β, that are embedded within the calcified matrix are released and activated 
175. These local factors, along with the systemic factors PTH, estrogen, and prostaglandin, 
recruit new osteoblasts at the BMU to fill the gap created by osteoclasts.
4.2 Bone Marrow
Bones are not entirely compact, and the center of the bone generally consists of spongy bone 
or a bone cavity, which are lined by endosteal cells. These spaces are occupied by red or 
yellow bone marrow (BM). Red BM facilitates active hematopoiesis, but with increasing age, 
the rate of hematopoiesis diminishes and more and more of it is converted to yellow BM — 
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consisting almost entirely of fat cells. However, under appropriate stimuli, such as extreme 
blood loss, yellow BM can convert to red BM again. In adults, red marrow is found mainly in 
the spongy bone of flat bones, such as iliac creast and sternum, and in the proximal ends of 
the long bones femur and humerus. Interestingly, these bones are relatively often affected 
by cancer metastasis, suggesting that red BM might be somehow involved 2,5.
 Hematopoietic stem cells (HSCs) can reside in BM in two niches, the osteoblastic niche 
and the vascular niche (reviewed in 176-178). The osteoblastic niche is formed by endosteal 
osteoblasts that provide a quiescent environment for HSCs maintenance, support expan-
sion of HSCs into the different hematopoietic lineages, and control HSC numbers 179,180. In 
contrast, the vascular niche has been identified in association with fenestrated endothelium 
of sinusoids, and facilitates HSC transendothelial migration during mobilization or homing, 










Figure 4 The basic multicellular unit. Bone is continuously remodeled by basic multicellular units (BMUs), the 
temporary anatomic structures that resorb bone and subsequently induce bone formation. Multinucleated 
osteoclasts (arrowhead) resorb the calcified matrix of a bone trabecula, the ‘resorption phase’. In a tight 
coupling, pre-osteoblasts migrate and differentiaite into osteoblasts (empty arrowheads). These lay 
down new bone matrix, which is not yet calcified and is reffered to as osteoid, the ‘formation phase’. 
Subsequently, the osteoid becomes mineralized. At the end phase of this remodeling, the surface of 
new bone is covered by flattened osteoblasts or ‘lining cells’ characterized by low/absent bone forming 
activity, the ‘resting phase’. Osteoblasts that are trapped in the matrix become osteocytes (arrow with 
empty arrowhead); others die or form new, flattened osteoblast or ‘lining cells’ (arrow). The number of 
BMUs can be modulated by mechanical loading, hormones and cytokines, marrow hematopoiesis and 
drugs (bone resorption inhibitors); adapted from 344.


































Figure 5 Osteoblastic and vascular niche in bone. Under normal physiological conditions, HSCs reside in either 
the osteoblastic or vascular niche. In response to low levels of SDF-1 in the bone marrow, a portion of 
HSC daughter cells will leave the bone marrow and begin to mobilize and circulate. HSC homing is the 
reverse of mobilization, occurring in response to higher levels of SDF-1 in the bone marrow, particularly 
produced by the immature osteoblasts that align the periosteum. The osteoblastic niche may provide 
a quiescent microenvironment for HSC maintenance. In contrast, the vascular niche facilitates HSC 
transendothelial migration during mobilization or homing and may favor HSC proliferation and further 
differentiation. Higher oxygen concentration gradients as the cells progress from the osteoblastic niche 
to the vascular niche might play a role in recruitment, proliferation, and differentiation of HSCs/HPCs. 
Stress such as thrombocytopenia can induce HSCs to enter into the cell cycle, mobilize to the vascular 
niche, and differentiate. SNO, spindle shaped N-cadherin+ osteoblast; adapted from 178.
 Endothelial cells, osteoblasts, and other stromal cells constitutively express the 
chemoattractive cytokine, or chemokine, SDF-1 (alias CXCL12), while HSCs express its 
receptor CXCR4 182. SDF-1 generated by endothelial cells induces HSCs from the circulation 
to undergo transendothelial migration mediated by E- and P-selectins 183,184. Subsequently, 
HSCs could migrate toward the osteoblastic niche, where HSCs have been shown to adhere 
only to a subset of immature osteoblasts, the spindle-shaped N-cadherin+CD45- osteoblas-
tic (SNO) cells 180. Accordingly, an increase of these SNO cells correlated with an increase 
in HSCs, suggesting that SNO cells function as key components of the osteoblastic niche 180. 
Little is presently known about the molecules that define the vascular niche, and its rela-
tionship with the osteoblastic niche.
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 Granulocyte-macrophage colony stimulating factor (GM-CSF, alias CSF2) induces HSC 
and progenitor cell mobilization and is widely used clinically during stem cell-based trans-
plantation procedures. The mechanism involved is a reduced concentration of SDF-1 in BM, 
whereas SDF-1 in the peripheral circulation is less affected after GM-CSF treatment 185. In 
bone marrow, GM-CSF induces proteolytic enzymes such as elastase, cathepsin G, MMP-2, 
and MMP-9, which inactivate SDF-1 and are required for cells to penetrate the endothelium 
186. In addition, GM-CSF could regulate SDF-1 expression in osteoblasts at the transcrip-
tional level 187,188.
4.3  TGF-β Superfamily
The TGF-β superfamily consists of more than 30 proteins in mammals, including TGF-βs, 
activins, BMPs, growth/differentiation factors and anti-Müllerian hormone (Fig. 6). These 
growth factors, and their antagonists, control many different biological processes such as 
proliferation, differentiation, apoptosis, and invasiveness in many different epithelial as well 
as non-epithelial cells 189-192. In mammals, three isoforms of TGF-β, i.e., TGF-β1, TGF-β2 and 
TGF-β3, and more than 20 BMP–related proteins have been identified 193. In general, TGF-β 
isoforms have highly comparable structures and in vitro biological activities 194. In contrast, 
different BMPs often exert different, and even opposing, effects 161. Therefore, they should 
be regarded as individual proteins rather than be classified as a group in respect to cell 
function.
 TGF-β1 is the most abundant isoform with the largest sources in platelets (20 mg/kg) 195 
and bone (200 mg/kg) 196,197. In comparison, the sources of BMP2, BMP4, and BMP7 in bone 
are 21 mg/kg, 6 mg/kg, and 84 mg/kg, respectively 170.
The source of TGF-β/BMPs in the bone/BM microenvironment may be acellular, released 
by osteoclastic resorption of the extracellular bone matrix, or cellular, derived from cells 
that reside in bone (e.g., osteoclasts, osteoblasts, and osteocytes) or in bone marrow (e.g., 
megakaryocytes) (reviewed in 198).
4.4.1  Signaling Pathways
Members of the TGF-β superfamily mediate their pleiotropic effects by signaling through 
transmembrane serine/threonine kinase type I and type II receptors (Fig. 7) 39,193,199. The 
type II receptor kinases are constitutively active without ligand stimulation. Upon ligand–
induced heteromeric complex formation between type II receptors and type I receptors, type 
I receptors become phosphorylated by the type II receptors and activate downstream sig-
naling components among which Smad (Sma-Mad related protein) molecules proteins play 
a pivotal role 193,200. Unlike other members of the TGF-β superfamily, BMPs have a higher 
affinity for the type I receptor, rather than for the type II receptors 201,202. In mammals, five 
type II receptors and seven type I receptors have been identified 39,161,203 (Table 2). The type 
II receptors include activin type II and type IIB receptors (ActRII and ActRIIB), TGF-β type II 
receptor (TβRII), BMP type II receptor (BMPRII) and anti-mullerian hormone type II recep-








tor (AMHRII). Type I receptors are termed activin receptor-like kinases (ALKs) 1 through 7. 
It is theoretically possible to form more than 30 different combinations of type II and type 
I receptors. However, under physiological conditions the combinations of type II and type I 
























Figure 6 Phylogenetic tree of TGF-β superfamily. The phylogenetic tree is derived from protein alignment of 
the human, putative mature and fully processed forms. The length of the horizontal lines connecting 
one sequence to another is proportional to the estimated difference between the proteins. BMPs and 
TGF-βs are shown in black, other members of TGF-β superfamly in grey.  AMH, anti-Müllerian hormone; 
BMP, bone morphogenetic protein; GDF, growth and differentiation factor; TGF-β, transforming growth 
factor-β; based on 415.
 In most cell types, ALK5 (TGF-β type I receptor) is the predominant type I receptor 
that is activated by TGF-β through TβRII (Fig. 8) 204. ALK3 and ALK6 (BMP type IA and IB, 
respectively) are structurally highly comparable to each other and function as BMP type 
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I receptors for BMPs. In addition, BMP6 and BMP7 have also been shown to bind ALK2 
201,205. Different BMPs bind with different affinity to the type I receptors, e.g., BMP6 and 
BMP7 binds with higher affinity to ALK2 and ALK6 than to ALK3 201,206 (Fig. 8). The expression 
of ALK3, ALK6 and BMPRII was observed in normal and benign prostate tissue, and was 
found to correlate with low tumor grade (well-differentiated) in prostate cancer. In addition, 




















































Figure 7 General Mechanisms of TGF-β/BMP-induced Smad activation. At the cell surface, a ligand (homo- or 
heterodimer) binds a complex of transmembrane receptor serine/threonine kinases (types I and II) and 
induces transphosphorylation of the GS segments (black) in the type I receptor by the type II receptor 
kinases. The consequently activated type I receptors phosphorylate selected Smads at C-terminal 
serines, and these receptor-activated Smads (R-Smads) then form a complex with the common Smad, 
Smad4. Activated Smad complexes translocate into the nucleus, where they regulate transcription of 
target genes, through physical interaction and functional cooperation with DNA-binding transcription 
factors (TF) and coactivators or repressors. Activation of R-Smads by type I receptor kinases is inhibited 
by Smad6 or Smad7. The E3 ubiquitin ligases Smurf1 and Smurf2 mediate ubiquitination and consequent 
degradation of R-Smads; based on 199.
Table 2 Type I and II receptors for TGF-ß superfamily members in mammals. Alk, activin receptor-like kinase; ActRII and 
ActRIIB, activin type II and IIB receptors; TßRII, TGF-ß type II receptor; BMPRII, BMP type II receptor.
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 Besides the signaling type I and type II receptor, several accessory type III receptors, are 
known, e.g., betaglycan (TβRIII) 209 and endoglin (CD105) 210. While endoglin inhibits TGF-β1-
induced ALK5–Smad3 signaling, it promotes BMP7–Smad1/Smad5 signaling 211,212. On the 
other hand, betaglycan acts as a co-receptor for TGF-β that modulates the binding of TGF-β 
to its receptors, thus enhancing signaling via ALK5 213. Moreover, it can also function as a 
co-receptor for inhibin, disrupting activin and BMP signaling 214.
 Smads, which are intra-cellular substrates for the TGF-β superfamily receptors can be 
subdivided into: 1) receptor-activated Smads (R-Smads) which include Smad2 and Smad3 
for TGF-β and activin signaling, and Smad1, Smad5, and Smad8 for BMP signaling, 2) the 
common mediator Smad (Co-Smad), commonly refeered to as Smad4, and 3) inhibitory 
Smads (I-Smads), which include Smad6 and Smad7 39,193. R-Smads contain a conserved SSXS 
phosphorylation motif in their very C-termini, of which the last two serine residues become 
phosphorylated following interaction with activated type I receptors 39. Phosphorylation of 
R-Smads results in their heteromerization with Smad4 followed by nuclear translocation 
and regulation of gene transcription in association with other transcription factors 161,200.
 Smads are not equally activated by their cognate receptors. For example, ALK3 and ALK6 
activate all three BMP R-Smads, whereas ALK2 can activate only Smad1 and Smad5, but 
not Smad8 205,206. Although Smad2 and Smad3 are structurally very similar to each other, 
Smad3 can directly bind DNA, whereas Smad2 signaling requires a specific combination of 
other transcription factors 215. In fibroblasts, TGF-β-mediated induction of matrix metal-
loproteinase-2 (MMP-2) was selectively dependent on Smad2, whereas induction of c-fos, 
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tr ansc r i ption 
† 
Figure 8 Type I and II receptors, and R-Smads involved in BMP7 and TGF-β signaling. It is important to note 
that the presence of particular type I and II receptors, and R-Smads greatly differs in various cell types. 
† = activates only SMAD1 and -5, but not -8; § = BMP7 binds with low affinity to BMPRII/Alk3 complex; 
‡ = pathway known in endothelial, but not epithelial, cells.  Alk, activin receptor-like kinase; ActRII and 
ActRIIB, activin type II and IIB receptors; TβRII, TGF-β type II receptor; BMPRII, BMP type II receptor; 
based on data from 201,205,416-419.
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Smad7, and TGF-β1 autoinduction relied on expression of Smad3 216. Moreover, in tubular 
epithelial cells it was found that TGF-β-induced increases in CTGF and decreases in E-cad-
herin expression were Smad3-dependent, whereas an increase in MMP-2 expression was 
Smad2–dependent 217. In NMuMG mammary epithelial cells it was reported that complexes 
of Smad4 with both Smad2 or Smad3 can induce full EMT, however, the Smad3–Smad4 com-
plex was most efficient 36
 Non-Smad pathways may also play an important role in understanding the diversity 
of signals generated by the TGF-β superfamily proteins. MAP (mitogen-activated pro-
tein) kinases, including ERK (extracellular-signal-related kinase), JNK (JunN-terminal 
kinase), and p38MAPK, can, among many other growth factors, also be activated by BMPs 
and TGF-βs in certain cell types. Moreover, signaling by Smads is modulated by various 
other signaling pathways allowing TGF-β superfamily ligands to elicit different biological 
responses in target cells (reviewed in 193,199,200).
4.4.2  Regulation of Activity
The level of activity of the TGF-β superfamily members is determined by the regulation of 1) 
bioavailability and 2) cellular signaling.
 The bioavailability of TGF-β superfamily members is regulated by several types of mech-
anism, including proteolytic processing, secretion, interaction with ECM components, and 
extracellular binding proteins, and each step in the activation pathway is tightly controlled. 
For TGF-β and BMP7 post-translational processing is shown in figure 9 198,218-222. During 
transit through the rough endoplasmic reticulum, the signal peptide is removed from the 
pre-pro-protein and, following dimerization, another cleavage occurs by the convertase 
family of endoproteases 219. Within the secretory vesicles or in the extracellular space, 
these proteases cleave the precursor into a C-terminal mature peptide and an N-terminal 
precursor remnant, referred to as latency associated peptide (LAP) for TGF-β, and pro-
domain for BMP7. Thus control and/or localization of convertase activity may represent 
an important level of regulation. After cleavage, mature TGF-β and LAP remain attached 
via non-covalent bonds to form the small latent complex (SLC). LAP shields the receptor 
interacting epitopes in the mature protein and this keeps TGF-β in its latent form 223. The 
SLC can covalently attach to the large latent TGF-β-binding protein (LTBP) to form the large 
latent complex (LLC) 224,225. Most cell types secrete TGF-β as part of LLC, although some 
cells (such as the bone cell line UMR-106) secrete SLC 226. Four different LTPBs have been 
identified, of which LTBP1, LTBP3 and, to a lesser degree, LTBP4 covalently bind to LAPs of 
all three TGF-β isoforms 227. After secretion, LLC is targeted to ECM molecules, e.g., in the 
bone matrix. LTBP show remarkable homology with fibrillins, which are extracellular gly-
coproteins that are required for elastic fiber formation. Besides binding to ECM molecules, 
the C-terminal region of LTBP1 can also bind to the N-terminal region of fibrillin-1, linking 
LLC also to elastic microfibrils 228.
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Figure 9 TGF-β and BMP7 posttranslational processing. The mature BMP7 has three potential N-linked 
glycosylation sites, from which only the glycosylation sites at residue 372 in the TGF-β conserved domain 
region is heavily or completely glycosylated (top of figure: arrowhead). The signal peptide, which targets 
the proteins to the secretory pathway, is cleaved off during transit through the rough endoplasmatic 
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reticulum (RER). Subsequently, two monomers dimerize by way of disulfide bridges between cysteine 
residues. The protein is cleaved by subtilisin-like proprotein convertases (SPCs) at the RXXR motif. This 
yields the prodomain, or latency associated protein for TGF-β, and the mature peptide. This mature petide 
stays noncovalently associated with its prodomain, forming the soluble BMP7 complex for BMP7 or the 
small latent complex (SLC) for TGF-β. The noncovalent association prevents the premature activation 
of mature TGF-β. The SLC can become covalently attached to a Large Latent Binding Protein (LTBP) 
to form the Large Latent Complex (LLC), and the SLC to LLC ratio depends on the cell type. After its 
secretion, the LLC is directed to fibrillin-1 and/or the ECM and stored through binding of the LTBP with 
these components. Inflammatory proteolytic enzymes, including elastase, release LLC from fibrillin-1, 
and Several proteases, such as plasmin, mast-cell chymase and thrombin, release LLC from the ECM. 
The SLC is more readily available for activation, and can be activated by proteases or conformational 
change in the LAP induced by interaction with, e.g., thrombospondin or integrins. The pro-domain of 
BMP7 targets the soluble BMP7 complex to the fibrilin-1 and -2 in the extracellular matrix. The precise 
mechanisms of posttranslational processing are less well understood for BMP7 and remains to be 
elucidated. Based on data from 219-221 (BMP7) and 198,222 (TGF-β).
 In order to exhibit their biological activity, the latent TGF-β complexes need to be released 
from microfibrils and ECM. A recent study revealed that LLC release can be initiated by the 
displacement of LTBP bound to fibrillin-1 218. Degradation of microfibrils by inflammatory 
proteolytic enzymes (such as elastase) releases fragments of fibrillin-1, including an inter-
nal fibrillin fragment that efficiently binds to the N-terminal region of fibrillin-1 and dis-
places LTBP, releasing LLC from microfibrils 218. The release of LLC from the ECM in bone 
and other tissue is mediated by several proteases, including plasmin, mast-cell chymase 
and thrombin (reviewed in 198,222).
 Subsequently, the truncated LLC and SLC can be subjected to three different mecha-
nisms of in vivo activation: 1) degradation of the latency-associated peptide (LAP) by pro-
teases, 2) induction of a conformational change in the LAP, e.g., by interaction with integrins 
and thrombospondin, and 3) rupture of the noncovalent bonds between LAP and mature 
TGF-β 223. In contrast, the soluble BMP7 complex — consisting of the mature peptide and its 
noncovalently associated prodomain — is already active, and is targeted to fibrillin-1 and 
-2 220. Therefore, it may be that proteases, such as elastases, are critically involved in the 
release of the soluble BMP7 complex from the elastic microfibers. However, the precise 
mechanisms of post-translational processing, secretion and interaction with ECM compo-
nents are less well understood for BMP7 and remain to be elucidated.
 In contrast, extracellular BMP antagonists are relatively well-studied secreted peptides 
that bind BMPs with high affinity and prevent their interaction with their cognate receptors. 
These antagonists can be categorized into subgroups, i.e., noggin 229, twisted gastrulation 
protein 230, the chordin family 231, and the DAN family 232.
 TGF-β/BMP signaling is limited by 1) dominant negative non-signaling membrane pseu-
doreceptors, 2) I-Smads, 3) ubiquitination and proteasomal degradation of signaling effec-








tors, 4) corepressors, and 5) phoshorylation of the linker region of R-Smads (reviewed 
in 233,234). Many of the negative regulators involved are potently induced by BMP/TGF-β sig-
naling, and may thus participate in a negative feedback loop to control the intensity and 
duration of TGF-β signaling 235-239. The pseudoreceptor BAMBI (BMP and activin membrane-
bound inhibitor) is a truncated, kinase-deficient, type I receptor that binds to ligand com-
petitively and thereby inhibits BMP and TGF-β signaling 240.
 The I-Smads, Smad6 237,241 and Smad7 242, inhibit signal transduction by interference with 
the activation of R-Smads and prevention of heterodimerization between R-Smads and 
Smad4. In addition, I-Smads can also interact with type I receptors through Smurfs (Smad 
ubiquitin regulatory factors), inducing ubiquitination and degradation of the activated recep-
tor complexes 244-247. The Smurf1/2–Smad7 complexes play an important role in regulating 
ubiquitination of TGF-β receptor complexes 248-250, Smurf1–Smad6/7 complexes appear to 
target BMP receptor complexes for degradation 247. So, whereas Smad7 acts as a general 
inhibitor of TGF-β superfamily member signaling pathway (BMP and TGF-β), Smad6 prefer-
entially blocks BMP signaling 236,237,241-243.
 TGIF (TGF-β-induced factor) is a transcriptional corepressor, i.e., a Smad binding pro-
tein that interferes with the ability of Smads to bind coactivators. It binds Smad2 and -3, 
thereby preventing the interaction of Smads with coactivators, resulting in reduced target 
gene expression. The competition for Smad binding between coactivators and corepres-
sors determines the magnitude of the transcriptional output from a given level of signaling. 
Sloan-Kettering retrovirus (Ski) and and its relative Ski-related novel gene N (SnoN) 251,252 
are also corepressors, which suppress Smad signaling by associating with the MH2 binding 
domain of Smads. Both Ski and SnoN bind Smad2 and -3, thereby inhibiting TGF-β signaling 
238,251-254. In addition, Ski, but not SnoN, can also interact with Smad1 and -5 and antago-
nize BMP signaling 251,255-257. By interacting with Smad1, -5, -6, -7, and -8, the transducer of 
ErbB-2 (Tob) also represses BMP signaling 258,259.
 Inhibition of the Smad pathway can also occur via growth factor induced phosphorylation 
of the linker region of R-Smads, reducing ligand-induced nuclear accumulation of R-Smads. 
Acivation of Erk by EGF and HGF, or activated Ras can induce this phosphorylation 260-262.
4.4.3  Physiologic and Pathophysiologic Functions
BMPs are paradigmatic molecules directly regulating osteoblast generation and were first 
identified by their ability to form new bone in vivo (reviewed in 161,263). They play a crucial role 
in skeletal and joint morphogenesis, bone remodeling, and fracture repair by inducing pro-
liferation, lineage determination, differentiation, and apoptosis in chondrocyte and osteo-
blast precursors 203,264. Subsequently, they were shown to act as multifunctional regulators 
of embryonic patterning and organogenesis, tissue remodeling, and repair 265.
 BMPs have also been implicated in cancer development. Elevated levels of BMP6 are 
associated with higher grade primary tumors and advanced prostate cancer with metasta-
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sis 266,267, and BMP2 induces migration and invasion in breast 268 and prostate 269-271 cancer 
cells. BMP7 regulates multiple cellular processes including cell proliferation, migration, 
and apoptosis. In cells from the osteoblast lineage, exogenous addition of BMP7 can result 
in inhibition or stimulation of cell proliferation, totally dependent on the cell line type 272,273. 
In PC-3 and DU 145 prostate cancer cells, BMP7 inhibited cell proliferation by arresting 
cells in G1 phase via up-regulation of the cyclin-dependent kinase (Cdk)-inhibitors. How-
ever, in C4-2B prostate cancer cells, BMP7 promotes cell survival by inhibiting stress-
induced apoptosis via both the Smad/survivin and c-jun NH2-terminal kinase pathways 274.
 Yet a different function for BMP signaling was demonstrated when Zhang and co-work-
ers demonstrated that conditional deletion of ALK3 (BMPRIA) lead to increased numbers of 
SNO cells and subsequently to higher HSC numbers. Thus BMP signaling via ALK3 complex 
controls the number of HSCs by regulating the niche size 180.
 TGF-β is a potent growth inhibitor in normal and non-malignant epithelial cells 32,33. How-
ever, different types of carcinomas often escape this tumor-suppressing activity and become 
refractile to growth inhibition 33,111,275. In fact, TGF-β can potentiate tumorigenesis and contribute 
to the progression and invasiveness of various carcinomas by inducing EMT 34-38. Accordingly, 
it has been shown that a blockade of TGF-β (signaling) inhibits tumor cell viability, migration, 
and metastasis 276-279. Moreover, TGF-β stimulates the PTHrP production in metastatic cancer 
cells, thereby being an important mediator in lytic bone destruction (as discussed in more 
detail in the paragraph 5.2.1, ‘Osteolytic Bone Metastasis’).
 Although some BMPs, such as BMP2 280 and BMP4 281, have also been shown to induce an 
EMT in certain cell types under specific conditions, the homodimeric protein BMP7 can induce 
the opposite, a mesenchymal-to-epithelial transition (MET) in normal and non-transformed 
cells 192,282. For instance, during kidney development, BMP7 is essential for the condensation 
and epithelialization of the metanephric mesenchyme in the kidney, resulting in the forma-
tion of the tubular epithelium 95,96,98. In the adult kidney, BMP7 appears to be involved in the 
preservation of the epithelial phenotype of renal tubular cells 283, and inhibition of fibrosis 284,285 
and inflammation 286,287. Moreover, BMP7 treatment partly inhibited the pathologic effects in 
experimentally induced acute 287 and chronic 284,288,289 kidney disease, including its complica-
tions renal osteodystrophy 290,291 and vascular calcification 292. In clinical practice, BMP7 is used 
as an osteoinductive agent in treatment of non-union fractures 293.
5 ‘Seed–Soil’ Interactions
The establishment of a metastasis is dependent on the reciprocal interactions between 
cancer cells and the microenvironment. In order to form an overt bone metastasis, cancer 
cells first have to extravasate into, colonize and then grow in, the BM. Thus, the first interac-
tion between the ‘seed’ and the ‘soil’, is when circulating cancer cell in blood interact with 
the endothelium of a specific tissue 294. In most tissues, the endothelium differs in surface 








markers, morphological phenotype and specialized functions 295, and is still susceptible to 
further modification by specific stimuli, such as inflammation. The specific combination of 
chemoattractive and adhesion molecules on the endothelium in the BM has been demon-
strated to be particularly favorable for the retention and extravasation of circulating cancer 
cells 294.
 As discussed in paragrapgh 4.2, BM endothelium-derived SDF-1 induces CXCR-4 express-
ing HSCs to undergo transendothelial migration mediated by E- and P-selectins 183,184. Simi-
larly, metastatic prostate cancer cells that adhere specifically to BM endothelial cells have 
also been reported to make use of E-selectin ligands for entry into BM 296-298. Moreovcer, the 
chemokine receptors CXCR4 and CCR7 are also expressed by a variety of osteotropic epithelial 
cancer cell types 298-301, also mediating their adhesion to BM endothelium.
 OPN, BSP, and type I collagen are major components of mineralized bone. These proteins 
mediate local adhesion, motility, survival and growth by interactions with matrix adhesion 
molecules, namely integrins, and are expressed by several types of cells, including HSCs. 
Similarly, cancer cell adhesion to OPN, BSP and type I collagen is also integrin-dependent 
167,168. So, integrin expression may not only be critical for guiding HSC to hematopoietic sites, 
but also for BM colonization by cancer cells 302. Mainly the αvβ3 (alias vitronectin receptor) 
and αIIbβ3 integrins seem to participate in determining the osteotropism of cancer cells 
303-306. Accordingly, the MDA-MB-231-BO2 breast cancer cell line, which is a subclone of 
MDA-MB-231 (MDA-231), constitutively overexpresses αvβ3 integrin and only metastasizes 
to bone 307. Similarly, de novo expression of αvβ3 integrin in 66cl4 breast cancer and CHO 
ovarian cancer cells that metastasize to lungs, but not to bone, is sufficient to promote their 
dissemination to bone 307,308. Moreover, αvβ3 integrin was shown to cooperate with BSP, 
MMP-2 and -9 in promoting osteotropic cancer cell invasion 309,310. CD44 is a non-integrin, 
ubiquitous and multifunctional surface adhesion molecule, which has been identified 
as a receptor for both the glycosaminoglycan hyaluronan and OPN. It is expressed by 
various cancer cell types and has a well-established role in skeletal metastasis 311. Taken 
together, the bone/BM microenvironment is able to actively allow circulating cancer cells to 
preferentially arrest in, extravasate into, and colonize BM, adopting similar pathways that 
are used by the homing of normal HSC to the bone/BM microenvironment 312.
 Besides high affinity for bone matrix, breast and prostate cancer cells can also produce 
bone matrix proteins such as OPN, osteonectin 313, and BSP 314. This acquisition of bone cell-
like properties by tumor cells, is called osteomimicry 313,315,316, and improves homing, adhe-
sion, proliferation, and survival in the bone/BM microenvironment.
 According to the ‘Seed and Soil’ hypothesis, interaction between tumor cells and the 
microenvironment is supposed to occur only after tumor cells reach the microenvironment. 
However, this classical ‘Seed and Soil’ hypothesis appears to be too simplistic, since the 
recent discovery of the so-called pre-metastatic niche (PMN) 317. Kaplan and co-workers 
showed that VEGFR1+ BM-derived hematopoietic progenitor cells (HPCs) were mobilized by 
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factors secreted from primary tumors (melanoma and lung carcinoma) to form fibronectin-
rich patches in (non-bone) target organs. Remarkably, these niches are formed prior to 
the arrival of metastatic tumor cells. Blocking the PMN formation by VEGFR1 antibodies 
significantly inhibited metastasis. Strikingly, the PMN was shown to dictate the metastatic 
pattern, since conditioned media from a melanoma cell line could redirect lung carcinoma 
cells to metastatic sites that are favored by melanoma, but not lung cancer. Two cytokines 
produced by primary tumors, VEGF and placental growth factor (PlGF), were suggested 
to mediate the formation of the PMN, although additional chemokines or growth factors 
are certainly necessary to facilitate different organ-specific metastasis 317,318. In summary, 
the PMN-model indicates that long range communication between tumor cells and tar-
get organs can occur before the arrival of tumor cells at distant sites. Understanding the 
molecular mechanisms involved in the formation and maintenance of PMNs and normal 
HSC niches (osteoblastic and vascular) and their role in supporting organ-specific metas-
tasis may provide new approaches for developing novel treatment strategies. However, it 
remains to be investigated whether the PMN-model is also applicable to other types of can-
cer, including breast and prostate cancer.
5.1 Bone Turnover and Skeletal Metastasis
The rate of bone turnover is closely associated with the number of sites with increased 
paracrine availability of growth factors due to osteoclastic bone resorption, and, accord-
ingly, the probability that the cancer cell (the ‘seed’) will find a favorable ‘soil’ in the bone/
BM environment. The latter part of this hypothesis is based on experimental studies, which 
have shown that the rate of bone turnover is associated to the occurrence and progression 
of bone metastases indicating that the growth support provided by the bone microenviron-
ment is active during bone resorption 319-321 (see ‘Osteolytic Bone Metastasis’). Recently, this 
view was further substantiated by clinical studies, showing a strong and highly significant 
association between the rate of bone resorption and incidence of subsequent skeletal com-
plications in breast and prostate cancer patients 322-325.
 Serum alkaline phosphatase (sALP) and urinary hydroxyproline are common and non-
expensive markers of bone formation and bone resorption, respectively. They are useful 
tools for assessing the overall bone turnover rate in cancer patients at risk to develop bone 
metastasis. Recently, more sensitive and specific biochemical markers have become avail-
able. Immunoassays for bone-specific alkaline phosphatase and type I collagen propep-
tides are currently the most sensitive markers for assessing bone formation. Best indices 
of bone resorption are the immunoassay for the pyridinoline cross-links and the related 
peptides that can be measured in urine and serum 326. These markers for bone turnover may 
be useful in planning the rational use of preventive treatment with bone resorption inhibi-
tors as will be discussed in more detail in paragraph 7, ‘Treatment of Bone Metastasis’.








5.2 Bone Metastatic Phenotype
Whereas prostate cancer predominantly elicits an osteoblastic response resulting in osteo-
sclerotic lesions, breast, lung and kidney cancer preferentially trigger an osteoclastic reac-
tion mainly resulting in osteolytic lesions (reviewed in 18,22). Although an osteolytic lesion is 
dominantly destructive, there is usually also a local bone formation response, which pre-
sumably represents an attempt at bone repair. Moreover, up to 25% of patients with bone 
metastases from breast cancer also have blastic lesions that are similar in appearance to 
those from patients with metastatic prostate cancer, and vice versa, some prostate cancer 
patients have osteolytic lesions that are similar in nature to those seen in patients with 
metastatic breast cancer. In other words, the common concept that there are basically two 
types of bone metastases, should rather be replaced by a view that the type of lesion is the 
result from a (dis)balance between anabolic and catabolic factors.
 With regard to bone integrity, bone regions affected by either osteolytic or osteosclerotic 
lesions are both more prone to pathological fractures due to architectural distortion and 
deposition of bone of the woven (immature or embryonic) type, which is much less mechani-
cally competent than the lamellar (mature) type.
 An increase in the RANKL to OPG ratio is one of the major determinants of an osteolytic 
phenotype, and vice versa, a decrease in the ratio is a major determinant of an osteoblastic 
phenotype (reviewed in 146,327).
5.2.1 Osteolytic Bone Metastasis
In osteolytic bone metastases, the destruction of bone is mediated by osteoclasts, as could 
histologically be observed by the numerous osteoclasts eroding the relatively scarce bone 
matrix 328,329.
 PTHrP is regarded as the main mediator of osteoclast activation in bone metastatic 
breast cancer 18,20. PTHrP induces RANKL and downregulates OPG in cells of the osteoblast 
lineage 330. It is produced by most solid osteotropic cancers 331,332, and plays a major role 
in the development of the osteolytic features of their bone metastatic lesions 333. Further-
more, PTHrP is considered to be responsible for the humoral hypercalcemia of malignancy 
(reviewed in 20). In breast cancer 90% of metastases in bone were found to express PTHrP, 
compared to only 17% at non-bone sites and 60% of the primary tumors 331,334. Initially, 
expression of PTHrP in the primary tumor appeared to be associated with formation of bone 
metastases 335,336. However, a large prospective study of 526 consecutive patients with oper-
able breast cancer demonstrated the opposite, PTHrP expression in primary breast cancer 
was significantly associated with fewer (bone) metastases 337,338. Therefore, the most likely 
explanation for the observed increased PTHrP expression in bone metastases 334,339, is that 
the bone microenvironment induces cancer cells to express PTHrP rather than cancer cells 
that metastasize to the bone have an intrinsically higher PTHrP expression.
 The hypothesis that PTHrP is induced by the bone microenvironment is also substantiated 
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by experimental evidence from Yin and co-workers demonstrating that PTHrP production 
in MDA-231 breast cancer cells was stimulated by TGF-β 340. Accordingly, introduction of a 
TβRII lacking a cytoplasmic domain (TβRIIDcyt) that exhibited dominant-negative effects 
into these cells prevented an increase in PTHrP production in response to TGF-β. Moreover, 
in an experimental model of bone metastasis (see paragraph 6, ‘Animal Models of Bone 
Metastasis’), mice receiving MDA-231 cells lacking TGF-β signaling had fewer and smaller 
osteolytic lesions than mice inoculated with parental or empty vector-transfected cells. 
Taken together, PTHrP increases osteoclastic bone resorption with consequent release and 
activation of matrix-integrated growth factors, especially TGF-β and IGFs, stimulating both 
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Figure 10 The vicious cycle of the osteolytic bone metastasis. Release of osteolytic factors, such as parathyroid 
hormone-related protein (PTHrP), by bone metastatic breast cancer cells causes nearby osteoblasts to 
change the mix of signals that they release: they increase RANKL synthesis. RANKL induces osteoclast 
precursors to mature into functional osteoclasts. The latter undertakes osteolysis, which causes bone 
demineralization, exposes the extracellular matrix within the bone, and results in liberation of various 
growth factors, including TGF-β, IGFs, BMPs, PDGF. These growth factors cause cancer cell proliferation and 
survival, and the additional presence of TGF-β stimulates production of PTHrP by the cancer cell, resulting in 
a self-sustaining positive-feedback loop that has been termed the ‘vicious cycle’ of osteolytic metastasis.
 In addition to PTHrP, RANKL expression on osteoblasts/stromal cells can be upregulated 
by many other tumor secreted factors such as IL-1, IL-6, IL-8, IL-11, and tumor necrosis fac-
tor (TNF)-α. In addition, these osteolytic factors are also capable of modulating osteoclas-








togenesis independent of RANKL (reviewed in 341). For example, IL-8 was shown to directly 
bind to CXCR1 present on osteoclast precursors 342. More recently, the intra-cellular com-
ponent NF-κB was demonstrated to play a crucial role in osteolytic bone metastases from 
breast cancer 343. GM-CSF (alias CSF-2) was identified as the key target of NF-κB that medi-
ates osteolytic bone metastasis of breast cancer by stimulating osteoclast development, 
thereby identifying new potential targets for prevention and treatment of skeletal metasta-
sis from breast cancer.
 The concept of the ‘vicious cycle’, in which cancer cells express osteolytic factors under 
influence of growth factors that are released from the bone matrix, has important thera-
peutic consequences: inhibition of bone resorption may interrupt this vicious cycle and thus 
may preserve bone mass, prevent pathological bone fractures, and even arrest tumor pro-
gression in the bone metastasis.
5.2.2 Osteosclerotic Bone Metastasis
Compared to osteolytic bone metastasis, mechanisms determining the exaggerated 
response in osteosclerotic bone metastasis are still poorly understood. It is believed that 
the excess production of mineralized bone matrix adjacent to the metastatic tumor cell 
deposit is due to an increased secretion of factors inducing proliferation, differentiation, 
and recruitment of osteoblast progenitors by the metastatic cancer cells (Fig. 11) (reviewed 
in 18,21,22,344). Nonetheless, markers of bone resorption are also increased in metastatic pros-
tate cancer, accurately reflecting the extent of disease progession 322-325,345. In fact, bone 
resorption markers are even more elevated than in patients suffering from lesions from 
breast cancer 325, providing the rationale for treatment with bone resorption inhibitors, such 
as bisphosphonates, in prostate cancer patients (see paragrapgh 7.1.1, ‘Bone Resorption 
Inhibitors’).
 BMPs are paradigmatic molecules that directly regulate osteoblast proliferation  and 
differentiation (reviewed in 263). Both normal and neoplastic human prostate tissue have 
been shown to express a variety of BMPs, namely BMP2, BMP3, BMP4, BMP6, and BMP7 346. 
Therefore, BMPs have been postulated to play an important role in the etiology of the osteo-
blastic phenotype of bone metastasis. Indeed, prostate cancer secreted BMPs in culture 
media were shown to promote mineralization in vitro (potency from high to low: BMP6 > 
BMP7 > BMP4) 347. Moreover, forced overexpression of noggin — a BMP2, -4, -6, and -7 
antagonist — in osteoinductive cell lines abrogated the osteoblastic response in vivo 270,348, 
however, tumor progression was not significantly affected 270,348. Direct experimental evi-
dence that a specific BMP could affect the osteoblastic response was provided by using 
neutralizing BMP6 antibodies, which inhibited the blastic response 269.
 Prostate and breast cancer cells express a variety of Wnt proteins, which can enhance 
bone mass 349. Interestingly, in breast cancer and myeloma — characterized by osteolytic 
lesions with suppression of osteoblastic activity — Wnt signaling is inhibited by the extra-
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cellular Wnt-antagonist dickkopf (DKK-1) expressed by the tumor cells 348,350,351. Moreover, 
in vitro differential expression analysis in breast and prostate cancer cell lines showed that 
the expression of the Wnt and BMP antagonists, DKK-1 and noggin, respectively, rather 
than expression of Wnts and BMPs determines the manifestation (blastic/lytic) of the bone 
metastasis 348.
 Other factors that have also been implicated as direct stimulators of osteoblast recruit-
ment, proliferation, and differentiation in osteosclerotic bone metastases are IGF-I and -II, 
FGF-1 and -2, VEGF, platelet derived growth factor (PDGF-BB), and TGF-β 346,349,352.
 Prostate cancer patients with osteoblastic metastases have high serum levels of 
endothelin-1 (ET-1) 353. Besides being a potent vasoconstrictor, ET-1 is also a direct mitogen 
for osteoblast progenitors 354. A causative role for ET-1 in the pathophysiology of osteoscle-
rotic bone metastasis has been demonstrated in pre-clinical models from prostate 354,355 
and breast cancer 356. The inhibition of bone metastatic but not primary tumor growth by 
treatment with ET-1-selective receptor antagonists in pre-clinical models suggests that a 
vicious cycle may also occur in osteoblastic metastasis 356.
 In addition to factors that directly affect osteoblasts, prostate cancer cells also produce 
factors that indirectly affect osteoblast function by modifying the bone microenvironment, 
such as VEGF, and the proteases urokinase-type plasminogen activator (uPA) and prostate-
specific antigen (PSA) 352. uPA stimulates osteoblast proliferation, probably by hydrolyzing 
IGF-binding proteins and thereby increasing free IGF levels 357. PSA is a serine protease of 
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Figure 11 Pathophysiology of osteosclerotic bone metastasis. Release of endothelin (ET-1) and different Wnts 
by bone metastatic prostate cancer cells causes nearby osteoblasts progenitors to differentiate into 
osteoblasts. Mature osteoblasts also secrete growth factors such as TGF-β that may stimulate bone 
metastatic growth. Therefore, a ‘vicious cycle’ is also considered to occur in osteoblastic metastasis.








the kallikrein family and a well-known marker of prostate cancer progression. It can cleave 
IGF-binding protein (IGFBP)-3, thereby reducing the ability of IGFBP-3 to antagonize the 
effects of IGF-I 358. In addition, PSA can cleave PTHrP, thus allowing the osteoblastic reac-
tion to predominate by decreasing bone resorption 359.
 In conclusion, tumor cells (the ‘seeds’) can accomplish metastases only in the organs 
where the microenvironment (the ‘soil’) is permissive for their growth, i.e., reciprocal 
interaction between the bone/BM microenvironment and cancer cells is fundamental for 
establishing bone metastatic growth. Subsequently, the reciprocal interaction can result in 
exaggarated stimulation of bone degradation and/or formation, ultimately determining the 
bone metastatic phenotype.
6 Animal Models of Bone Metastasis
In clinical studies, the possibility to manipulate different variables is, obviously, very lim-
ited. Therefore, animal models have become important tools to investigate the pathogen-
esis of bone metastasis as well as to develop novel therapeutic strategies. In general, the 
incidence of bone metastases from spontaneous breast and prostate cancer in rodents and 
non-human primates is extremely rare. So, bone metastases in animal models need to be 
induced experimentally. These include syngeneic transplantation of spontaneously occur-
ring rodent cancers and xenograft models with tumors or cell lines derived from human 
cancers into immunodeficient rodents (e.g., nude mice and rats, and severely compromised 
immunodeficient (SCID) mice). Furthermore, newly developed transgenic mice and immu-
nodeficient mice transplanted with human bone fragments have been actively pursued as 
alternative models (reviewed in 360,361).
6.1 Spontaneous Mammary and Prostate Cancer in Animals
Benign and malignant mammary neoplasms frequently develop in rats and mice, and the 
incidence is dependent on the strain. Unfortunately, these may not be good models for 
human disease. Most spontaneous mammary carcinomas in mice and rats have mild local 
tissue invasion, with low incidence of spontaneous metastasis to regional lymph nodes or 
lungs, and bone metastases are very rare. Moreover, spontaneous tumors can have long 
latency-periods. Compared to breast cancer, the incidence of prostate cancer in rodents 
and non-human primates is very rare 362. However, specific strains of rats exist that have 
increased incidence of prostate neoplasia, but again, the incidence of bone metastasis for-
mation is very rare 363,364. Spontaneous prostate cancer occurs most commonly in dogs, 
including the formation of osteoblastic bone metastases 362.
6.2 Transgenic Induction of Mammary and Prostate Cancer in Mice
Mutations introduced in the genome — e.g., in the tumor suppressor p53 — by genetic engi-
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neering have yielded transgenic mice that are prone to spontaneous development of a vari-
ety of neoplasms 365. Tumors arising specifically in the mammary or prostate gland can 
be accomplished using oncogene expression — such as SV40 large T antigen — driven by 
tissue selective promoters. The whey acidic protein, C(3)1, and MMTV promoters are often 
used for the mammary gland 366, whereas the probasin, C(3)1, PSP94 and PSA promoters 
are used for the prostate gland 367. Similarly, tissue-specific inactivation of (tumor suppres-
sor) genes using the Cre/loxP site-specific recombination system could also result in tis-
sue-specific carcinogenesis, as was shown by inactivation of p53 and E-cadherin genes 368. 
The advantages of transgenic models of cancer include their predictability and the autoch-
tonous development of cancer, i.e., originating where normally found. The disadvantage of 
the transgenic models is the low incidence of metastasis often due to rapid progression of 
the primary neoplasm. Moreover, in the transgenic models that do metastasize, metastases 
are usually found in lungs, but not in other organs such as bone 277.
6.3 Syngeneic and Xenograft Models of Bone Metastasis
Compared to transgenic mice, one of the major advantages of both syngeneic and xenograft 
models — using cancer cells and mice with an identical or different genetic background, 
respectively — is that cancer cells can be relatively easily subjected to genetic engineer-
ing ex vivo. In addition, these models also facilitate selection of cancer cell lines that have 
specific properties, such as a high propensity to spread to bone. These cell lines can be 
grown in vitro and, subsequently, re-injected intravenously, intracardially, orthotopically, or 
directly into the BM cavity. It is important to keep in mind that with respect to immunology, 
the use of immunocompetent mice in the 4T1 and other syngeneic models is preferred over 
xenograft models, which uses immunodeficient mice. On the other hand, cancer cells in the 
syngeneic model are not of human origin which may also lead to pitfalls when translating 
to the human situation.
6.3.1 Routes of Cancer Cell Inoculation
In syngeneic and xenograft experimental bone metastasis models, three major routes of 
cancer cell inoculation are commonly used, including 1) direct injection into bone microen-
vironment, 2) systemic injection, particularly intracardially, and 3) injection at orthotopic 
sites.
 Cancer cells can be injected locally adjacent to a bone surface 369 or into a marrow cav-
ity 370,371 (this thesis, chapter 2–6) to create an animal model for tumor growth in the bone 
microenvironment. However, local injection of tumor cells does not represent the entire 
process of bone metastasis and there can be distortions from injection caused by the injury 
to the bone (environment). Therefore, orthotopic or systemic injection is preferred.
 Arguello and co-workers were the first who systemically injected cancer cells directly 
into the left ventricle of the heart 372. Subsequently, cancer cells are dispersed throughout 








the whole body, and metastases only develop in particular organs, i.e., reciprocal interaction 
between the cancer cell (the ‘seed’) and the microenvironment (the ‘soil’) is fundamental for 
establishing metastatic growth. The original model used immunocompetent mice, but later 
models used immunocompromised mice. At present, this technique has been adopted by 
many research groups using different types of cell lines, including the PC-3M-Pro4 pros-
tate cancer cell line 373 (this thesis, chapter 7) and the broadly used MDA-231 breast cancer 
cell line 66,333,374,375 (this thesis, chapter 4,6). When MDA-231 wild type cells are intracardia-
cally injected into young (4–6 weeks old) female nude (or SCID) mice, metastases develop in 
specific organs, including bone. In this model, bone metastases can be clearly monitored by 
radiography after 3–4 weeks. Histologically, numerous osteoclasts and aggressive tumor 
colonization can be detected 66,333,374,375. Bone metastases occur particularly in the meta-
physes of the long bones, which are sites of active bone modeling and remodeling in young 
mice. Active bone turnover, high blood flow, and fenestrated sinusoids at these sites may 
predispose the metaphyses to the development of tumor growth. Blood vessels at the meta-
physes have 180° turns and are common sites for embolization in young animals. Therefore, 
the anatomic arrangement of blood vessels in metaphyses may predispose to tumor cell 
embolization and development of bone metastases in growing rodents 376. One of the disad-
vantages of the intracardiac injection model is that it lacks the critical early steps occurring 
between early growth at the primary site and entry into the circulation.
 Kuperwasser and co-workers have developed an orthotopic xenograft model in which 
both the stromal and epithelial component of the reconstructed mammary gland are of 
human origin, enabling to genetically modify both epithelial and stromal cells ex vivo. They 
demonstrated that an altered stromal environment — stromal cells overexpressing TGF-β 
or HGF — promoted breast cancer progression 377. However, this model as well as other 
orthotopic models — including syngeneic and xenograft models — rarely show involvement 
of bone metastases. An exception is the 4T1 syngeneic model, in which orthotopic injection 
of 4T1 murine breast cancer cells results in formation of a primary tumor that disseminates 
to lung, adrenal glands, and bone 378,379. Even more, syngeneic as well as xenograft models 
facilitate selection of sublines of cancers in vivo that have an increased incidence of bone 
metastasis after injection in vivo. For example, the 4T1.2 subclone of the 4T1 subline has an 
increased incidence of metastasis to bone after re-injection into the mammary fat pad 378.
 Alternatively, experimental models can also use tumor tissue instead of tumor cells. 
Tumor tissue can be generated by implanting human cancer cell lines subcutaneously 
in nude mice, resulting in hybrid tumors containing a mixture of human cancer cells and 
murine stroma and blood vessels. Implantation of such a hybrid tumor, containing human 
MDA-MB-435 breast cancer cells, into the mammary glands of nude mice resulted in for-
mation of bone metastases 380.
 Human prostate cancer cell lines have also been transplanted orthotopically in mice, 
successfully representing different stages of cancer progression in vivo ranging from 
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androgen-dependent growth, androgen-independent growth to metastatic growth, includ-
ing formation of osteoblastic bone metastases 381-383.
6.4 Subcutaneous Transplantation of Human Bone
Human fetal bone has been transplanted successfully to the subcutis of immunodeficient 
SCID mice to serve as a preferential site of metastasis of human prostate cancer cells 
injected into the left ventricle of the heart or as a site of tumor growth after local injection of 
cancer cells near the viable bone substrate 384. Similar results were also reported with the 
use of adult human bone in SCID mice 385. Similarly, orthotopic injection of a specific human 
breast cancer cell line, SUM1315, into SCID mice resulted in metastasis to the engrafted 
human bone, and not to mouse skeleton 386. Hence, these models demonstrated a prefer-
ential selection of human cancer cells to localize and proliferate in human bones compared 
with mouse bones. Furthermore, it was very recently demonstrated that SUM1315 cells 
were also able to metastasize to tissue-engineered bone, manufactured by BMP2-stimu-
lated human BM stromal cells on a silk scaffold in vitro 387.
6.5 In Vivo Imaging
Studying bone metastasis in small animal models has often relied on histological analyses, 
PCR amplification, and radiography. However, assays that utilize excised tissues are subject 
to sampling limitations and cannot assess the overall extent of disease in a given animal. 
To overcome this limitation, in vivo detection of bone metastases using high-resolution Fax-
itron radiography has been used in an attempt to provide temporal information. However, it 
does not detect micrometastatic lesions, the desired targets for therapeutic intervention, or 
the actual tumor burden. Therefore, newer imaging modalities — e.g., based on the optical 
imaging — need to be developed and utilized to improve detection and quantification bone 
metastases in animal models 388,389 (this thesis, chapter 3).
7 Treatment of Bone Metastases
Once patients show evidence of bone metastasis, the disease is incurable with currently 
available therapies. At present, therapies focus on symptomatic management and limiting 
the progression of established disease (reviewed in 17,18). Therefore, the ultimate goal is to 
develop new and better treatment strategies that can either prevent or treat bone metasta-
ses. For this we need a better understanding of which processes are crucially important in 
the formation and development of bone metastases.
7.1 Treatment Strategies
The selection of the appropriate systemic anti-tumor treatments, hormone and cytotoxic treat-
ments, that are presently given are very much dependent on the type of cancer. In addition, 








external beam radiotherapy can provide excellent palliation for localized metastatic bone pain, 
which can be achieved with a short treatment schedule of one to five fractions in most clinical 
situations 390. Radiopharmaceuticals are now also available for the palliation of metastatic bone 
pain, with Strontium-89 as an effective wide-field radiotherapeutic in prostate cancer 391.
7.1.1 Bone Resorption Inhibitors
Other treatment strategies for bone metastatic disease are based on the interference with 
the bone microenvironment and the concomitant release of growth factors from mineral-
ized bone during bone resorption that may support bone metastatic growth. Differently from 
most other tissues, drugs that can limit local turnover are available for bone. Suppression 
of bone turnover should interfere with the growth support for the tumor. Consequently, 
bone resorption inhibitors are becoming an attractive strategy for preventive and adjuvant 
therapies in patients with bone lesions.
7.1.1.1 Bisphosphonates
Bisphosphonates (BPs) are non-hydrolysable pyrophosphate analogues, and effective 
pharmacological bone resorption inhibitors that bind preferentially to bone at sites of 
active bone metabolism. They are released from the bone matrix during bone resorption 
and taken up by osteoclasts. BPs potently inhibit osteoclast activity and survival, thereby 
reducing osteoclast-mediated bone resorption 392-394. In clinical practice, BPs have been 
widely used to control skeletal complications in various neoplastic diseases. The bisphos-
phonates zoledronic acid, ibandronate, clodronate and pamidronate are currently given to 
breast and prostate cancer patients with already established bone metastases to efficiently 
reduce the number of skeletal-related events (SREs) 392,395-398. In addition, BPs may delay 
the progression and prevent the development of new bone metastatic foci in patients either 
established or without bone metastasis at the beginning of the treatment 399,400. However, 
a similar study failed to demonstrate a reduction in the number of metastases 401. Subse-
quently, three clinical trials primarily focused their investigation on the possibility that BP 
may prevent the development of metastases in women affected by primary breast cancer, 
but free of bone metastases at the moment of diagnosis. In two of these studies the pre-
ventive administration of BP significantly reduced the number of patients developing bone 
metastases and the number of bone metastases per patient 397,402. In one study there was 
also a significant reduction of the number of visceral metastases 402. However, in the third 
study BP treatment did not prevent the development of bone metastases and even seemed 
to increase the development of non-skeletal metastases 403. To resolve the apparent contra-
diction, two large phase III trials using BPs as adjuvant therapy for primary breast cancer, 
each enrolling more than 3000 patients with early-stage breast cancer, are underway. The 
National Surgical Adjuvant Breast Project B-34 trial will determine whether orally admin-
istered clodronate (1600 mg daily for 3 years) alone or in combination with chemotherapy 
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and/or hormonal therapy reduces the incidence of skeletal and non-skeletal metastases 
or improves overall or relapse-free survival. The Southwest Oncology Group 0307 trial will 
compare zoledronic acid (4 mg administered intravenously every 4 weeks for 6 months, then 
every 3 months for 2.5 years), clodronate (1600 mg taken orally daily for 3 years), and the 
BP ibandronate (50 mg taken orally daily for 3 years) as adjuvant therapy for primary breast 
cancer. The first results from these clinical trials are expected to be available in 2008. For 
prostate cancer similar prevention trials are ongoing.
7.1.1.2 Osteoprotegerin
Although the current therapy with BP results in a significant reduction in morbidity, an 
unmet medical need remains for a more convenient, effective, and safe therapy. Parental 
BPs must be administered by i.v. infusion. They are not effective in all patients, and renal 
toxicity and osteonecrosis may limit the dose and use of these agents in certain patients.
 OPG is a potent natural bone resorption inhibitor that antagonizes the ability of RANKL 
to bind its receptor RANK 139,147,148. Using the model of intracardiac injection with MDA-231 
cells, treatment with Fc-OPG inhibited bone metastases formation from breast cancer 374. 
In addition, in murine models of hypercalcemia, the Fc-OPG was shown to have a greater 
effect on reduction of bone turnover and osteoclast numbers than BP (pamidronate or zole-
dronic acid) treatment 404. Moreover, in a phase I trial a single s.c. dose of OPG (AMGN-0007) 
suppressed bone resorption in patients with multiple myeloma and bone metastases from 
breast cancer at least as potently as with i.v. infusion with pamidronate 405. Furthermore, 
Denosumab — a fully humanized, neutralizing monoclonal antibody to RANKL — decreased 
bone turnover markers in patients with multiple myeloma and bone metastases from breast 
cancer by a similar magnitude but more sustained than with pamidronate (i.v.) 406. Phase III 
clinical trials are now focusing their investigation on whether or not denosumab is able to 
prevent formation of bone metastases from breast cancer and inhibit bone loss induced by 
hormone ablation therapy in prostate and breast cancer.
7.1.1.3 Cathepsin K Inhibitors
Another class of bone resorption inhibitors that also target osteoclastic bone resorption are 
cathepsin K inhibitors. In a recent preclinical study, it was shown that a cathepsin K inhibitor 
reduced breast cancer-induced osteolysis and skeletal tumor burden 407.
7.1.1.4 Other Treatments
Atrasentan is a small molecule that blocks the functional binding of ET-1 to ETA receptor 
408. ET-1 is a potent mitogen for both prostate cancer cells and osteoblasts, and it is consid-
ered to be involved in the generation of pain 409. Prospective randomized placebo-controlled 
Phase II and III trials showed that atrasentan (10 mg/day, orally) provided adequate anal-
gesia and a consistent trend demonstrating a delay in disease progression in patients with 








metastatic hormone-refractory prostate cancer 408,410,411. In theory, ET receptor antagonists 
seem better suited to act in the early phases of the cancer cell-bone interaction. Therefore, 
atrasentan is under investigation in a maturing phase 3 study in >900 men with non-meta-
static hormone refractory prostate cancer to test the hypothesis that it delays the onset of 
metastatic disease.
7.2 Future Perspectives
Advances in structural deciphering of biomolecules that are involved in the pathogenesis of 
bone metastasis — such as OPG, integrins and MMPs — have allowed scientists to design 
molecules that mimic these critical targets. These artificially designed molecules can be 
used to block or increase the activity of a particular therapeutic target, and have significant 
potential in the treatment of bone metastasis. Measurements of bone turnover markers 
may be beneficial for the planning of a preventive treatment with bone resorption inhibitors, 
either newly designed molecules or more conventional ones. In the near future, gene signa-
tures from primary cancers that predict bone metastatic potential are also very promising 
tools to plan adequate treatment 412-414.
8 Aim and Outline of Thesis
Once a bone metastasis has developed, patients cannot be cured. From then on, their quality 
of life is often adversely affected by the frequency and morbidity of skeletal-related events 
(SRE). Therefore, new and better treatments need to be developed, both to inhibit SRE as 
well as to inhibit the initial formation of bone metastases. To determine the efficacy of such 
treatments, more sensitive and less invasive methods to directly detect and monitor in vivo 
minimal residual disease (MRD) in preclinical cancer models are required.
 In chapter 2 of this thesis, the possible contribution to metastasis in breast cancer of 
periodic-acid Schiff (PAS)-positive structures in the primary tumor and its lymph node 
metastases is studied. In chapter 3, whole-body bioluminescent reporter imaging (BLI) is 
described as a new and better method to detect, monitor and quantify microscopic bone 
metastases in experimental models. Therefore, optical imaging is used in the following 
chapters to detect and quantify the effects of different kinds of treatments. In chapter 4, 
clinically relevant doses of bisphosphonate, given in a preventive or treatment protocol, are 
used to investigate the effects on progression of bone metastases. Subsequently, in chap-
ter 5, high-dose bisphosphonate (BP) and osteoprotegerin (OPG) are given to maximally 
inhibit bone resorption using two different mechanisms of action to study the effects on 
established bone metastases. In chapters 6 and 7, bone morphogenetic protein (BMP7) is 
tested as a novel therapeutic molecule for repression of local and bone metastatic growth 
of breast and prostate cancer. Finally, general conclusions and discussions are described 
in chapter 8.
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Invasive ductal carcinoma is by far the largest histological subtype of breast cancer, but 
clinical behavior can differ greatly. Reliable morphological markers are, therefore, of 
invaluable help to distinguish between patients with good and poor prognosis. Histological 
patterns stained with periodic acid-Schiff (PAS) were previously shown to be of prognostic 
significance in cutaneous and uveal melanoma. In this study, we examined the presence of 
different PAS-positive (PAS+) structures in 54 women with infiltrating ductal adenocarci-
noma of the breast and at least one axillary lymph node metastasis but no distant metas-
tases who were followed for at least 11 years.
 We found that the complexity of the thin PAS+ patterns in lymph node metastases is 
associated with a shorter period of disease-free survival (DFS) as well as of total survival 
(Kaplan Meier curves). Furthermore, the presence of PAS+ networks – the most complex 
thin PAS+ pattern – in lymph node metastases is one of the two independent factors associ-
ated with the occurrence of a distant metastasis (multivariate Cox model). Moreover, the 
presence of PAS+ networks in positive lymph nodes is the feature most strongly associated 
with DFS.
 In conclusion, the presence of PAS+ networks in lymph node metastases is a new, reli-
able and convenient indicator for prognosis of breast cancer patients.
Jeroen_Buijs_18.indd   72 26-11-2008   10:18:13
 PAS+ networks correlate with poor prognosis in breast cancer 73
Introduction
Breast cancer is the most frequent type of cancer among women in industrialized countries. 
Approximately one in twelve women will develop breast cancer during their lifetime, and the 
incidence is increasing in many countries. Locoregional metastasis to adjacent lymph nodes 
is a crucial event of breast cancer progression and, consequently, axillary nodal status is 
the best predictor of survival 1.
 During cancer progression blood supply is required for tumors to survive, grow, and 
metastasize 2,3. Tumor angiogenesis, the process of blood vessel formation into a growing 
tumor, is necessary, as a tumor can not grow beyond 3 mm3 in the absence of angiogenesis 
due to the concomitant lack of oxygen and nutrients 4-6. Several groups have shown that high 
blood vessel counts in primary breast, and other, cancers provide an independent predictor 
of poor prognosis 7-10.
 In addition to angiogenesis, evidence is accumulating that malignant tumors are often 
capable of inducing other structures that may contribute to (invasive) growth and dissemi-
nation. In both uveal and cutaneous melanoma the presence of networks that stain positive 
with periodic acid-Schiff (PAS) has been described 8,11-13 and these have been shown to be 
of prognostic significance 13-15. The PAS reaction is a non-specific indicator for polysaccha-
rides, which are present in the basement membranes, including those of blood vessels. The 
PAS+ patterns may represent (a mixture of): blood vessels/ vascular network 12,14, fibrov-
ascular tissue 16,17, tumor cells 18 or a fluid conducting meshwork 11. Hence, at present, no 
consensus exists about the exact nature and origin of the PAS+ pattern. In melanoma PAS+ 
meshworks that were most interconnected correlated with the poorest prognosis, suggest-
ing that these structures may facilitate tumor growth and/or dissemination 13-15.
 Invasive ductal carcinoma is by far the largest histological subtype of breast cancer (at 
least 80%), but clinical behavior can be quite different. Reliable morphological markers are, 
therefore, needed for distinguishing patients with good and poor prognosis. In the present 
study, we investigated the presence of different PAS+ patterns in the primary tumor and its 
lymph node metastases of women with infiltrating ductal adenocarcinoma of the breast. 
Our results show that the presence of these patterns has significant prognostic value for 
both disease-free survival and total survival.
Patients & Methods
Patients
Out of 251 women with breast cancer operated between April 1984 and November 1989 in 
the Leiden University Medical Center, 170 had infiltrating ductal adenocarcinomas, no dis-
tant metastases at the time of surgery, no other malignant tumors and at least one paraffin 
embedded tissue was available for examination. Of these, 79 had at least one positive lymph 








node and were included in the study. Twenty-three patients were excluded for the follow-
ing reasons: no follow-up (4), paraffin blocks of either the primary tumor or its lymph node 
metastases were not available (20), or paraffin blocks of the primary tumor or its lymph 
node metastases had such quality that tumor histology and staining could not be examined 
properly (1). This analysis, therefore, includes 54 patients with infiltrating ductal adeno-
carcinomas with at least one lymph node metastasis, but no distant metastases, in whom 
material from both the primary tumor and the lymph nodes was available. The excised 
breast carcinomas and lymph nodes were fixed with formalin and embedded in paraffin for 
routine histopathological examinations. All primary breast tumors were revised and graded 
according to Bloom and Richardson (BAR) by a pathologist (V.T.H.B.M.S.). Patients were fol-
lowed periodically according to existing protocols.
Periodic Acid-Schiff (PAS)
Periodic acid-Schiff (PAS)-staining was performed on 5 µm paraffin embedded sections. 
Sections were deparaffinized and rehydrated in the following immersion steps: 5’ Paraclear 
(2x)(Klinipath, Duiven, The Netherlands), 2’ 100% ethanol (2x), 2’ 96%, 2’ 80%, 2’ 70%, 2’ 50% 
and 2’ distilled water. The sections were incubated for 30 minutes in a 56 oC pre-warmed 
0.6% periodic acid solution. The sections were rinsed with distilled water, and Schiff’s rea-
gent (Feulgen stain, Klinipath, Duiven, The Netherlands) was added. After 30 minutes, the 
sections were washed for 15 minutes with tap water. Samples were counterstained with 
Mayer’s Hematoxylin (Merck, Amsterdam, The Netherlands) for 1 minute and washed with 
tap water for 10 minutes before being dehydrated and mounted in xylol under glass cover-
slips with Aquamount.
Immunohistochemistry
All 5 µm paraffin embedded sections were mounted on slides coated with aminopropyl-
ethoxysilane (APES) followed by glutaraldehyde. After overnight drying in an oven at 37 oC, 
slides were stored in slide boxes at a temperature of 4 oC, to avoid loss of antigen epitopes 
19. The sections were deparaffinized and rehydrated in the following steps: 5’ Paraclear (2x)
(Klinipath, Duiven, The Netherlands) and 2’ 100% ethanol (2x). To block endogenous peroxide 
activity of the tissue, 20 minutes incubation at room temperature with 1% hydrogen peroxide 
in methanol was done. Microwave antigen retrieval (AR) was done for vimentin 20, in brief: 
sections were boiled for 10 minutes in a solution of 10 mmol/L citrate buffer pH 6 in a domes-
tic microwave oven at full power (Electrolux 700W). Enzymatic digestion was performed 
with trypsin (CD31), treatment at 37 oC for 20 minutes, using 0.1% trypsin (Sigma T-8128) in 
0.1% calcium chloride pH 7.4. All incubations and washing with phosphate-buffered saline 
were performed at room temperature. Sections were incubated with the primary antibod-
ies overnight, followed by 30 minute incubations with biotin-labeled rabbit-anti-mouse Ig 
or biotin-labeled goat-anti-rabbit Ig and a preformed complex of biotin-labeled horserad-
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ish peroxidase and streptavidin (DAKO). CD31 (clone JC/70A, dilution 1:200) and von Wille-
brand Factor (vWF)(polyclonal, dilution 1:400) were supplied by DAKO (Glostrup, Denmark), 
vimentin (clone V9, dilution 1:300) by Monosan (Uden, The Netherlands) and Smooth Muscle 
Actin (clone ASM-1, dilution 1:1000) by Progen (Heidelberg, Germany). Immune complexes 
were visualized with 0.05% diaminobenzidine and 0.0015% hydrogen peroxide. Slides were 
counterstained in Mayer’s hematoxylin (Merck, Amsterdam, The Netherlands) for 30 sec-
onds and washed with tap water for 10 minutes before being dehydrated and mounted in 
xylol under glass coverslips with aquamount.
Statistical Analyses
Patients were divided into two groups, according to the presence or absence of a particular 
PAS+ pattern. Subsequently, Kaplan-Meier curves were calculated and compared with a 
log-rank test for survival and disease free survival. The level of significance was set at 
P = 0.05. Afterward, the relative importance of all PAS+ patterns and the major clinical 
and prognostic characteristics (histological grade, stage, age, the number of positive lymph 
nodes at time of surgery and treatment of primary tumor) were determined by multivariate 
analysis using the Cox proportional hazards model. The Cox model was constructed using a 
forward stepwise selection procedure on the basis of the likelihood ratio statistic with chi-
square scores with significance levels of 0.05 or less for entry, and chi-square scores with 
significance levels of 0.10 or greater for removal.
SPSS-10 was used for all calculations.
Results
Patients
Stage, histological grade, treatment of primary tumor, kind of adjuvant treatment, age at 
time of surgery, disease free survival (DFS; end-point is the occurrence of a distant metas-
tasis) and total survival (end-point is the occurrence of cancer-related death) are summa-
rized in table 1.
Morphological PAS-positive Patterns
Sections stained with PAS were interpreted by two investigators (J.T.B. and G.v.d.P.) and a 
pathologist (V.T.H.B.M.S.). Different morphological patterns were identified within the tumor 
(Fig. 1). A subset of the patterns in this study, the ‘thin PAS-positive (PAS+) patterns’ or the 
‘thin PAS+ meshwork’ (E-J), as described by Foldberg and co-workers 12, existed within a 
compact tumor mass. We discerned 10 distinct PAS+ patterns in primary breast cancer and 
their lymph node metastases:
A. Small curves of extra cellular matrix: curves of PAS+ connective tissue (CT) around small 
groups of tumor cells (3-10 cells)(Fig. 1A).








Table 1 Classification of all patients included in the study. Stage, Histological Grade (both a.), treatment of primary 
tumor, adjuvant therapy (b.), age, disease freesurvival (DFS) and survival (all c.) are summarized. MRM = modified 
radical mastectomy, BCT = breast conserving treatment, RT = radio therapy, Horm = hormone therapy and Chem = 
chemotherapy , Age = age at time of surgery, St.dev = standard deviation, SEM = standard error of the mean.
(a) Stage Histological Grade
All patients II A II B III A III B  1 2 3
54 (100%) 7 (13.0%) 19 (35.2%) 7 (13.0%) 21 (35.5%) 4 (7.4%) 17 (27.8%) 33 (61.1%)
(b) Adjuvant therapy
None Chem Horm RT RT + RT + Total
Treatment of 
primary tumor 
MRM 11 3 1 21 9 4 49 (90.7%)
BCT + RT 2 2 1 x x x 5 (9.3%)
(c) Age (in years) DFS (in years) Survival (in years)
Average 57.83 4.63 6.58
Median 57.29 3.74 5.72
St.dev 12.09 4.19 4.13
SEM 1.54 0.53 0.52
Range 27.77 - 84.20 0.20 - 16.15 0.20 - 16.15
B. Small cellclusters surrounded by CT: dominant PAS+ CT network with small cluster, <10 
cells, of breast cancer cells (Fig. 1B).
C. Large cellclusters surrounded by CT: dominant PAS+ CT network with clusters, ≥ 10 cells, 
of breast cancer cells (Fig. 1C).
D. Thick circular loops of CT: composed of thick, circular PAS+ CT layers around clusters of 
breast cancer cells (>20 cells)(Figure 1.d). Because of their circular shape, these thick 
circular loops of CT may be confused with looping patterns that form networks. However, 
‘thick circular loops of CT’ are presented as thick, dominant layers, obviously consisting 
of CT. (Fig. 1D)
E. The parallel pattern: straight thin PAS+ patterns are arranged parallel to one another 
without dichotomous branching or cross-linking (Fig. 1E).
F. The parallel with cross-link pattern: parallel straight thin PAS+ patterns are linked to each 
other in a fashion reminiscent of switching tracks in a rail yard (Fig. 1F).
G. Arcs: thin PAS+ arcs are incomplete loops (i.e. loops that are not closed). We made 
no attempt to obtain serial sections through tumors to determine whether these arcs 
become complete loops in deeper section planes (Fig. 1G).
H. Arcs with branching: PAS+ arcs demonstrate dichotomous branching (Fig. 1H).
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I. Loops: completely closed thin PAS+ circles. The presence of one closed loop is sufficient 
evidence to record this pattern as present (Fig. 1I).
J. Interconnected Loops: back-to-back closed PAS+ loops. By definition, if interconnected 
loops are present, loops must be present (Fig. 1J).
Immunohistochemical Characterization of the Thin PAS+ Patterns
Antibodies to vWF or CD31 (PECAM-1) have been frequently used to visualize the blood ves-
sels, and antibodies to Flt-4 (VEGFR-3) have been used to visualize lymph vessels, although 
blood vessels in a tumor might be stained as well 21.
 In this study, the expression of vWF and Flt-4 (Fig. 2) was indeed mainly restricted to (blood) 
vessels (overview in Table 2). CD31 was also found to be expressed on blood vessels. In addi-
tion, the different thin PAS+ patterns depicted in figure 1 stained positive for smooth muscle 
actin (SMA)(Fig. 3). Occasionally, lumina were found in the PAS+ patterns. Lumina stained both 
unilaterally and bilaterally for SMA (Fig. 3E,F), but were negative vWF and Flt-4. Tumor cells 
and, sporadically, erythrocytes were found in these lumina. The vWF+/CD31+ tumor blood ves-
sels (Fig. 2A,B and 4A), which contained numerous erythrocytes, were located in bifurcations 
of this SMA+/PAS+ meshwork and might be interconnected to these lumina, suggesting an 
additional form of perfusion/dissemination for the tumor in the PAS+ meshwork. In summary, 
two different types of structures were observed in the thin PAS+ meshwork:
1. Tumor blood vessels, vWF+/CD31+.
2. “Additional meshwork”, PAS+/SMA+ (vWF-negative).
Table 2 Summary of staining of specific tissues as seen in the study. Vessels with erythrocytes were considered as 
blood vessels. Specific staining  for lymph vessels was not scored, since lymph vessels and blood vessels without 
erythrocytes can not be distinguished. VWF = von Willebrand Factor, SMA = smooth muscle actin.
Antibody Blood Vessels Stroma Arcs (G+H) Loops (I) Networks (J)
CD 31/PECAM-1 + - Patchy Patchy Patchy
VEGFR-3 (Flt-4) + - - - -
VWF + - - - -
SMA + + + + +
Vimentin + + Patchy Patchy Patchy
Other 
PAS-staining + + + + +
 The expression of CD31 in some primary breast carcinomas and concomitant lymph 
node metastases appeared not exclusive for blood vessels containing a lumen ((Fig. 4C,D). 
In addition, expression of CD31 was repeatedly found as a patchy, discontinuous staining 
alongside parts of the PAS+/SMA+ meshwork. Patchy staining alongside the entire mesh-
work was found for vimentin expression as well (data not shown).








 Occasionally, it was found that breast cancer cells were polarized to the meshwork, 
resembling the organization of normal breast ductal epithelial cells that are polarized to 
myoepithelial cells (Fig. 4D).
PAS-positive Patterns and Prognosis
The presence or absence of each morphological pattern in both primary tumor and positive 
lymph node was recorded for each patient with no knowledge of the clinical outcome (Table 
3). The identification of thin PAS+ patterns was highly reproducible (Table 4). Various types 
of thin PAS+ patterns were frequently observed within the same tumor. In primary breast 
cancer as well as in its lymph node metastasis the incidence of thin PAS+ patterns that were 
most interconnected, the PAS+ networks (14.8% and 13.0%, respectively) and loops (20.4% 
and 18.5%, respectively), was lower than the incidence of thin PAS+ patterns that were less 
interconnected. In the primary tumor and its positive lymph node the presence of any thin 
PAS+ pattern was 29.6% and 35.2%, respectively. The presence of any thin PAS+ pattern 
was for 63% concordant between the primary tumor and its positive lymph node (data not 
shown). Apart from ‘thick circular loops of CT’, other PAS+ structures, which were thick and 
associated with CT, were scored more frequently.
Table 3 Distribution of Morphological PAS-positive (PAS-+) Patterns in Primary Breast Carcinomas and their lymph 
node metastases. In brackets is the percentage of the patients having a particular PAS+ pattern. 
ECM = extracellular matrix, CT = connective tissue.






Small curves of ECM (A) 18 (33.3%) 32 (59,3%)
Small cellclusters surrounded by CT (B) 33 (61.1%) 17 (27.8%)
Large cellclusters surrounded by CT (C) 34 (63.0%) 15 (27.8%)
Thick circular loops of CT (D) 12 (22.2%) 7 (13.0%)
Thin PAS+ 
patterns
Parallel (E) 10 (18.5%) 14 (25.9%)
Parallel with Cross-Links (F) 10 (18.5%) 13 (24.1%)
Arcs (G) 12 (22.2%) 14 (25.9%)
Arcs with Branching (H) 12 (22.2%) 13 (24.1%)
Loops (I) 11 (20.4%) 10 (18.5%)
Networks (J) 8 (14.8%) 7 (13.0%)
Any thin PAS+-pattern 16 (29.6%) 19 (35.2%)
Total number of patients 54 (100%)
 To determine which of the ten PAS+ patterns might be associated with clinical outcome, 
Kaplan-Meier (KM) survival curves (Fig. 5 and 6) were estimated from the data (Table 5). 
None of the (thin) PAS+ patterns in the primary mammary carcinoma was significantly 
associated with poor prognosis.
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Table 4 Agreement between two independent observers for each thin PAS+ pattern.
Thin PAS+ patterns % Agreement Chance corrected measure of 
agreement (kappa statistics)
Parallel (E) 88 0.639
Parallel with Cross-Links (F) 88 0.639
Arcs (G) 85 0.677
Arcs with Branching (H) 85 0.677
Loops (I) 85 0.641
Networks (J) 88 0.693
any thin PAS+ pattern 85 0.687
Note: P ≤ 0.001 for all observations
Table 5 Kaplan-Meier Analysis for Disease Free Survival (DFS) and Total Survival for the Presence of Morphological 
PAS-positive (PAS+) Patterns in Primary Breast Carcinomas and their Lymph Node Metastases. ECM =extra 
cellular matrix, CT = connective tissue.





































Small curves of ECM (A) 0.54 0.4604 0.01 0.9302 1.18 0.2771 1.09 0.2975
Small cellclusters surrounded by CT (B) 0.07 0.7929 < 0.01 0,9894 3.11 0,0779 5.16 0,0231
Large cellclusters surrounded by CT (C) 0.02 0.8950 0.02 0.8950 1.10 0.2935 0.24 0,6221




Parallel (E) 0.08 0.7808 0.05 0.8170 3.13 0.0770 0.18 0,6689
Parallel with Cross-Links (F) 0.08 0.7808 0.05 0.8170 3.26 0,0711 0.16 0,6918
Arcs (G) 0.02 0.8930 0.57 0.4485 8.48 0,0036 11.09 0.0009
Arcs with Branching (H) 0.02 0.8930 0.57 0.4485 7.62 0,0058 8.92 0,0028
Loops (I) 0.10 0.7503 0.80 0.3700 13.89 0,0002 17.49 < 0,0001
Networks (J) 1.26 0.2620 1.06 0.3023 18.86 < 0,0001 17.02 < 0,0001
Any thin PAS+-patterns 0.63 0.4275 0.67 0.4131 9.73 0,0018 3.00 0,083
Table 6 Cox Proportional Hazards Model Using Forward Stepwise Selection of Prognostic Factors in Breast Cancer for 
DFS. DF = degrees of freedom, SE = standard error.






95 % Confidence 
interval
PAS+ network 1 2.463 0.524 22.077 < 0.0001 8.78 3.27 - 23.60
Stage-classification 1 0.413 0.151 7.481 0.005 1.50 1.13 - 1.98
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Figure 1 (left) Primary Breast Carcinoma Could Contain a Combination of Different PAS+ Patterns. Typical 
patterns are shown by an example. A, small curves of ECM with total lack of structure around small 
numbers of tumor cells (arrows) (magnification 400x). B, small cellclusters surrounded by CT: dominant 
CT network with breast cancer cells (magnification 200x). C, large cellclusters surrounded by CT: dominant 
PAS+ CT network with clusters of breast cancer cells (> 10 cells)(magnification 200x). D, thick circular 
loops of CT: thick, circular PAS+ CT layers around clusters of breast cancer cells (>30 cells) (magnification 
100x). E, parallel pattern; straight vessels are arranged parallel to one another without dichotomous 
branching or cross-linking (magnification 400x). F, parallel with cross-link pattern: parallel straight 
vessel are linked to each other in a fashion reminiscent of switching tracks in a rail yard (magnification 
400x). G, arcs are incomplete loops (i.e., the loops that are not closed) (magnification 400x). H, arcs with 
branching demonstrate dichotomous branching (magnification 100x). I, loops: completely closed. The 
presence of one closed loop is sufficient evidence to record this pattern as present (magnification 200x). 
‘Arcs with branching’ are often founded in ‘loops’ (magnification 200x). J, network: Adjacent back-to-back 
closed loops forming interconnected loops.
A B
C D
Figure 2 Vessels in a lymph node metastasis from breast cancer. A, B, the tumor is well vascularized as shown 
by the von Willebrand Factor (vWF)-positive blood vessels, which have erythrocytes inside (arrowheads). 
Besides the blood vessels, no additional patterns have been stained with the vWF staining (magnifications 
100x and 200x, respectively). C, D, expression of Flt-4 shows staining of vessels. The additional PAS+ 
patterns (arrows) are not stained with Flt-4 or vWF (magnifications 100x and 200x, respectively).











Figure 3 Expression of Smooth Muscle Actin (SMA)(Compared to a PAS-staining) in a Primary Mammary 
Carcinoma and Lymph Node Metastasis. Staining for SMA (A, C) and the PAS-staining (B, D) on 
sequential slides show both the same loops, in primary mamma carcinoma (A, B) as well as in lymph 
node metastasis (C, D). With a higher magnification erythrocytes could be clearly seen (arrowheads, 
magnification not shown) (magnifications 200x). Both unilateral (E) and bilateral (F) staining with SMA of 
the lumen is seen (magnifications 400x).
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 In contrast, the KM survival curves for patients with positive lymph nodes consisting of 
PAS+ networks or loops revealed a highly significant shorter period of DFS (p < 0.0001 and 
p = 0.0002, respectively) and survival (both p-values < 0.0001) compared to patients lacking 
these structures (Fig. 5A,B and 6A,B). All patients with PAS+ arcs or arcs with cross-linking 
in their positive lymph nodes also had a significant shorter period of DFS (p = 0.004 and p = 
0.005, respectively) and total survival (p = 0.003 and p = 0.0009) than patients without PAS+ 
arcs (with cross-linking) (Fig. 5C,D and 6C,D). There was a trend for patients with lymph 
node metastases containing PAS+ parallel lanes and PAS+ parallel lanes with cross-linking 
(p = 0.07 and p = 0.08, respectively) for a shorter period of DFS (Fig. 5E,F). However, the 
presence of PAS+ parallel lanes (with cross-links) did not give a poor prognosis for total 
survival (Fig. 6E,F). Nevertheless, the presence of any thin PAS+ pattern – including (inter-
connected) loops, arcs (with branching) and parallel lanes (with cross-links) – in positive 
lymph nodes is a prognostic indicator for DSF (p = 0.002) and, to a lesser extent, for survival 
(p = 0.08) (Fig. 5G and 6G).
 The Cox proportional hazard model using forward selection showed that PAS+ networks 
in positive lymph nodes and the stage-classification are the two independent risk factors for 
the occurrence of a distant metastasis (Table 6). Other risk factors were not independently 
associated with disease free survival, since no other risk factor entered into the Cox model. 
Furthermore, the presence of a PAS+ networks in positive lymph nodes was the risk factor 
most strongly associated with poor prognosis.
Discussion
We demonstrate here that, in addition to the tumor blood vessels, different thin PAS+ mesh-
works may exist in primary breast carcinomas and their lymph node metastases. These 
PAS+ meshworks are characterized by continuous expression of SMA and patchy expres-
sion of CD31. Within these PAS+ meshworks Flt-4+ and vWF+ vessels are embedded.
 More importantly, we found that prognosis of clinical outcome is inversely related to the 
complexity of the PAS+ meshwork in lymph node metastases. Furthermore, the presence 
of the most complex PAS+ pattern, the PAS+ network, in lymph node metastases from inva-
sive ductal carcinoma of the breast and stage classification of the tumor are the only two 
independent risk factors associated with the occurrence of a distant metastasis. The pres-
ence of a PAS+ network in a positive lymph node is the factor most strongly associated with 
poor prognosis. In line with previously published studies comparing overall survival and 
disease free survival in patients that received MRM and BCT as original treatment, the type 
of treatment was not an independent risk factor for poor prognosis 22-24. The histological 
grade was not an independent risk factor, since patients selected in the study had at least 
one lymph node metastasis and there was, therefore, a bias for a high histological grade. 
Similarly, the number of positive lymph nodes was not an independent risk factor, since it 
already entered in the model with the variable stage classification.








 Immunohistochemically, these PAS+ meshworks showed continuous expression of SMA 
(normally expressed by pericytes) and patchy expression of CD31. The presence of lumina 
in the PAS+ meshwork might be indicative for septa that may facilitate perfusion and/or 
dissemination of cancer cells. Indeed, tumor cells were frequently present in the lumina, 
whereas, erythrocytes were occasionally found in these structures.
 In 63 % of the patients thin PAS+ patterns were present in both the primary tumors and in 
their respective lymph nodes. Some tumors may, therefore, have the capability to form such 
PAS+ patterns, however, none of the PAS+ patterns scored in primary tumors appeared 
to be of prognostic significance. The non-prognostic value of PAS+ networks in primary 
A B
C D
Figure 4 Expression of CD31 and SMA in Lymph Node Metastasis from a Primary Mammary Carcinoma. The 
staining for CD31 (A) and SMA (B) on sequential slides show co-expression on blood vessels. Additionally, 
SMA-positive (SMA+) lumina could be seen (arrows). The CD31-positive (CD31+) vessels seems to be 
connected to each other by the (lumina of) SMA+ framework. C, occasionally, however, CD31+ patterns 
are present alongside the SMA-positive/PAS-positive (SMA+/PAS+) framework. D, CD31+ patterns 
alongside the SMA+/PAS+ framework are also present in the primary mammary carcinoma. Sometimes, 
breast cancer cells are ordered to the SMA+/PAS+ framework (arrowheads), resembling the manner of 
normal breast ductal epithelial cells that are polarized to myoepithelium (all magnifications 200x).
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Figure 5 Kaplan-Meier Survival Curves for Total Survival of 
Breast Cancer Patients with Different Thin PAS+ 
Patterns in their Lymph Node Metastases. Lymph 
node metastases with/without the presence of the 
following thin PAS+ patterns: networks (A), loops 
(B), arcs with cross-linking (C), arcs (D), parallel 
lanes with cross-linking (E), parallel lanes (F) and 
any thin PAS+ pattern (G).














Figure 6 Kaplan-Meier Survival Curves for Disease 
Free Survival of Breast Cancer Patients with 
Different Thin PAS+ Patterns in their Lymph 
Node Metastases. Lymph node metastases 
with/without the presence of the following 
thin PAS+ patterns: networks (A), loops (B), 
arcs with cross-linking (C), arcs (D), parallel 
lanes with cross-linking (E), parallel lanes (F) 
and any thin PAS+ pattern (G).
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tumors can be explained by the co-existence of other PAS+/SMA+ structures in primary 
tumors or normal breast tissue, that hamper the interpretation. Most probably, myoepi-
thelial cells and myofibroblasts interfere with scoring of the PAS+ patterns in the primary 
breast cancer. Other apparent inconsistencies, e.g. the association of PAS+ parallel lanes 
(with cross-links) in lymph nodes with poor prognosis for DFS, but not for total survival, are 
most likely due to the relatively small number of cases.
 It has been well established that malignant breast cancer cells can acquire a mesen-
chymal phenotype, and transit into a myofibroblast, a process known as epithelial-to-
mesenchymal transition (EMT)25-27. It is tempting to speculate that tumor cells that align 
hollow tubular structures are phenotypically distinct from other tumor cells and acquire 
a fibroblast-like phenotype. Accordingly, the process of epithelial-mesenchymal transition 
might be a prerequisite for a tumor to form such a network 28. The generation of such a 
PAS+ network by genetically deregulated, aggressive tumor cells was termed ‘vasculo-
genic mimicry’ (VM) to emphasize their de novo generation without participation of endothe-
lial cells and independent of angiogenesis 16,18,29-33. In VM, the PAS+ interconnected loops 
are the tumor-lined vessels providing perfusion of erythrocytes. Recent reports suggest 
that VM also exists in ovarian 34, prostate 28 and breast cancer 29,35. After establishing an 
inflammatory breast cancer (IBC) xenograft with VM features 36, Shirakawa and co-workers 
examined surgically resected breast cancers and classified 7,9 % as containing VM 35. The 
existence of VM increased the likelihood of hematogenous spread and gave a poorer prog-
nosis for the patient. However, in this study, erythrocytes were only occasionally detected 
within the PAS+ network. The PAS+ network may also consist of the PAS+ fluid-conducting 
spaces without erythrocytes in the form of stromal sheets between nests of tumor cells 
that could provide nutrition for the tumor cell, and probably facilitate metastasis 11.
 In addition, Foss and co-workers provided evidence that PAS+ extracellular septa could 
be particularly favorable substrates for the in-growth of angiogenic, and possibly lymphatic, 
vessels 16. Consequently, tumors that contain these PAS+ structures might be more aggres-
sive, as these structures provide better means for (blood) vessel in-growth than tumors 
lacking these structures. The lack of continuous flt-4 expression in the PAS+ networks of 
breast cancer patients may, therefore, indicate that these structures do not entirely rep-
resent lymphatic vasculature. Indeed, the differences in distribution of flt-4+ and CD31+ 
patterns within the PAS+ networks in our tissue specimens from the patients, supports 
the notion that PAS+ meshworks are complex and consist of multiple types of vasculature 
(blood vessels, and possibly lymphatics). If the septa consist of two layers of ECM elabo-
rated by opposing layers of tumor cells, the layers could separate, forming channels and 
laminar openings. Such openings could particularly lead to capillary growth. The patchy 
expression of the endothelial marker, CD31, is in agreement with this hypothesis. Finally, it 
has been suggested that the open ends of the growing capillaries could feed blood into the 
channels, therefore, the presence of erythrocytes in the channels could be explained, and 
different hypotheses could be reconciled 37.








 In conclusion, we show here that the presence of PAS+ networks in lymph node metas-
tases from invasive ductal carcinoma of the breast is one of the two independent risk fac-
tors for the occurrence of distant metastases. Moreover, the presence of a PAS+ network 
in a positive lymph node is the factor most strongly associated with occurrence of a distant 
metastasis. Therefore, by examining the presence of PAS+ networks in invasive ductal car-
cinoma of the breast, clinical behavior of this heterogeneous group of patients can be better 
predicted leading to early more aggressive management. Further research should focus in 
elucidating the exact nature and origin of the PAS+ network in different carcinomas. The 
investigation of the – possibly tumor-derived – PAS+ patterns, as observed in breast cancer, 
can have pathophysiological and therapeutic implications ranging from predisposition to 
blood-borne spread of tumor cells, to facilitated entry of drugs into tumors, and to efficacy 
of anti-cancer drugs as anti-angiogenic agents.
Acknowledgment
The authors thank Ronald Brand from the Dept. of Statistics for his advise and comments on 
the statistical analyses. This work has been supported by the Dutch Cancer Society (Grant 
nr. RUL 2001-2485).
References
1. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival--a 
Bayesian meta-analysis. Ann Surg Oncol 1999; 6:109-16.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-
31.
3. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-4.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during 
tumorigenesis. Cell 1996; 86:353-64.
5. Rak J, Kerbel RS. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. 
Cancer Metastasis Rev 1996; 15:231-6.
6. Kumar R, Fidler IJ. Angiogenic molecules and cancer metastasis. In Vivo 1998; 12:27-34.
7. de Jong JS, van Diest PJ, Baak JP. Hot spot microvessel density and the mitotic activity index are 
strong additional prognostic indicators in invasive breast cancer. Histopathology 2000; 36:306-
12.
8. Engels K, Fox SB, Harris AL. Angiogenesis as a biologic and prognostic indicator in human 
breast carcinoma. EXS 1997; 79:113-56.:113-56.
9. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in 
breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13:765-82.
10. Harris AL, Zhang H, Moghaddam A, Fox S, Scott P, Pattison A et al. Breast cancer 
angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, 
and vascular targeting. Breast Cancer Res Treat 1996; 38:97-108.
11. Clarijs R, Otte-Holler I, Ruiter DJ, de Waal RM. Presence of a fluid-conducting meshwork in 
xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci 
2002; 43:912-8.
12. Folberg R, Pe’er J, Gruman LM, Woolson RF, Jeng G, Montague PR et al. The morphologic 
characteristics of tumor blood vessels as a marker of tumor progression in primary 
human uveal melanoma: a matched case-control study. Hum Pathol 1992; 23:1298-305.
Jeroen_Buijs_18.indd   88 26-11-2008   10:18:22
 PAS+ networks correlate with poor prognosis in breast cancer 89
13. Thies A, Mangold U, Moll I, Schumacher U. PAS-positive loops and networks as a prognostic 
indicator in cutaneous malignant melanoma. J Pathol 2001; 195:537-42.
14. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe’er J et al. 
The prognostic value of tumor blood vessel morphology in primary uveal melanoma. 
Ophthalmology 1993; 100:1389-98.
15. Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A et al. Prognostic 
significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin 
Cancer Res 2001; 7:473-7.
16. Foss AJ, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S. Reassessment of the 
PAS patterns in uveal melanoma. Br J Ophthalmol 1997; 81:240-6.
17. McLean IW, Keefe KS, Burnier MN. Uveal melanoma. Comparison of the prognostic value 
of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. 
Ophthalmology 1997; 104:777-80.
18. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J et al. Vascular channel formation 
by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 
155:739-52.
19. van den Broek LJ, van de Vijver MJ. Assessment of problems in diagnostic and research 
immunohistochemistry associated with epitope instability in stored paraffin sections. Appl 
Immunohistochem Molecul Morphol 2000; 8:316-21.
20. Hazelbag HM, van den Broek LJ, van Dorst EB, Offerhaus GJ, Fleuren GJ, Hogendoorn PC. 
Immunostaining of chain-specific keratins on formalin-fixed, paraffin-embedded tissues: a 
comparison of various antigen retrieval systems using microwave heating and proteolytic 
pre-treatments. J Histochem Cytochem 1995; 43:429-37.
21. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M et al. VEGFR-3 and its ligand 
VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154:1381-90.
22. Lee HD, Yoon DS, Koo JY, Suh CO, Jung WH, Oh KK. Breast conserving therapy in stage I & II 
breast cancer in Korea. Breast Cancer Res Treat 1997; 44:193-9.
23. Noguchi M, Yagasaki R, Kawahara F, Minami M, Tsuyama H, Earashi M et al. Breast conserving 
treatment versus modified radical mastectomy in Japanese patients with operable breast 
cancer. Int Surg 1997; 82:289-94.
24. van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F et al. Prognosis after 
treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two 
randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group 
and the Danish Breast Cancer Cooperative Group. Eur J Cancer 1999; 35:32-8.
25. Petersen OW, Lind NH, Gudjonsson T, Villadsen R, Ronnov-Jessen L, Bissell MJ. The plasticity 
of human breast carcinoma cells is more than epithelial to mesenchymal conversion. 
Breast Cancer Res 2001; 3:213-7.
26. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 
2:442-54.
27. Dandachi N, Hauser-Kronberger C, More E, Wiesener B, Hacker GW, Dietze O et al. Co-
expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic 
transdifferentiation during tumour progression: correlation with histopathological 
parameters, hormone receptors, and oncoproteins. J Pathol 2001; 193:181-9.
28. Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Jr., Cohen MB et al. Prostatic tumor 
cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: Role 
in vasculogenic mimicry. Prostate 2002; 50:189-201.
29. Hendrix MJ, Seftor EA, Kirschmann DA, Seftor RE. Molecular biology of breast cancer 
metastasis. Molecular expression of vascular markers by aggressive breast cancer cells. 
Breast Cancer Res 2000; 2:417-22.
30. McDonald DM, Munn L, Jain RK. Vasculogenic mimicry: how convincing, how novel, and how 
significant? Am J Pathol 2000; 156:383-8.
31. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J 
Pathol 2000; 156:361-81.
32. Fausto N. Vasculogenic mimicry in tumors. Fact or artifact? Am J Pathol 2000; 156:359.
33. Bissell MJ. Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. 
A rose by any other name? Am J Pathol 1999; 155:675-9.








34. Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE et al. Molecular 
determinants of ovarian cancer plasticity. Am J Pathol 2001; 158:1279-88.
35. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K et al. Vasculogenic mimicry 
and pseudo-comedo formation in breast cancer. Int J Cancer 2002; 99:821-8.
36. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M et al. Absence of endothelial cells, 
central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. 
Cancer Res 2001; 61:445-51.
37. Ruoslahti E. Specialization of tumour vasculature. Nature Cancer Reviews 2002; 2:83-90.
Jeroen_Buijs_18.indd   90 26-11-2008   10:18:23
Chapter 3
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The development of novel anti-cancer strategies requires more sensitive and less invasive 
methods to detect and monitor in vivo minimal residual disease in cancer models. Bone 
marrow metastases are indirectly detected by radiography as osteolytic and/or osteoscle-
rotic lesions. Marrow micrometastases elude radiographic detection and, therefore, more 
sensitive methods are needed for their direct identification. Injection of cancer cells into 
the left cardiac ventricle of mice closely mimics micrometastatic spread. When luciferase-
transfected cells are used, whole body bioluminescent reporter imaging (BLI) can detect 
microscopic bone marrow metastases of ≈0.5 mm3 volume, a size below the limit where 
tumors need to induce angiogenesis for further growth. This sensitivity translates into early 
detection of intra-medullary tumor growth, preceding the appearance of a radiologically 
evident osteolysis by ≈2 weeks. BLI also enables continuous monitoring in the same animal 
of growth kinetics for each metastatic site and guides end-point analyses specifically to the 
bones affected by metastatic growth. This model will accelerate the understanding of the 
molecular events in metastasis and the evaluation of novel therapies aiming at repressing 
initial stages of metastatic growth.
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Introduction
Because of the progress made in early detection and surgical treatment of the primary 
tumor, mortality in cancer patients is increasingly linked to metastatic disease. Bone is the 
second most common site of metastasis 1 and the frequency of bone metastases at autopsy 
of cancer patients varies between 60 and 85%, depending on the cancer type 2-4.
 Clinical and experimental observations indicate that the hematopoietic marrow, rather 
than the bone tissue, is the initial site of cancer cell seeding 5. Indeed, small clusters of 
cancer cells (= micrometastases) can be detected in a vast proportion of the bone marrow 
aspirates of subjects affected by a variety of epithelial cancers with no radiological or scin-
tigraphic evidence of bone metastasis at the time of diagnosis and/or surgery of the primary 
tumor 6,7. Micrometastases represent the pathophysiological basis of minimal residual dis-
ease 8,9 (MRD) that will eventually lead to cancer relapse as overt metastases. However, they 
cannot be detected by conventional staging methods and are poorly influenced by current 
treatment 8-10. Hence, there is a need for alternative therapeutic strategies that should be 
tested in experimental models able to mimic micrometastatic spread.
 Injection of cancer cell lines into the left cardiac ventricle of immunodeficient (nu/nu) 
mice is a widely used animal model of bone/bone marrow metastasis 11,12. This experimen-
tal setting closely resembles the clinical situation of MRD after removal of the primary 
tumor. However, detection of bone metastasis by radiography 13 makes it not an ideal model 
of MRD. In fact, radiologically evident osteolytic/osteosclerotic metastases are a late and 
macroscopic event in the evolution of metastatic bone disease. Thus, the model lacks the 
sensitivity that would be necessary to dissect the initial processes, such as the “angiogenic 
switch” 14, essential for tumor progression 15. Furthermore, the radiological detection of 
osteolytic and/or osteosclerotic metastases is an indirect measure of the tumor burden. 
Only a parallel histomorphometric analysis allows the distinction between a therapeutic 
effect exerted directly on tumor cells or indirectly through inhibition of bone resorption. 
Therefore, more sensitive methods to detect and monitor directly metastatic growth in bone 
marrow/bone of whole animals need to be developed.
 Expression in vivo of reporter genes encoding bioluminescent 16 or fluorescent 17 proteins 
can be detected externally by sensitive detection systems. Cancer cell lines permanently 
transfected either with the firefly luciferase (Luc) or the green fluorescent protein (GFP) 
have been used to monitor in living mice local tumor growth 18 and development of metasta-
sis to different organs 17.
 We investigated the possibility to apply an equivalent bioluminescent imaging method to 
visualize in vivo the development of bone marrow/bone metastases after injection of luci-
ferase-transfected MDA-MB-231 cells, a human mammary carcinoma cell line 19, into the 
left cardiac ventricle of immunodeficient (nu/nu) mice.








 Here we demonstrate that whole-body bioluminescent reporter imaging (BLI) effectively 
allows sensitive localization and growth monitoring of minimal metastatic deposits in the 
bone marrow at a stage largely preceding tumor-induced osteolysis.
Materials and Methods
Animals
Female BALB/c nu/nu mice were purchased from Iffa Credo (L’Arbresle, France). They were 
housed in individual ventilated cages under sterile condition according to the Swiss guide-
lines for the care and use of laboratory animals. Sterile food and water were provided ad 
libitum. Mice were 5 to 6 weeks old when used for the intracardiac (i.c.) injection of tumor 
cells. For intraosseous (i.o.), intra-muscle (i.m.) and subcutaneous (s.c.) implantation of 
tumor cells they were 10-12 weeks old.
 For surgical manipulation, mice were anaesthetized by an intra-peritoneal (i.p.) injec-
tion of a mixture of Domitor (1mg/kg body weight; Pfizer, Sandwich, UK), Climasol (10mg/
kg body weight; Gräub, Bern, Switzerland) and Fentanyl (100µg/kg body weight; University 
Hospital pharmacy). Mice were recovered from anaesthesia by a s.c. injection of a mixture 
of the following antidotes: Antisedan (5mg/kg body weight; Pfizer), Sarmasol (1mg/kg body 
weight; Gräub) and Narcan (2.4mg/kg body weight; Dupont Pharma, Wilmington, DE).
 Mice subjected to i.c. injection of tumor cells were sacrificed by CO2 euthanasia at first 
signs of distress and/or paraplegia. Mice injected s.c., i.m. and/or i.o. with tumor cells were 
sacrificed immediately after BLI analysis, and those with tumor cells implanted i.o. were 
sacrificed at the end of the 5-week observation period.
Cell lines
The human mammary carcinoma cell line MDA-MB-231 (MDA-231) was obtained from the 
American Type Culture Collection (Rockville, MD). A sub-clone inducing invariably bone metas-
tases after i.c. inoculation (bone-seeking clone, MDA-231-B) has been established by sequen-
tial cycles of i.c. inoculation of MDA-231 in vivo and expansion in vitro of the cell population 
recovered from the resulting bone metastases. Briefly, parental MDA-231 cells (1x105/100 µl 
PBS) were injected i.c. in female BALB/c nu/nu mice. Development of osteolytic bone metas-
tases was monitored by radiography. When the bone metastases reached the size of ≈2 mm 
diameter, they were dissected out, cut into small fragments and transferred to 12 well-plates. 
After 3 days of culture, remnants of the original tissue fragments were removed and each area 
of cell outgrowth was individually trypsinized with the aid of cloning rings. The individual cell 
populations resulting from each area of outgrowth were separately expanded by limiting dilu-
tion. After expansion, the origin of the clones from the cancer cell population of the original 
metastases was confirmed by species-specific polymerase chain reaction (PCR) analysis for 
human β2-microglobulin, as described earlier 20. Positive clones only were selected for a new 
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cycle of i.c. inoculation in vivo and expansion in vitro of the cell population recovered from the 
resulting bone metastases. The MDA-231-B sub-clone was obtained after a total of four of 
these consecutive cycles. It showed the capacity, after i.c. inoculation, to induce bone metas-
tases, as detected by radiography, in 100% of the animals. For this reason it was selected for 
the establishment of stable transfectants expressing the luciferase gene.
 Cell lines and the explanted fragments of bone metastases were grown in DMEM Medium 
(Biochrom, Basel, Switzerland) containing 4.5g glucose/l and supplemented with 10% new-
born calf serum (Biowhittaker, Verviers, Belgium) and 1% gentamycin. Cells were regularly 
certified free of mycoplasma contamination.
Establishment of stable transfectants expressing the luciferase reporter gene
A CMV-promoter driven mammalian expression vector for luciferase (CMV-Luc) was gener-
ated by cloning a full-length firefly luciferase cDNA21 into the pcDNA3.1 plasmid (Invitrogen, 
Breda, Netherlands). MDA-231-B cells were transfected with 1 µg CMV-Luc using fugene-6 
(Roche Biochemicals, Almere, Netherlands). Stable transfectants were selected with G418 
(800ug/ml; Life Technologies, Basel, Switzerland). Twenty-five different G418-resistant 
clones were isolated, sub-cloned and tested for luciferase activity. Six clones were found 
to express luciferase activity. One clone (MDA-231-B/Luc+), expressing the highest levels 
of luciferase activity (5-12 RLU/µg cell protein) was selected for further experimentation. 
The clone has been cultured up to 40 passages and, even though in some passages the cells 
have been propagated in absence of G418 selection, the clone maintains currently the same 
level of luciferase expression of early passages.
Induction of metastases by intracardiac and intra-venous injection of cancer cells
A single cell suspension of MDA-231-B/Luc+ cells (1x105/100 µl PBS) was injected into the 
left heart ventricle according to the method described by Arguello and co-workers.11 Some 
animals were injected into the tail vein with an equal number of MDA-231-B/Luc+ cells. The 
development of metastases was weekly monitored by BLI and radiography. Some of the 
mice were also imaged 10 minutes and 24 hours after i.c. injection to visualize the early body 
distribution of MDA-231-B/Luc+cells.
Intraosseous implantation of cancer cells
For direct i.o. implantation of MDA-231-B/Luc+ cells, two holes, distant 4-5 mm from each 
other and each with a diameter of about 0.35 mm, were drilled through the bone cortex of 
the upper third of the right tibia with the aid of a dental drill (Hedstroem file, 28mm/30; 
Maillefer Instruments, Ballaigues, Switzerland). Space in the marrow cavity was created by 
flushing out the bone marrow of the proximal segment of the bone shaft. The upper hole was 
sealed by surgical bone wax (Ethicon, Johnson & Johnson, Somerville, NJ) and a single cell 
suspension of MDA-231-B/Luc+ cells (1x104/2 µl of PBS) slowly inoculated via a 30-gauge 








needle inserted through the lower hole. Finally, the lower hole was sealed with surgical 
bone wax and the cutaneous wound was sutured. Local tumor development was monitored 
twice a week by BLI and radiography. This method was adopted to prevent spill of cancer 
cells from the channel created by the needle and subsequent growth outside the marrow 
cavity into the surrounding soft tissues during the following period (28 days) of monitoring.
Determination of the lowest cell number detectable in bone
The knee articulation was forced in a flexed position and a 27-gauge needle was inserted 
through the patellar tendon and guided toward the articular surface of the femur with gen-
tle drilling motion until the bone cortex was perforated.22 Ten thousand to 1 million MDA-
231-B/Luc+ cells in a total volume of 5 µl of PBS were slowly injected into the bone marrow 
cavity. As control, 1 x 104 cells were injected i.m., in the vastus lateralis. As further control, 
1 x 101, 1 x 102, 1 x 103 and 1 x 104 cells were injected s.c., in the ventral region. A single BLI 
analysis was performed after 15 minutes. The choice of this less invasive and faster method 
of cell inoculation was essentially dictated by the necessity to detect bioluminescent emis-
sion immediately after cell implantation and by the fact that in this case spill of cancer cells 
into the soft tissue was less an issue since tumor growth was not followed up.
Bioluminescent reporter imaging (BLI)
An imaging system essentially equivalent to that described by Contag and co-workers 18 
was used. The imaging unit consists of an intensified charge-coupled device (CCD)-cam-
era (VIM camera, model C2400-47, Hamamatsu Photonics, Hamamatsu, Japan) fitted to a 
light-tight chamber (Hamamatsu Photonics) and equipped with a 50 mm/f 1.2 Nikkor lens 
(Nikon, Küsnacht, Switzerland). The images are generated on an Argus-20 image proces-
sor (Hamamatsu Photonics) and transferred via SCSI using a software module (Openlab, 
Improvision, Coventry, UK) to a computer (Macintosh G4, Apple Computer, Cupertino, CA) 
and processed by an image analysis software (Openlab, Improvision, Coventry, UK).
 For the detection of luciferase expressing cells, mice were anaesthetized as described 
above, but using half the doses of each sedative. Thirty µl of a 250 mM aqueous solution of 
luciferin (D-Luciferin Na salt; Molecular Probes, Leiden, Netherlands) were injected i.p. 15 
minutes before beginning photon recording. Mice were placed in the light-tight chamber 
and a grey-scale image of the animal was first recorded with dimmed light. Photon emission 
was then integrated over a period of 5 minutes and recorded as pseudo-color images. For 
co-localization of the bioluminescent photon emission on the animal body, grey-scale and 
pseudo-color images were merged by using the Openlab imaging software.
Quantification of the bioluminescent signal
The bioluminescent signal was quantified by measuring the amount of highlighted pixels in 
the area shaped around each site of photon emission with the aid of the Openlab imaging 
software.
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Detection of bone lesions by radiography
Radiographs of the mice, anaesthetized as described above for the BLI analysis, were taken 
using X-Omat TL films (Kodak, Lausanne, Switzerland).
Immunohistochemistry
The mice injected i.c. MDA-231-B/Luc+ cells were perfused, after sacrifice, with 60 ml of 
HBSS containing 20U heparin/ml and, then, with 100 ml of 4% paraformaldehyde in Dul-
becco’s PBS, pH 7.4. Bones that were shown by BLI to be site of bioluminescent emission 
were selectively excised and further fixed overnight by immersion in fixative at 4°C. After 
decalcification in EDTA they were processed for paraffin embedding.
 Five µm serial sections, after re-hydration and endogenous peroxidase block, were 
digested for 20 minutes at 37°C with trypsin (0.1% in 25mM Tris, 140 mM NaCl and 10mM 
CaCl2) for antigen retrieval. Rabbit antibodies (10 µg/ml) against human pan-cytokera-
tin (Dako, Zug, Switzerland) or control normal rabbit IgG (Jackson ImmunoResearch, La 
Roche, Switzerland) were followed by biotinylated swine anti-rabbit Ig antibodies (Dako) 
and streptavidin-biotinylated peroxidase complex (Amersham, Dubendorf, Switzerland). 
The reaction was developed with 3- amino-9-ethyl-carbazole as chromogen. Sections were 
slightly counter-stained with hematoxylin. Size measurements of metastatic lesions were 
performed with the aid of an image analysis software (NIH Image; http://rsb.info.nih.gov/
nih-image).
Results
Monitoring in vivo development of metastases after intracardiac and intra-venous injection of cancer 
cells
In general, within 2 hours from the intracardiac injection of MDA-231-B/Luc+ cells 14 % of 
the mice died or showed signs of distress, for which they were subjected to euthanasia. The 
surviving mice all developed bone metastases, as detected by BLI. In contrast, none of the 
mice (n = 4) injected intra-venously showed either bone or soft tissue metastases during the 
entire period of observation (4 weeks), as detected both by BLI and radiography.
 Ten minutes after i.c. injection of MDA-231-B/Luc+ cells, BLI showed diffuse photon 
accumulation over the entire animal body, with exclusion of the distal fore- and hind-legs, 
and of the tail (Fig. 1A). Twenty-four hours later photon emission from the same animal was 
abolished (Fig. 1B). However, after 4 weeks BLI could detect distinct areas of photon accu-
mulation, suggestive of metastatic tumor growth, over the hind-legs and over the maxillo-
facial region of the same animal (Fig. 1C).
 First evidence of bioluminescent emission from bones, indicative of bone metastasis, 
was seen at day 24 after i.c. injection of cancer cells. In all mice (n = 4) discrete photon accu-
mulation was localized over the distal metaphyses of the femurs (Fig. 2A-D) and over the 








Figure 1 Fate of MDA-231-B/Luc+ cells injected into the left cardiac ventricle. Bioluminescent photon emission 
was externally imaged from the ventral projection of the same mouse 10 minutes (A), 24 hours (B) and 
28 days (C) after injection. Signals are displayed as pseudo-color image (blue least intense, white most 






Figure 2 BLI monitoring in vivo the kinetics of bone metastatic growth. Bioluminescent photon emission was 
externally imaged 24 days after injection of MDA-231-B/Luc+ cells into the left cardiac ventricle. A-D, 
ventral projections of four different mice. Signals are displayed as pseudo-color image at the most 
sensitive 0-3 bit range.
Jeroen_Buijs_18.indd   98 26-11-2008   10:18:23




Figure 3 BLI monitoring in vivo the kinetics of bone metastatic growth. Bioluminescent photon emission was 
externally imaged 33 days after injection of MDA-231-B/Luc+cells into the left cardiac ventricle. Ventral 
(A, C, E) and dorsal (B, D, F) projections of the three mice shown in panels B, C, and D, respectively, of 
figure 2. Signals are displayed as pseudo-color image at a 0-5 bit range, less sensitive than that of figure 
2, to optimize the anatomical localization.








dorsal projection of the thoracic vertebrae (not shown). In one mouse photons accumulated 
also over the proximal metaphysis of the tibia (Fig. 2B). Whole body radiographs taken at day 
25 did not show any sign of osteolysis in any of the bones and, more specifically, in any of the 
bone locations that were origin of photon emission recorded the previous day (not shown).
 The intensity of photon emission at the bone sites described above increased substan-
tially from day 24 to day 33. Furthermore, at day 33, additional bone sites of bioluminescence 
became apparent (Fig. 3A-F). At this time point, the average number of bone metastasis/
mouse attained to 6.33 (± 1.45, SEM). However, whole body radiographs taken at the same 
day showed bone lesions only in 1/3 of the bone sites revealed by photon detection (total 
19 versus 6 bone sites, as detected by BLI and radiography, respectively; n mice = 3) (not 
shown). One animal survived until day 38 after i.c. injection of cancer cells. In this mouse 
an additional bioluminescent site appeared in the region of the sacral vertebrae (Fig. 4B). 
Meanwhile, the signal intensity over all the other bone sites further increased (Fig. 4A-C), as 
compared to day 33. However, the radiographic analysis of the bone lesions at day 38 did not 
reveal a modification in their number (Fig. 4D), as compared to day 33. In all cases the bone 
lesions were characterized by subtle modifications of the metaphyseal spongiosa due to 
increased bone remodeling and/or limited areas of osteolysis (Fig. 4E,F). At any time point, 
none of the animals of this series did show photon emission at extra-skeletal locations.
 The quantification of the bioluminescent signal localized over the different bone meta-
static sites from the time of their first appearance to the time of animal sacrifice (Fig. 4G) 
allowed continuous monitoring in vivo of the growth kinetics for each single bone lesion.
 Immunohistochemical analysis for human pan-cytokeratin expression confirmed the 
presence of cancer cells in all the bones that were shown by BLI to be site of biolumines-
cent emission. One bone metastatic growth was identified both by BLI and radiography as 
located in the proximal metaphysis of the humerus (Fig. 4A,D). The histological and immu-
nohistological analyses showed that cancer cells have extensively invaded the proximal 
half of the bone marrow cavity of this bone (Fig. 5A,C). In contrast, small bone metastases 
were apparently located by BLI on the distal region of both tibiae (Fig. 3D,F and Fig. 4A-C), 
but their presence was not corroborated by radiological signs of increased bone turnover 
located in the same or in neighboring bones. However, the histological and immunohisto-
chemical analysis of the bones in this region revealed that a single metastatic focus was 
located in the epiphysis of each calcaneus bone (Fig. 5B,D).
 MDA-231-B/Luc+ cells were i.c. injected in another series of mice (n = 12) to further inves-
tigate the potential of this specific bone-seeking clone to metastasize to organs other than 
bone and to demonstrate the ability of BLI to detect development of soft tissue metastasis. 
Bone metastases developed in 100% of the mice (12/12; average number of bone metas-
tases/mouse: 5.33 ± 0.78 SEM). Soft tissue metastases were detected by BLI in 33 % of 
the mice (4/12; average number of soft tissue metastases/mouse: 0.33 ± 0.14 SEM). Lung 
and brain were the organs affected by the metastatic process in 25% (3/12) and 8% (1/12), 
respectively, of the mice injected.
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Figure 4 BLI and radiographic monitoring in vivo the kinetics of bone metastatic growth. Bioluminescent photon 
emission was externally imaged 38 days after injection of MDA-231-B/Luc+ cells into the left cardiac 
ventricle. Ventral (A), dorsal (B), and  lateral (C) projections of the mouse shown in panels E and F of figure 
3. Signals are displayed as pseudo-color image at a 0-6 bit range, less sensitive than that of figure 4, to 
optimize anatomical localization. D, whole body radiograph. R = right side, and L = left side of the mouse. 
The two regions delimited by the rectangular frames (E) on the proximal humerus and (F) on the distal 
femur are magnified in (E) and (F), respectively, showing details of the bone density. Arrowheads point at 
osteosclerotic rims delineating areas of discrete osteolysis. G, growth curve obtained by quantification 
in the same mouse of the bioluminescent signal localized over the left femur(¢) at day 24, as shown in 
figure 2, D, and over the central portion of the spine () and the distal regions of the right (®) and left (¦) 




































Figure 5 Histological and immunohistological identification of MDA-231-B/Luc+ cells in two representative 
sites of metastasis. Hematoxylin-eosin staining of sections from the left humerus (A) and the left 
calcaneus (B). Cytokeratin immunohistochemistry of adjacent sections from the same humerus (C) 
and calcaneus (D). Cells immuno-reactive with the anti-human pan-cytokeratin antibody are stained in 
brownish-red.  Bars represent 100 µm.
 During the entire experimental period in both series of i.c. inoculated mice none of the 
bone metastases detected by BLI showed a decline in bioluminescent activity. Furthermore, 
conventional radiography never detected an osteolytic lesion not showing bioluminescent 
emission.
Monitoring in vivo tumor growth after intraosseous implantation of cancer cells
Soon after implantation of 1x104 MDA-231-B/Luc+ cells into the tibia marrow cavity, no bio-
luminescent emission could be detected externally. However, already after 4 days there was 
a defined, although weak, photon emission localized over the area of implant. The signal on 
the same area increased progressively and became intense from day 14 (Fig. 6A). Neverthe-
less, radiographs taken at equivalent time points (Fig. 6B) showed initial signs of osteolysis 
only at day 14. The osteolysis in the trabecular bone became clearly evident at day 25, and 
substantial erosion of the cortical bone was obvious at day 36.
 The quantification at different time points of the bioluminescent signal localized over the 
site of implantation (Fig. 6C) allowed continuous monitoring in vivo of tumor growth.
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Determination of the lowest cell number detectable in bone by BLI
Soon after direct inoculation of MDA-231-B/Luc+ cells into the marrow cavity of the femur, 
BLI could detect a signal from a number of cells as low as 2 x 104. However, 1 x 104 and 0.1 
x 104 cells could be detected if injected i.m. and s.c., respectively (not shown). Similarly, 
microscopic foci of spontaneous bone metastasis could easily be detected. In the specific 
case shown in figure 5 (B and D) the three major diameters of the metastatic lesion and the 
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Figure 6 BLI and radiographic monitoring in vivo the growth kinetics of 2 x 104 MDA-231-B/Luc+ cells implanted 
in the marrow cavity of the right tibia. A, bioluminescent photon emission was recorded immediately 
(day 0) and at various time points in the 5 weeks following implantation. Signals are displayed as 
pseudo-color image at the most sensitive 0-3 bit range. Arrow at day 4, 7 and 11 highlights the initial 
photon accumulation over the area of implantation. B, radiographs of the corresponding tibia starting 
from day 14. Small arrow at day 14 and 18 points at the cortical hole that results from surgical drilling. 
Arrowheads at day 18 highlight the initial area of osteolysis. C, Growth curve obtained by quantification 
of the bioluminescent signal over the area of implantation during the 5-week recording period.








density of the cancer cells were determined in serial sections comprehensive of the entire 
extension of the metastatic lesion. Assuming an ellipsoid shape, the total volume of the 
metastatic lesion resulted of ≈ 0.5 mm3 volume and the total number of cells contained in it 
was calculated as ≈ 1.7 x 104.
Discussion
This investigation shows for the first time that the i.c. injection of MDA-231-B/Luc+ cancer 
cells combined to BLI is an ideal model for minimal residual disease (MRD), due to the 
remarkable sensitivity of the optical imaging in detecting microscopic bone marrow metas-
tases in vivo.
 The fate of the MDA-231-B/Luc+ cells could already be monitored by BLI immediately 
following intracardiac injection. The diffuse photon signal imaged over the entire animal 
body 10 minutes after injection was likely to be emitted by cancer cells not yet extravasated, 
and the areas of denser emission reflected presumably organs with the highest blood flow. 
The absence of signal 24 hours later conforms to the already reported rapid clearance and 
elimination of the majority of i.c. injected cancer cells 23. Consistently with the elective bone 
/bone marrow tropism of the parental clone MDA-231-B, the same animal developed exclu-
sively bone metastases within 4 weeks from i.c. injection of MDA-231-B/Luc+ cells. These 
findings further support the concept that organ specificity of metastases is not due to dif-
ferences in blood perfusion, but largely depends on local interactions between cancer cells 
and the organ specific microenvironment 24.
 All mice i.c. inoculated with the MDA-231-B sub-clone showed bone metastases, while 
only 1/4 of them showed soft tissue metastases, as detected by BLI. Thus the MDA-231-B 
possesses a higher bone-seeking capacity than the parental MDA-231 cell line, shown 
to induce bone metastases with lower incidence, but with a two-fold higher potential to 
metastasize to soft tissues 20. This modified profile of organ distribution of metastases 
resembles very closely that already reported for another MDA-231 subclone similarly 
derived from a bone metastasis 25. In contrast, none of the animals injected intravenously 
with the MDA-231-B sub-clone did develop either bone or soft tissue metastases. This seems 
to indicate that the cells are completely cleared by the lung already during the first passage 
through its circulation, further supporting the rationale for the intracardiac inoculation, as 
stated in the original description of the method 11. The absence of metastatic growth in the 
lung after i.v. injection and the remarkable potential to metastasize to bone marrow after i.c. 
inoculation may suggest that the MDA-231-B sub-clone has acquired a growth advantage 
specific for the bone marrow microenvironment. Bone metastases induced by parental 
MDA-231 cells, when compared to brain and lung metastases, show increased expression 
of parathyroid hormone-related protein (PTH-rP) 20,25, macrophage colony stimulating 
factor (M-CSF) and vascular endothelial growth factor (VEGF) –A, -B and –C 20. All these are 
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bone-resorbing or angiogenic cytokines and they may represent the molecular basis for the 
enhanced osteotropism of bone-seeking clones derived from cancer cell lines 20,25,26.
 When compared to the conventional radiographic detection of osteolytic and/or osteoscle-
rotic lesions, BLI offers the important advantage of detecting tumor growth in the marrow 
cavity much before development of radiologically evident osteolytic and/or osteosclerotic 
lesions. The early detection is explained by the fact that BLI detects directly tumor burden 
long before it reaches a critical size able to induce modifications of the local bone remod-
eling relevant enough to be recognized by radiography. As a consequence, the number of 
metastatic sites detected by BLI largely exceeds those identified by conventional radiog-
raphy. It derives a gain in statistical significance and a reduction in the number of animals 
needed for each experimental group.
 Radiography could not detect in any of the animals an osteolytic lesion that did not show 
also bioluminescent activity. Furthermore, a decline of bioluminescent activity of already 
developed metastases was never observed. Taken together, these observations indicate 
that luciferase expression in vivo, under non-selective conditions, was stable over the entire 
experimental period.
 BLI could easily image in vivo a bone metastatic lesion that at the end-point histological 
analysis resulted in a tumor of ≈0.5 mm3 volume, corresponding to ≈1.7x104 cells. A similar 
number of cells could be detected when inoculated directly into the bone marrow cavity. 
Considering that during the time elapsed between first detection (day 33 after i.c injection 
of cancer cells) and analysis ex vivo (day 38) the spontaneous metastatic lesion has grown, it 
is likely that BLI can detect bone metastatic growth of even smaller size. Nevertheless, BLI 
could detect a discrete signal from 1x 104 and 0.1x 104 cancer cells implanted i.m and s.c., 
respectively, clearly indicating that intensity of the signal detected by BLI is a function of 
the tissue composition and depth of the bioluminescent source. This is possibly due to light 
scattering and quenching by tissue components such as hemoglobin16,27.
 Polymerase chain reaction- (PCR-) based methods also allow sensitive detection and 
quantification of cancer cell burden in bone/bone marrow 20,28,29. However, being methods 
ex vivo, they have severe limitations. First, in temporal studies several animal groups need 
to be sacrificed at different time points. Second, the bone sample is randomly selected 
and its size necessarily small and inevitably subject to sampling bias. Thus, large numbers 
of animals per group are needed to reach statistical significance. Third, these methods 
require disruption of the tissue samples. This precludes the possibility to perform parallel 
histology-based and gene expression analyses on the same bone sample. In contrast, BLI 
allows detailed anatomical information, continuous monitoring and precise quantification of 
bone metastatic growth in vivo, consistent reduction in the number of experimental animals 
and opportunity to perform end-point histological, immunohistological and gene expression 
analyses guided to the bone(s) specifically affected by metastatic disease.








 A similar method of whole body reporter gene imaging able to visualize in vivo experimental 
metastases to bone and soft tissues has been reported 17. This method utilizes GFP, instead 
of luciferase, as reporter gene. A possible concern regarding the use of GFP as reporter gene 
in whole body imaging is the auto-fluorescence generated in animal tissues by external light 
excitation 16,17. This background fluorescence may decrease the sensitivity of detection and, 
thus, delay early identification of bone metastatic foci. The GFP-based whole body imaging 
could visualize a bone metastatic lesion of about 0.96 mm in diameter at best 17. At this tumor 
size the cancer cells may have already induced osteolytic and/or osteosclerotic lesions suf-
ficient to be recognized by radiography. However, the sensitivity of GFP-reporter external 
imaging was not compared to radiography, and no histological proof of the presence and his-
tomorphometric measurement of the size of the bone metastases were given 17.
 All carcinomas, both primary and secondary, when they reach the size of 2-3 mm3 depend 
on angiogenesis for further growth 14,15. The ability of BLI to detect externally bone meta-
static foci of even smaller size is extremely relevant in view of the necessity to investigate 
the pre- and peri-angiogenic phases of metastatic growth.
 The model of i.c. injection of Luc-transfected cancer cells coupled to BLI detection and 
continuous monitoring in vivo of bone metastases will facilitate studies on the molecular 
mechanisms involved in early stages of metastatic disease (MRD) and the development of 
innovative therapeutic strategies.
Acknowledgments
We thank the Department of Clinical Research, University of Bern for the financial and logis-
tic support. This work was supported by grants from the Swiss National Science Foundation 
Program 37 “Somatic Gene Therapy” (grant 4037-044804), Swiss National Science Founda-
tion (grant 32-57118.99), CaPCURE, and “Stiftung zur Krebsbekämpfung”.
References
1. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993; 43:7-26.
2. Jaffe HL. Tumors metastatic to the skeleton. Tumors and tumorous conditions of the bone and 
joints. Edited by Jaffe HL. Philadelphia, Lea and Febiger, 1968, pp. 589-618.
3. Drew M, Dickinson RB. Osseous complications of malignancy. Clinical cancer medicine, 
treatment tactics. Edited by Lokich J. Boston, Hall, 1980, pp. 97-124.
4. Thalmann G, Anezinis P, Devoll R, Farach-Carson C, Chung LWK. Experimental approaches to 
skeletal metastasis of human prostate cancer. Principles and practices of genitourinary 
oncology. Edited by Raghavan D, Scher HI, Leibel SA, Lange PH. Philadelphia, Lippincott-
Raven, 1997, pp 409-16.
5. Willis RA. The spread of tumors in the human body. London, Butterworth, 1973, pp. 229-250.
6. Braun S, Pantel K. Micrometastatic bone marrow involvement: detection and prognostic 
significance. Med Oncol 1999; 16:154-65.
7. McDonnell CO, Hill ADK, McNamara DA, Walsh TN, Bouchier-Hayes DJ. Tumor 
micrometastases: the influence of angiogenesis. Eur J Surg Oncol 2000; 26:105-15.
Jeroen_Buijs_18.indd   106 26-11-2008   10:18:29
 Mouse model of minimal residual disease 107
8. Hirsch-Ginsberg C: Detection of minimal residual disease: relevance for diagnosis and 
treatment of human malignancies. Annu Rev Med 1998; 49:111-122.
9. Kostler WJ, Brodowicz T, Hejna M, Wiltschke C, Zielinski CC. Detection of minimal residual 
disease in patients with cancer: a review of techniques, clinical implications, and emerging 
therapeutic consequences. Cancer Detect Prev 2000; 24:376-403.
10. Klein CA. The biology and analysis of single disseminated tumour cells. Trends Cell Biol 2000; 
10:489-93.
11. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and 
bone marrow. Cancer Res 1988; 48:6876-81.
12. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone disease in breast cancer. Breast Cancer Res 
Treat 1994; 32:73-84.
13. Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. 
J Orthop Sci 2000, 5:75-81.
14. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during 
tumorigenesis. Cell 1996, 86:353-364.
15. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257.
16. Contag CH, Jenkins D, Contag PR, Negrin RS. Use of reporter genes for optical measurements 
of neoplastic disease in vivo. Neoplasia 2000; 2:41-2.
17. Yang M, Baranov E, Jiang P, Sun FX, Li XM, Li L et al. Whole-body optical imaging of green 
fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci USA 2000; 97:1206-
11.
18. Edinger M, Sweeny TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH. Noninvasive assessment 
of tumor cell proliferation in animal models. Neoplasia 1999; 1:303-310.
19. Cailleau R, Yong R. Olive M, Reeves WJ. Breast tumor cell lines from pleural effusions. J Natl 
Cancer Inst 1974; 53:661-74.
20. van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos SE, Löwik CWGM. 
Monitoring metastatic behavior of human tumor cells in mice with species-specific 
polymerase chain reaction: elevated expression of angiogenesis and bone resorption 
stimulators by breast cancer in bone metastases. J Bone Miner Res 2001; 16:1077-91.
21. Nordeen SK. Luciferase reporter gene vectors for analysis of promoters and enhancers. 
Biotechniques 1988; 6:454-58.
22. Wang CW, Chang YW. A model for osseous metastasis of human breast cancer established by 
intrafemur injection of MDA-MB-435 cells in nude mice. Anticancer Res 1997; 17:2471-74.
23. Basse P, Hokland P, Heron I, Hokland M. Fate of tumor cells injected into the left ventricle of 
heart in Balb/c mice: role of natural killer cells. J Natl Cancer Inst 1988; 80:657-65.
24. Fidler IJ. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother 
Pharmacol 1999, 43:S3-S10.
25. Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R: A bone-seeking clone exhibits 
different biological properties from the MDA-MB-231 parental human breast cancer cells 
and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001; 16:1486-95.
26. Koeneman KS, Yeung F, Chung LWK. Osteomimetic properties of prostate cancer cells: a 
hypothesis supporting the predilection of prostate cancer metastasis and growth in the 
bone environment. Prostate 1999; 39:246-61.
27. Colin M. Haemoglobin interferes with the ex vivo luciferase luminescence assay: consequence 
for detection of luciferase reporter gene expression in vivo. Gene Ther 2000; 7:1333-6.
28. Negrin RS, Blume KG. The use of the polymerase chain reaction for the detection of minimal 
residual disease. Blood 1991; 78: 255-8.
29. Sung V, Cattell DA, Bueno JM, Murray A, Zwiebel JA, Aaron AD, Thompson EW. Human breast 
cancer cell metastasis to long bone and soft organs of nude mice: a quantitative assay. Clin 
Exp Metastasis 1997; 15: 173-83.
Jeroen_Buijs_18.indd   107 26-11-2008   10:18:29
Jeroen_Buijs_18.indd   108 26-11-2008   10:18:29
Chapter 4
Interference with the Microenvironment Support Impairs the 
De Novo Formation of Bone Metastasis In Vivo
Cancer Res 2005; 65:7682-90.
Gabri van der Pluijm1 
Ivo Que1 
Bianca Sijmons1 
Jeroen T Buijs1 
Clemens WGM Löwik1 
Antoinette Wetterwald2 
George N Thalmann2 
Socrates E Papapoulos1 
Marco G Cecchini2
1Department of Endocrinology, 
Leiden University Medical Center, 
Leiden, The Netherlands; 













Interference with the microenvironmental growth support is an attractive therapeutic 
strategy for repressing metastatic tumor growth. Bone is a highly dynamic tissue that is 
continuously remodelled by bone resorption and subsequent bone formation. Growth fac-
tors supporting bone metastatic growth are released especially during bone resorption. 
Differently from most of the other tissues, drugs that can limit local turnover, namely 
bisphosphonates (BPs), are available for bone. Thus, we investigated whether pharmaco-
logical interference with bone turnover could repress development and growth progression 
of experimental bone metastasis. Whole body bioluminescent imaging (BLI) was adopted 
as a validated and reliable method for sensitive detection, monitoring and quantification in 
vivo of the growth progression of bone metastases induced by intracardiac or intraosseous 
injection of luciferase-transfected breast cancer cells (MDA-231-B/Luc+). Preventive BP-
induced reduction of bone turnover, prior to bone colonization by cancer cells, inhibited by a 
great extent the number of developing bone metastases. Nevertheless, tumor growth in the 
few, but still developing bone metastases, was affected only transiently. Reduction of bone 
turnover was also unable to control growth progression of bone metastases, either induced 
by hematogenous spreading or by intraosseous inoculation, which were already established 
when BP-treatment was initiated. This, despite a substantial anti-osteolytic effect induced 
by BPs. Therefore, bone metastatic cancer cells, after an initial growth phase dependent on 
the interaction with the local stroma, become independent on microenvironmental growth 
factor support and progress autonomously. Inhibition of bone turnover may represent a 
useful adjuvant therapy for cancer patients at risk to develop bone metastasis.
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Introduction
Micrometastases, persisting in various tissues of cancer patients after removal of the pri-
mary tumor, represent the pathophysiological basis for cancer relapse as overt metastases. 
Preferential colonization of certain tissues by cancer cells and their subsequent growth are 
determined by interaction with the tissue-specific microenvironment (Seed & Soil theory) 1,2. 
Therefore, pharmacological interference with the microenvironmental growth support, is 
becoming an attractive therapeutic strategy for repressing metastatic tumor growth 3.
 Bone metastases are common in cancer, especially breast and prostate carcinoma. They 
cause considerable morbidity characterized by severe bone pain and high incidence of skel-
etal, neurological and hematopoietic complications (hypercalcemia, fracture, spinal cord 
compression and bone marrow aplasia 4-9. Evidence from animal studies supports the con-
cept that the rate of bone turnover is directly related to the occurrence and progression of 
bone metastases 10-13. Recently, this view has been further substantiated by a clinical study, 
showing a strong and highly significant association between the rate of bone resorption and 
incidence of subsequent skeletal complications in breast and prostate cancer patients 14,15.
 The skeleton is a highly dynamic tissue that is continuously renewed through the proc-
ess of bone remodelling. This occurs at multiple sites in the skeleton by temporary struc-
tures called ‘basic multicellular units’ (BMU) 16,17. The result is the replacement of old bone 
with new bone, thus maintaining the structural integrity and the mechanical competence 
of the skeleton throughout adult life. The number and the activity of these BMUs deter-
mine the rate of bone turnover 18. During bone remodelling osteoblasts and osteoclasts, 
the cellular components of the BMU, secrete paracrine factors that induce chemotaxis and 
cell adhesion, support cell survival and growth, and stimulate angiogenesis 19,20. Further-
more, there is experimental evidence showing that growth factors like transforming growth 
factor-β (TGF-β)are released from the bone matrix and stimulate the secretion of bone 
active cytokines, which not only enhance bone resorption, but also stimulate further tumor 
growth (‘vicious circle’) 19-25.
 Taken together the evidence above suggests that pharmacological suppression of bone 
turnover may not only protect skeletal integrity at the metastatic site and reduce the inci-
dence of skeletal complications, as has been shown with bisphoshonates (BPs), but may also 
interfere with the local growth support of cancer cells, thus preventing the development and 
progression of bone metastases. We tested this hypothesis by BP-induced inhibition of bone 
turnover in animal models of bone metastasis induced by luciferase-expressing human MDA-
MB-231 breast cancer cells. Metastatic tumor development and progression was monitored 
by whole body bioluminescent reporter imaging (BLI) as described earlier 26.
 BLI allows spatio-temporal and quantitative analyses of tumor growth and, due to its 
sensitivity, is ideally suited to evaluate the effectiveness of therapeutic approaches that 
target both early stages of metastatic development and advanced metastatic disease. BLI 








gives detailed information on localization and growth of minimal metastatic deposits in 
the bone marrow of experimental animals at a stage largely preceding tumor detection by 
other methods. Simultaneous assessment of bone destruction by morphometrical analyses 
(radiographs, histomorphometry) and of tumor burden (BLI) allows discrimination between 
bone sparing effects (inhibition of tumor-induced osteolysis) and interference with tumor 
progression (viability and growth). Evidence is presented that bone metastatic cancer cells, 
after an initial stage that is probably necessary to initiate a self-maintaining autocrine 
growth, become independent from the microenvironmental growth factor support and, 
thus, expand autonomously, independent of pharmacological reduction of bone turnover.
Materials and Methods
Cell line and culture conditions
MDA-MB-231 (MDA-231), an estrogen independent human breast cancer cell line, was 
obtained from the American Type Culture Collection (Rockville, MD, USA). A subclone induc-
ing invariably bone metastases after intracardiac inoculation (bone-seeking clone MDA-
231-B) has been established by 4 consecutive sequential cycles of intracardiac inoculation 
of MDA-MB-231 in vivo and subsequent expansion in vitro of the cell population recovered 
from the resulting bone metastases as described earlier 26. MDA-231-B cells were sta-
bly transfected with a CMV-promotor driven mammalian expression vector for luciferase, 
CMV-luc, and one clone with the highest expression of luciferase expression (MDA-231-B/
Luc+) was successfully used for in vivo optical imaging as described previously 26. MDA-
231-B/Luc+ cells were cultured in Dulbecco’s modified Eagle’s Medium (DMEM, Gibco-BRL, 
Breda, the Netherlands) containing 4.5 g of glucose/L and supplemented with 10 % fetal calf 
serum (Gibco-BRL, Breda, the Netherlands), and 800 µg/ml geneticyne/G418 (Gibco-BRL, 
Breda, the Netherlands). Cells were regularly certified free of mycoplasma contamination.
 All MDA-231-B/Luc+cell cultures were harvested at sub-confluence after being re-fed 
with fresh medium 24 hours before inoculation preparation. Cell suspensions of MDA-
231-B/Luc+(1 x 105 cells/100 µl PBS for intracardiac inoculation or 1 x 105 cells /10 µl PBS 
for intraosseous inoculation) were prepared as described previously 26-28.
Animals
Female nude (BALB/c nu/nu) mice were purchased from Charles River (L’Arbresle, France). 
They were housed in individual ventilated cages under sterile condition according to the 
Dutch guidelines for the care and use of laboratory animals (DEC). Sterile food and water 
were provided ad libitum. Mice were 6 weeks old when used for the intracardiac or intraos-
seous inoculation of cancer cells.
 For surgical and analytical procedures (intraosseous inoculation, whole body imaging 
and skeletal radiography) mice were anaesthesised by intraperitoneal injection of a 50 µl 
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1:1:1 mixture; Ketamine HCl (Stock solution of 100 mg/ml Nimatek; Vetimex Animal Health 
B.V., Bladel, The Netherlands.) + Xylazine (2 % Rompun, Bayer AG, Leverkusen, Germany) 
+ PBS (pH 6.8). Intracardiac inoculation of cancer cells was performed under Isofluorane 
anaesthesia (0.8 L/min, Isofluorane, Air Products, Waddinxveen, The Netherlands) using 
the Vapex3 system (VetTech Solutions Ltd, United Kingdom). At the end of the experimental 
period animals were sacrificed by cervical dislocation.
Induction of systemic metastates by intracardiac (i.c.) injection of MDA-231-B/Luc+cells
A single cell suspension of 1 x 105 MDA-231-B/Luc+cells /100 µl PBS was injected into the 
left cardiac ventricle (i.c.) according to the method originally described by Arguello and co-
workers 29 and modified for MDA-MB-231 cells by Sasaki and co-workers 30. The progres-
sion of the cancer cell growth was monitored weekly for by optical imaging as described 
previously 26. At the same time points, osteolytic bone metastases were monitored by radio-
graphs and analyzed as published earlier 26-28. After the experimental period, the animals 
were sacrificed, and selected long bones site of cancer metastasis dissected and processed 
for further histomorphometric and immunohistochemical analysis (see below).
Intraosseous inoculation (i.o.) of MDA-231-B/Luc+cells
A single cell suspension of MDA-231-B/Luc+cells was injected into the right tibiae as 
described previously 26-28. In brief, two holes, 4 to 5 mm apart and each with a diameter of ~ 
0.35 mm, were drilled through the bone cortex of the upper right tibia with the aid of a dental 
drill. Space in the bone marrow was created by flushing out the bone marrow from the prox-
imal end of the shaft. The upper hole was sealed by surgical wax and 1 x 105 MDA-231-B/
Luc+cells per 10 µl PBS were slowly inoculated via a 30-gauge needle through the lower 
hole. Finally the lower hole was sealed with surgical wax and the cutaneous wound was 
sutured. The progression of cancer cell growth was monitored weekly by optical imaging as 
described previously (see below). At the same time points, osteolytic bone metastases were 
monitored by radiographs and analyzed as described previously 26-28. After the experimen-
tal period the animals were sacrificed, the tibia site of intraosseous inoculation dissected 
and processed for further histomorphometrical and immunohistochemical analysis (see 
below).
Bioluminescent reporter imaging (BLI) and quantification of the bioluminescent signal
Whole body optical imaging of tumors induced by the luciferase-expressing human breast 
cancer cell line MDA-MB-231, inoculated either i.o. or i.c, was performed as described ear-
lier 26. After intra-peritoneal administration of 2 mg D-luciferin (Perbio Science Nederland 
B.V., Etten-Leur, The Netherlands), the animals were immediately transferred to a light-
tight chamber and reference gray-scale body-surface images were taken using a intensi-
fied charged-coupled device (CCD) camera (C2400-77AH-01, Hamamatsu Photonics K.K., 








Japan) fitted with a 25 mm/0.95 f (optical aperture) objective (Schneider Optik, Kreuznanch, 
Germany). Five minutes after administration of D-luciferin, photon emission was integrated 
for a period of 3 minutes and processed using an Argus 20 image processor and M4314 
image intensifier (Hamamatsu). Gray-scale images and bioluminescent images were super-
imposed using OpenLab software (Improvision, Coventry, UK). The relative light intensity 
was visualized by pseudocolors. Analyses for each metastatic site were performed after 
definition of the region of interest (= ROI, Openlab software) and quantified as described 
previously 26. Values are expressed as relative light units (RLU).
Radiographical Analyses
After intraosseous or intracardiac inoculation of MDA-231-B/Luc+breast cancer cells into 
6-week-old nude mice the formation of osteolytic lesions of the in the skeleton was assessed 
by radiography (Kodak X-OMAT TL film, Eastman Kodak Company, Rochester NY) using a 
Hewlett Packard X-ray system Faxitron 43805 as described previously 27,28. Osteolytic areas 
were measured using NIH-Image 1.62b7 software as described earlier 27,28.
Histomorphometry, Histochemistry and Immunohistochemistry
Dissected long bones were fixed in 4 % paraformaldehyde (pH 6.8), decalcified as described 
previously and processed for paraffin embedding 27,28. Longitudinal sections (5 µm) were cut 
through the sagittal plane of the tibiae containing tumors induced by the i.o. inoculation of 
MDA-231-B/Luc+cells. Sections were either submitted to Goldner staining or histochemical 
staining for tartrate resistant acid phospahtase (TRAcP) as described previously 27,28.
 Histomorphometric measurements of tumor burden were performed on central sections 
through the tumor (largest tumor area). Tumor growth in bone could be readily identified 
by cytokeratin staining alone or in combination with HE staining. Total tumor area, as an 
estimate of total tumor burden, was measured by image analysis using NIH-Image 1.62b7 
Image Analyses Software as described previously by us 27,28. Subsequently, a distinction was 
made between the total tumor burden and intra- and extraosseous tumor burden. For this 
the digital image of the total tumor area was subdivided into an area delimited by the bone 
cortex or, were this has been partially resorbed as a result of the tumor-induced osteoly-
sis, by a virtual line joining the remnants of the bone cortex, to define ‘intraosseous’ tumor 
growth. In addition, extraosseous tumor growth was defined as extramedullary growth of 
cancer cells (tumor cells growing surrounding the bone cortex or its remnants).
 Histomorphometric measurements of trabecular bone volumes were performed after 
Goldner staining on the same central sections as used for tumor burden measurements 
(see above). Trabecular bone volume (TBV) was estimated in the proximal tibia by measur-
ing the total area of trabecular structures in an area 0-2 mm distal to the capillary invasion 
front of the growth plate. TBV is expressed as percentage of the total area that was covered 
by trabeculae.
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Bisphosphonate treatment
Treatment protocols to establish the effects of olpadronate on the generation and progres-
sion of systemic bone metastases induced by i.c. injection of MDA-231-B/Luc+cells were 
performed according to the following two schemes (Fig. 1):
 Preventive protocol: effect of long-term BP treatment on ‘de novo’ generation and growth 
of systemic bone metastases (Fig. 1A). Beginning from two days prior to inoculation of MDA-
231-B/Luc+cells the mice were treated by daily s.c. injections with 1.6 µM olpadronate/kg/
day for the whole duration of the in vivo study (48 days). The generation and progression of 
bone metastases was monitored by BLI and radiography at day 7, 14, 21, 28, 33, 39 and 46. 
After 48 days of BP treatment (= day 46 from i.c. injection of cancer cells) the animals were 
sacrificed.
Olpadronate 
28 33 39 46 days 0 14 
Curative protocol
Intra - cardiac injection  
of MDA - 231 - B/luc+ cells 
Olpadronate 
Intra - cardiac injection  
of MDA - 231 - B/luc+ cells 
Preventive protocol
0 14 28 33 39 46 days- 2 
A
B
Figure 1 Preventive and curative protocols for bisphosphonate (BP) treatment in a heart injection model of 
bone metastasis. A, in the preventive protocol, 4-week-old female BALB/c nu/nu mice were treated 
with 1.6 µM/kg/day olpadronate for two days prior to inoculation of cancer cells. Subsequently 105 MDA-
231-B/Luc+cells were inoculated into the left cardiac ventricle and the animals were treated by daily 
s.c. injections with 1.6 µM/kg/d of olpadronate for the duration of the experiment. The formation of bone 
metastases (and quantification of individual metastasis) was monitored and quantified weekly by whole 
body bioluminescent reporter imaging (BLI). In the same animals, the formation of osteolytic lesions 
was followed by radiography. B, in the curative protocol, 105 MDA-231-B/Luc+cells were inoculated 
into the left cardiac of ventricle 4-week-old female BALB/c nu/nu. Animals were monitored weekly to 
assess the formation of distant metastases and osteolysis (BLI, radiography). Starting from 28 days after 
cancer cell inoculation, the animals were equally distributed into two experimental groups and they were 
given either 1.6 µM/kg/day olpadronate or vehicle. Subsequently the progression of bone metastasis 
was monitored by BLI and radiography at day 5, 11 and 18. After 18 days of BP treatment (= day 46 from 
intracardiac injection) the animals were sacrificed.








 Curative protocol: effect of short-term BP treatment on growth of established bone 
metastases (Fig. 1B). The presence of established bone metastases was verified by BLI and 
radiography. 28 days after i.c. injection of MDA-231-B/Luc+cells the animals were equally 
distributed into two experimental groups based on a comparable bone metastatic tumor 
burden/mouse, as detected by BLI. Subsequently, to one experimental group 1.6 µM/kg/day 
olpadronate was given, while to the other vehicle was administered (0.9% NaCl) for the fol-
lowing 18 days. The progression of bone metastasis was monitored by BLI and radiography 
at day 5, 11 and 18. After 18 days of BP treatment (= day 46 from i.c. inoculation of cancer 
cells) the animals were sacrificed.
 To investigate the effect of BP on tumor development and osteolysis subsequent to intra-
osseous inoculation of MDA-231-B/Luc+cells, beginning from day 3 after inoculation (day of 
inoculation = day 0) the animals were treated for a period of 40 days by daily subcutaneous 
(s.c.) injections of BP dissolved in 0.9 % NaCl (50 µl volume) at the following doses: 16 µM/
kg/d pamidronate, 1.6 µM/kg/d olpadronate. These doses were shown previously to com-
plete inhibit osteoclastic bone resorption in vivo (31, 32). After this treatment period the 
animals were sacrificed. Alternatively, in order to achieve constantly elevated blood levels 
of BP during the entire period of treatment, 16 µM/kg/day of olpadronate dissolved in 0.9 % 
NaCl, a dose of ten fold higher than the maximal resorption-inhibitory dose in vivo, was 
continuously infused by osmotic minipumps (200 µl, 0.25 µl/hr, model 2004; Alzet Scientific 
products, Alza Corporation, Mountain View, CA) over a period of 28 days, beginning from day 
0 after i.o. inoculation of MDA-231-B/Luc+cells. Osmotic minipumps filled with vehicle solu-
tion (0.9% NaCl in water) were implanted in a control group. The animals were sacrificed at 
the end of the treatment period.
BP effect on the expression of luciferase in MDA-231-B/Luc+cells
To exclude putative bisphosphonate effects on luciferase expression by MDA-231-B/
Luc+cells, the breast cancer cells were cultured in the continuous presence of bisphospho-
nates for up to 48 hours. Continuous treatment of MDA-231-B/Luc+cells with a dose range 
of bisphosphonates (10-4 – 10-8 M for 24 and 48 hours) did not affect functional expression 
of the luciferase gene in MDA-231-B/Luc+cells in vitro as measured in luciferase assays and 
semi-quantitative PCR (results not shown).
Statistical Analysis
All data are represented as mean ± s.e.m. for animal studies and mean ± SD for histo-
morphometrical analyses. Statistical evaluation was carried out by ANOVA or two-tailed 
Student’s t-test.
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Results
Effect of BP treatment on the ‘de novo’ generation and progression of systemic bone metastases 
(‘Preventive’ protocol).
In this experiment we investigated whether pharmacological inhibition of bone turnover 
prior to inoculation of cancer cells, and continued for the duration of the entire experi-
ment, could prevent the initiation and maintenance of a positive interaction between the 
bone microenvironment and cancer cells. For this purpose olpadronate was given two days 
prior to inoculation of MDA-231-B/Luc+cells into the left cardiac ventricle and continued 
throughout the entire duration of the experiment (48 days) (Fig. 1).
 Consistently with our previous findings 26 BLI showed that MDA-231-B/Luc+cells metas-
tasize exclusively to the skeleton. At the end of the experimental period (day 47) olpadronate 
treatment decreased significantly the number of bone metastases per animal, as detected 
by BLI, by about 70% (Fig. 2A). Radiographic analysis in the same animals showed, from 
day 40 onwards, almost no osteolytic bone lesions in BP-treated animals as compared to 
control (Fig. 2B).
 During the early experimental period olpadronate treatment significantly delayed the 
progression of the bone metastases, detected by BLI as total tumor burden per animal, 
(Fig. 2C, day 26-33), and tumor burden for each bone metastatic site (Fig. 2D, day 26-40). 
However, this effect was only transient and at later stages both the total burden per mouse 
(Fig. 2C, day 40-47) and the tumor burden per bone metastatic site (Fig. 2D, day 47) in the 
olpadronate treated animals became equivalent to those of the vehicle-treated animals.
Effect of BP treatment on growth of established bone metastases (‘Curative’ protocol).
In this experiment we investigated the effect of pharmacological inhibition of bone turnover 
on the bone microenvironmental growth support for cancer metastases that are already in 
an advanced stage of progression. For this purpose, daily s.c. administration of olpadronate 
(1.6 µM/kg/d for 18 days) was initiated when bone metastases had already developed (day 
28) following i.c. injection of MDA 231-B/Luc+ cells (Fig. 1B).
 As in the previous experiment MDA-231-B/Luc+cells metastasized exclusively to the 
skeleton. Olpadronate treatment did not affect the number of bone metastases detected by 
BLI (Fig. 3A), but significantly reduced at the end of treatment period (day 18) the number of 
osteolytic lesions per mouse as assessed by radiography (Fig. 3B). A discrepancy between 
BLI and radiography in the number of bone metastases detected in control and olpadronate 
treated animals can be noticed (Fig. 3A,B).
 Olpadronate treatment transiently affected (day 5), although not significantly, total tumor 
burden per animal, as detected by BLI (Fig. 3C). However, at later time points tumor growth 
was not further affected by olpadronate (Fig. 3C) and at the end of the experiment it even 
enhanced significantly tumor burden per bone metastatic lesion (Fig. 3C,D).








 As shown in a representative radiograph of an olpadronate treated animal (Fig. 4A), there 
is minimal osteolysis in the left proximal tibia and proximal humerus. However, the photon 
emission detected by BLI of the same bone areas (Fig. 4B) indicates that these bones are site 
of metastatic growth of MDA-231-B/Luc+cells. Due to the limited intraosseous space, most of 
this growth seems to have taken place in the soft tissues surrounding bone, as revealed on the 
radiograph by the tumor shadow present especially around the left humerus (Fig. 4).
Effect of BP-treatment on intraosseous growth of breast cancer cells.
To investigate in more detail the cellular events during inhibition of bone turnover, progression 
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Figure 2 Prevention of bone metastasis formation by the BP Olpadronate after inoculation of MDA-231-B/Luc+into 
the left cardiac ventricle of nude mice (‘Preventive protocol’). Olpadronate (or vehicle) was given two days 
prior to inoculation of MDA-231-B/Luc+cells into the left cardiac ventricle and continued for the duration of 
the experiment (1.6 µM/kg/d for 48 days). Distribution and growth of MDA-231-B/Luc+cells was monitored 
weekly by BLI and radiography. Under both experimental conditions, MDA-231-B/Luc+cells metastasize 
exclusively to the skeleton. A, number of bone metastases per mouse determined by BLI. B, number of bone 
metastases per mouse determined by radiographical analysis. C, Total tumor burden per mouse (BLI). D, 
tumor burden per bone metastatic lesion (BLI). BLI measurements (C and D) are expressed relative light units 
(RLU). Open bars and closed bars represent Vehicle-treated and olpadronate-treated animals respectively. 
Values are expressed as means ± s.e.m., n=8. * p ≤ 0.05, ** p ≤ 0.001.
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this purpose MDA-231-B/Luc+cells were inoculated directly into the tibiae of nude mice 26-28, 
which were then treated by daily s.c. injections with olpadronate or pamidronate.
 Continuous BP treatment did not significantly affect growth of the cancer cells as deter-
mined by BLI (Fig. 5A,C). As expected, both BPs strongly and significantly inhibited the 
development of radiologically evident osteolytic lesions (Fig. 5B,C). Histomorphometric 
analysis (Fig. 5D) confirmed that BPs inhibited cancer-induced bone destruction leading 
to a significant increase in trabecular bone area associated with a significant decrease in 
TRAcP+ resorbing osteoclasts at the bone surface (Table 1). As a consequence of this bone 
sparing effect of BP treatment, the intra-bone tumor burden was significantly decreased, 
although it was clear that the cancer cells were filling completely the bone marrow spaces 
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Figure 3 Effects of olpadronate treatment on existing bone metastases, induced by inoculation of MDA-231-B/
Luc+into the left cardiac ventricle of nude mice according to the ‘Curative protocol’ (see figure 1 B).
 Daily s.c. administration of olpadronate (1.6 µM/kg/d for 18 days), was initiated when bone metastases had 
already developed (day 28) following i.c. injection of MDA 231-B/luc+ cells. The fate and growth of MDA-231-B/
Luc+cells were monitored weekly by BLI and radiography. Under both experimental conditions, MDA-231-B/
Luc+cells metastasize exclusively to the skeleton. A, number of bone metastases per mouse determined by 
BLI. B, number of bone metastases per mouse determined by radiographical analysis. C, total tumor burden 
per mouse (BLI). D, tumor burden per bone metastatic lesion (BLI). BLI measurements (figures 2 C and D) are 
expressed relative light units (RLU). Open bars and closed bars represent Vehicle-treated and olpadronate-
treated animals respectively. Values are expressed as means ± s.e.m., n=8. * p ≤ 0.05.








(Fig. 5D). In contrast to the intraosseous tumor burden, no significant inhibition of the over-
all tumor burden (= intraosseous and in surrounding soft tissues) was observed (Fig. 5D), 
which is in line with the optical imaging data presented in figures 5A and C.
Table 1 Effects of bisphosphonate treatment on osteoclast numbers at the bone surface of MDA-231-B/Luc+breast 
cancer cells growing in tibiae of 6-week-old female nude mice.
 
No. osteoclast/mm bone surface, 
mean (SD)
P
Vehicle treated 22 (4) -
Pamidronate 1.6 μmol/kg/d 5 (1) < 0.01
Olpadronate 1.6 μmol/kg/d 4 (2) < 0.01
Note: n = 5 per experimental group. Ps represent bisphosphonate treated vs. vehicle treated animals.
 Previously it was found that the intensity of the signal detected by BLI is a function of 
the tissue composition and depth of the bioluminescent source 33,34. There is the possibility 
that changes in the tissue type invaded by the tumor growth and/or representation of bone 
ventral dorsal
Radiography                               Optical imaging             
R L
ventral
Figure 4 Representative radiograph and bioluminescent images of an olpadronate treated mouse according 
to the Curative protocol (18 days of treatment, day 46, see figure 3). Osteolysis is minimal in the 
left proximal tibia and proximal humerus (left panel, arrows). However, the photon emission spectra 
detected by BLI of the same bone areas (central and right panel) indicate that these bones are the site of 
metastatic growth of MDA-231-B/Luc+cells. Due to the limited intraosseous space, most of this growth 
seems to have taken place in the soft tissues surrounding bone, as revealed on the radiograph by the 
tumor shadow present especially around the left humerus.
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tissue, with consequent differences in light penetration and light scattering between the 
experimental groups (vehicle vs. BP), may have generated artifactual results in determin-
ing tumor burden by BLI. To exclude this, the treatment/control ratios of the tumor burden 
values obtained by BLI and histomorphometrical analyses were compared. No differences 
in ratios between these two measurement methods were found (0.98±0.16 and 1.17±0.22 
treatment/control ratios for pamidronate and olpadronate respectively). This correlation 
indicates that potential differences in quenching and/or light scattering by bone cannot 
account for the observed lack of in vivo growth inhibitory effects during BP treatment, and 
confirms the reliability of BLI as method to quantify tumor burden.
 Taken together, these results clearly show that BP, despite a significant decrease in 
intraosseous tumor burden due to their bone-sparing effect, do not affect tumor growth 
rate, but merely modify the direction of tumor growth. As a result cancer cells invade more 
conspicuously the soft tissues (muscle, tendon and connective tissue) surrounding the long 
bones.
 To ensure constant delivery of a dose of BP sufficient to inhibit the high bone turnover of 
rapidly growing animals in a further experiment, olpadronate was administered by osmotic 
mini-pumps. In line with the data obtained after s.c. administration with BP in the same intra-
osseous tumor model (Fig. 5A,C,D), continuous high dose olpadronate treatment did not affect 
the tumor growth as detected by BLI (Fig. 5E). As expected, continuous olpadronate treatment 
strongly and significantly inhibited tumor-induced osteolysis, as detected by radiography (Fig. 
5F). Histomorphometric analysis confirmed these effects of olpadronate by showing a signifi-
cantincrease in bone volume, a decrease in intra-bone tumor volume, and no significant effect 
on total tumor burden (Table 2).
Table 2 Histomorphometric analysis of TBV (%), intraosseous tumor volume (mm2), and total tumor volume (mm2) of 







TBV 3 (2) 13 (3) < 0.05
Intra-bone tumor burden 16 (4) 8 (1) < 0.05
Total tumor volume 39 (6) 25 (6) n.s.
Note: Olpadronate (or vehicle) was released at a high dose by osmotic mini-pumps (16 μmol/kg/d, 24 hours/d) for 28 days. n = 5, n.s. 
= not significant.
Discussion
Interference with the microenvironmental growth support is currently being evaluated as 
a therapeutic strategy for the treatment of metastatic disease. Bone metastasis is a para-
digm of the interactions that take place at the tumor-stroma interface 1,2 and evidence from 
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Figure 5 Effects of BP treatment on tumor growth of MDA-231-B/Luc+ breast cancer cells (BLI+histology) and 
osteolysis (radiography) in tibiae of 6-week-old female nude mice. MDA-231-B/Luc+cells were inoculated 
directly into the left tibia of nude mice, which were subsequently treated by daily s.c. injections with 1.6 µM/
kg/d olpadronate (closed triangles), 16 µM/kg/d pamidronate (open triangles) or vehicle (open circles). A, 
growth of breast cancer cells in the bone marrow cavity measured by BLI (RLU). B, development of osteolytic 
areas due to tumor-induced bone destruction as assessed radiographically (lytic area, mm2). C, representative 
animals of each experimental groups (BLI, radiography). D, histomorphometric analysis of intra-bone tumor 
burden, trabecular bone volumes and total tumor burden (= total of intra-bone + extramedullary tumor 
burden). E, continuous release of high dose of Olpadronate by osmotic mini-pumps (16 µM/kg/d, 24 hours/day) 
on intra bone tumor growth as detected by BLI. F, continuous release of high dose of Olpadronate by osmotic 
mini-pumps (16 µM/kg/d, 24 hours/day) on development of osteolytic lesions as assessed radiographically 
(mm2). Values are expressed as means ± s.d., n = 5, * p ≤ 0.05.
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animal and clinical studies support the notion that bone turnover, particularly bone resorp-
tion, contributes substantially to initiation and maintanance of local tumor growth through 
release of growth factors and bone resorbing cytokines (‘vicious cycle’). Differently from 
other tissues, bone turnover can be reduced by pharmacological means and, thus, animal 
models of bone metastasis offer the unique opportunity to test in vivo the therapeutic effi-
cacy of the interference with the tumor-stroma interface.
 In this study we investigated whether inhibition of bone turnover by BP administration 
could prevent the development of bone metastases and/or repress tumor growth in already 
developed bone metastases. Our results show unequivocally that inhibition of bone turno-
ver by BPs, prior to the establishment of a micrometastatic spreading induced by intrac-
ardiac inoculation of breast cancer cells (‘Preventive’ protocol), reduces by a great extent, 
although not completely, the development of bone metastases as detected by BLI. Although 
not significant, a tendency toward this effect is also present when BP are administered later, 
after the establishment of a micrometastatic spreading (‘Curative’ protocol), when some 
bone metastases had already been generated, but a residual number had still to develop. In 
this case, the limited entity of this residual number and, thus, the low statistical power, may 
explain the lack of significance.
 The dose of olpadronate given (1.6 µmol/kg body weight/day) has been shown previously 
to efficiently inhibit bone resorption in vivo 32, but in the present study, it did not prevent 
the formation of bone metastases by >70%. This level of inhibition is consistent with the 
observation that in the experimental animal not more than 70% of the bone resorption can 
be inhibited by high dose of BPs 35. Possibly, this persistently low level of bone resorption is 
sufficient to provide growth support to a minimal number of micrometastatic foci.
 Although preventive BP-inhibition of bone turnover precludes to a great extent the gen-
eration of bone metastases from experimentally-induced micrometastatic spread of breast 
cancer cells, the progression of tumor growth in the small number of still developing 
metastases, as detected by BLI, is significantly reduced only during early stages. A similar 
trend is also seen when BP are administered according to the ‘Curative protocol’ to mice 
with already developed bone metastases. However, at later stages, bone metastatic growth 
is even accelerated, leading to a significant increase of tumor burden per metastatic lesion 
in the ‘Curative protocol’ after 18 days of BP treatment. This result is in line with earlier 
observations by others demonstrating that BP treatment, despite preserving trabecular 
bone, does not inhibit bone metastatic growth, and may even increase skeletal tumor bur-
den 36. This suggests that bone metastatic growth, once it is initiated and reaches a critical 
mass, proceeds independently of the bone microenvironmental growth support and is self-
maintained by autocrine mechanisms.
 The lack of effect by interference with the microenvironmental support on growth pro-
gression of already developed bone metastases was corroborated in a further experiment 
in which bone tumors were induced by intraosseous inoculation of breast cancer cells. Also 
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in this case continuous inhibition of bone resorption, achieved by BP administered either 
s.c. or by sustained high dose release, did not affect tumor growth. Concomitant with BLI, 
radiographic and histomorphometric analysis could even better dissect the known BP 
bone sparing effect from an effect on tumor growth that may result either directly from 
these compounds or indirectly from the inhibition of bone turnover. In fact, histomorphom-
etry revealed that, although the tumor mass confined within the bone marrow cavity was 
decreased as effect of the reduced intra-medullary space made available by persisting 
bone trabeculae, the total tumor mass was compensated by growth of cancer cells forced 
to invade the soft tissues (muscle, tendon and connective tissue) surrounding the bone cor-
tex. Bone tissue may partially segregate the cancer cells within the medullary cavity and 
prevent them from invading the surrounding soft tissues. Instead, upon inhibition of bone 
resorption, the invasive growth is most likely forced to modify its direction from intra-med-
ullary to extramedullary. It is important to note that MDA-MB-231 breast cancer cells have 
been shown to be able to migrate from bone marrow to periosteal surfaces 26, probably 
through vascular channels thus providing an opening to the periosteum and bone surround-
ing tissues.
 Previous studies investigating the effect of BP-induced inhibition of bone resorption/
turnover on bone metastatic growth in comparable animal models have shown contradic-
tory results 30,36-40. BPs have been reported to reduce the tumor burden in established bone 
metastases, but not in soft tissue and visceral metastases. This effect seemed to be medi-
ated by induction of apoptosis in the cancer cells 30,37. Treatment with BP, given prior to the 
development of evident metastasis, resulted in a marked reduction of the number of bone 
metastases 30,38-40. However, in another preventive study it has been reported that BP treat-
ment resulted in an increased tumor burden in the developing bone metastases, but not in 
visceral metastases 38. In most of these investigations tumor burden has been quantified 
indirectly by measuring the osteolytic area on bone radiographs.
 The difference between BLI and radiography in the number of bone metastastic foci 
detected either in the BP- or in the vehicle-treated animals is consistent with our previous 
report 26 and corroborates further the higher sensitivity, reliability and statistical power of 
the BLI method. BLI provides a direct indication of tumor viability and growth, while radiog-
raphy does not detect actual tumor burden, but reveals only osteolysis, which is an indirect, 
late and inconsistent sign of the presence of a tumor 26. In fact, determination of the osteo-
lytic area depends not only on tumor cell mass, but also on the ability of the cancer cells to 
secrete bone-resorbing cytokines. Obviously, this consideration is especially true when bone 
resorption is pharmacologically inhibited. Furthermore, the determination of the osteolytic 
area does not take in account extension of the tumor burden in the surrounding soft tissues.
 From the considerations above it should be concluded that the determination of the 
osteolytic area is invalid as a measurement of bone tumor mass. Therefore, the results 
of previous studies, based exclusively on this method, should be reconsidered. Only histo-








morphometry could avoid the latter pitfall. However, when a parallel histomorphometric 
analysis was performed, only intraosseous tumor burden was measured. Only one study 
assessed this analysis to the neighboring tissues. In the latter paper, BP-induced inhibition 
of bone resorption restrained only intraosseous tumor growth, while increasing tumor bur-
den in the soft tissues 30. This effect is perfectly in line with the results presented here with 
both histomorphometry and BLI, a much more reliable and sensitive method for monitoring 
tumor burden in vivo.
 In vitro, BPs have been reported to exert direct anti-proliferative and pro-apoptotic effects 
on cancer cells 41-43, to interfere with cancer cell adhesion to bone matrix proteins 44,45, 
to inhibit matrix metalloproteinases 46,47, and to diminish cancer cell migration and inva-
sion 48,49. The results shown here exclude that BP may have a direct cytostatic effect in vivo.
 Collectively, the results obtained in this investigation substantiate the concept that inter-
ference with the bone microenvironmental growth support, namely through inhibition of 
bone resorption/turnover, may be of therapeutic relevance for inhibiting early developmen-
tal steps of bone metastasis. However, they seem to exclude that the same strategy could 
repress progression of overt bone metastases and, also, that BPs may exert an effect on 
cancer cell growth, either directly by induction of apoptosis or indirectly by inhibition of 
angiogenesis.
 How can the therapeutic effect of inhibition of bone resorption/turnover on early stages 
of bone metastasis development be explained? Bone remodelling does not occur through-
out the entire bone surface, but takes place at microscopic patches of bone resorption and 
subsequent bone formation, called basic multicellular units (BMUs). The number and the 
activity of these BMUs determine the rate of bone turnover. Osteoblasts and osteoclasts, the 
cellular components in an active BMU, secrete and/or release from bone matrix cytokines, 
like TGF-β and IGF-1, which physiologically modulate the biology of bone cells. However, they 
can also act as paracrine growth factors for neighboring cancer cells that may have colo-
nized bone marrow 19,22-25,28,50-55. Consequently, local growth factor release by an active BMU 
in close proximity of a bone marrow micrometastasis may evoke the growth and invasive 
potential of the cancer cells, ultimately leading to the development of a macrometastasis 
(Fig. 6). We hypothesize that the probability for a bone marrow micrometastasis of becom-
ing a clinically evident bone metastasis should be related to the chance that micrometa-
static cancer cells extravasate in the proximity of an active BMU. In contrast, cancer cells 
extravasating near to a non-remodelling, ‘resting’ bone surface will persist as ‘dormant’, 
and eventually become apoptotic. Accordingly, a higher number and density of active BMUs 
(high bone turnover rate) should favour the probability that bone marrow micrometastases 
‘home’ near active BMUs. This may explain the clinical and experimental evidence showing 
an association between high bone turnover rate and the preferential development of hema-
togenous metastases at sites of active bone remodelling 14,15. Conversely, a preventive inhi-
bition of bone turnover, e.g., by BP, prior to the generation of a self-maintaining, autocrine 
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Figure 6 Hypothesis regarding the importance of bone turnover rate and the therapeutic relevance for inhibiting 
early developmental steps of bone metastasis. Bone turnover takes place at microscopic patches of bone 
resorption and subsequent bone formation, called basic multicellular units (BMUs). The number and the 
activity of these BMUs determine the rate of bone turnover. Osteoblasts and osteoclasts, the cellular 
components of an active BMU, secrete cytokines from bone matrix, which can act as paracrine growth 
factors for neighboring cancer cells that may have colonized bone marrow (micrometastatic deposits). 
Consequently, local growth factor release by an active BMU in close proximity of a bone marrow 
micrometastasis may evoke the growth and invasive potential of the cancer cells, ultimately leading to 
the development of an overt bone metastases. Interference with the bone microenvironmental growth 
support through inhibition of bone resorption/turnover (for instance by BPs), may be of therapeutic 
relevance for inhibiting early developmental steps of bone metastasis. However, cancer cell growth of 
overt bone metastases during treatment with BPs is not affected. The probability of a bone marrow 
micrometastasis to become clinically evident bone metastasis may thus be related to the chance that 
micro-metastatic cancer cells extravasate in the proximity of an active BMU. In contrast, cancer cells 
extravasating near to a non-remodelling, ‘resting’ bone surface will persist as ‘dormant’, and eventually 
become apoptotic. Preventive inhibition of bone turnover, e.g., by BPs, prior the generation of a self-
maintaining, autocrine cancer cell growth, may arrest the ‘vicious cycle’ underlying the initial growth 
support by the BMU and, ultimately, frustrate the development of clinically evident macrometastasis.








cancer cell growth, may arrest the ‘vicious cycle’ underlying the initial growth support by 
the BMU and, ultimately, frustrate the development of clinically evident macrometastasis.
 Assessment of the bone turnover status may lead to a better identification and stratifica-
tion of the cancer patients at risk to develop bone metastases. Cancer patients, probably 
harboring micrometastasis in the bone marrow at the moment of diagnosis and/or surgery, 
but with high bone turnover rate, either basal (e.g., induced by menopause) or subsequent to 
surgical or chemical sex steroid deprivation, may benefit from a prophylactic, BP-induced 
reduction of the bone turnover rate.
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Breast cancer frequently metastasizes to bone, where tumor cells induce osteoclasts to 
locally destroy bone. During bone resorption, growth factors  are locally released that may 
support bone metastatic growth. Differently from most other tissues, drugs that can limit 
local turnover are available for bone. 
 We examined the hypothesis that inhibition of bone resorption by two different mecha-
nisms may also affect the growth of cancer cells in bone. For this, we have tested the effects 
of high doses of osteoprotegerin (OPG) and zoledronic acid (ZOL), the most potent bispho-
sphonate available, on progression of breast cancer cells in the bone microenvironment 
using whole body bioluminescent imaging (BLI).
 Both treatments significantly inhibited the development of radiographically detectable 
osteolytic lesions. Histological examination corroborated the radiographic findings, show-
ing that both treatments preserved the integrity of bone trabeculae and prevented bone 
destruction, (significantly higher trabecular bone volumes vs. vehicle). However, whereas 
practically no TRAcP-positive osteoclasts were observed in tibiae preparations of animals 
treated with Fc-OPG, TRAcP-positive osteoclasts were still present in the animals treated 
with ZOL. Intra-bone tumor burden was reduced upon ZOL and Fc-OPG treatment. Although 
there appeared to be a trend for less overall total tumor burden upon treatment with both 
compounds, this was not significant as assessed by BLI and histomorphometrical analysis 
due to the extramedullary growth of cancer cells which was not affected by these treat-
ments.
 Collectively, anti-resorptive agents with different mechanisms of actions — ZOL and 
FcOPG — significantly reduced cancer-induced osteolysis and intraosseous tumor burden, 
but failed to restrain local tumor growth. However, interference with the bone microenvi-
ronmental growth support could still be of therapeutic relevance when given to patients 
early in the course of bone metastatic disease.
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Introduction
Micrometastases persisting in various tissues of cancer patients after removal of the pri-
mary tumor represent the pathophysiological basis for cancer relapse as overt metasta-
ses. The survival of these cells and the development of metastases depend on the growth 
support provided by the microenvironment and the ability of cancer cells to adapt to this 
environment 1-3. Bone provides a favorable microenvironment for the survival and growth 
of certain common cancers, including breast cancer which metastasizes frequently to the 
skeleton and causes significant morbidity and deterioration of life 4-6.
 Studies in animal models of bone metastases strongly suggest that the rate of bone turn-
over enhances the occurrence and progression of metastases in the bone-bone marrow 
microenvironment 7-9. These findings are supported by clinical studies which showed a sig-
nificant association between the rate of bone resorption, assessed by biochemical markers of 
bone remodeling, and disease progression in the skeleton 10,11. It was, therefore, hypothesized 
that suppression of bone resorption by agents that inhibit the formation and/or activity of the 
osteoclasts may not only protect skeletal integrity in metastatic disease but may also affect 
local tumor growth.
 Previous studies of animal models with bone metastasis from breast cancer treated with 
bisphosphonates showed that reduction of bone turnover prior to bone colonization by can-
cer cells, could significantly reduce the number and progression of bone metastases 12-15. 
However, when bisphosphonates were given to animals with established bone metastases 
they did not consistently affect the growth potential of the breast cancer cells in the bone 
microenvironment, despite a substantial anti-osteolytic effect 12,13. There are several poten-
tial explanations for these findings: tumor growth response is related to the magnitude of 
suppression of bone resorption and, hence, the potency, and/or the dose (dosing regimen) 
of the bisphosphonates given; the fundamental mechanism of inhibition of bone resorption 
by the bisphosphonates; the initial growth phase of cancer cells in bone is dependent upon 
the interaction with the bone microenvironment, but eventually becomes independent of the 
bone microenvironent and can progress autonomously 13,50. To address these questions we 
assessed the effects of very high doses of the most potent bisphosphonate currently avail-
able, zoledronic acid (ZOL), and we compared these to the effects of osteoprotegerin (Fc-
OPG), that inhibits bone resorption by a different mechanism of action, in an experimental 
model of intra-tibial injection of human breast cancer cells.
MATERIALS & METHODS
Cell lines and culture conditions
The luciferase expressing bone-seeking clone MDA-MB-231 (MDA-231)-B/Luc+ was cul-
tured as previously described 16,17. Cell suspensions of MDA-231-B/Luc+(1.0 x 105 cells /10 µl 
PBS) were prepared for intraosseous injection as described previously 13,17.









Female nude (BALB/c nu/nu) mice were purchased from Charles River (L’Arbresle, France) 
and were used for the studies with human MDA-231-B/Luc+breast cancer cells.
 Mice were housed in individual ventilated cages under sterile condition. Sterile food and 
water were provided ad libitum. Mice were 6 weeks old when used for intraosseous inocula-
tion of cancer cells. Animal experiments were approved by the local committee for animal 
health, ethics and research of Leiden University and carried out in accordance with Euro-
pean Communities Council Directive 86/609/EEC.
 For surgical and analytical procedures (intraosseous inoculation, BLI, radiography) mice 
were anesthetized by intraperitoneal injection of a 50 µl 1:1:1 mixture; Ketamine HCl (Stock 
solution of 100 mg/ml Nimatek; Vetimex Animal Health B.V., Bladel, The Netherlands) + 
Xylazine (2 % Rompun, Bayer AG, Leverkusen, Germany) + PBS (pH 6.8). Intracardiac inocu-
lation of cancer cells was performed under Isofluorane anesthesia (0.8 L/min, Isofluorane, 
Air Products, Waddinxveen, The Netherlands) using the Vapex3 system (VetTech Solutions 
Ltd, United Kingdom). At the end of the experimental period animals were sacrificed by cer-
vical dislocation.
Histomorphometry, Histochemistry and Immunohistochemistry
Dissected long bones were fixed in 4 % paraformaldehyde (pH 6.8), decalcified as described 
previously and processed for paraffin embedding 16,18. Five micrometer longitudinal sec-
tions were cut through the sagittal plane of the tibiae containing tumors induced by the 
intra-bone inoculation of MDA-231-B/Luc+cells. Sections were either submitted to Gold-
ner staining or histochemical staining for Tartrate Resistant Acid Phosphatase (TRAcP) as 
described previously 13.
 Histomorphometric analysis of tumor burden was performed on central sections through 
the tumor (largest tumor area) as described previously 13. Subsequently, a distinction was 
made between intraosseous and extramedullary tumor burden. For this, the digital image 
of the total tumor area was subdivided into an area delimited by the bone cortex or, were 
this has been partially resorbed as a result of the tumor-induced osteolysis, by a virtual line 
joining the remnants of the bone cortex, to define ‘intraosseous’ tumor growth. Evidently, 
the intraosseous, or intra-bone, tumor burden was critically selected between the bone tra-
beculae. Accordingly, the extramedullary tumor growth was defined as tumor cells growing 
surrounding the bone cortex or its remnants.
 Histomorphometric measurements of trabecular bone volumes were performed after 
Goldner staining on the same central sections as used for tumor burden measurements. 
Trabecular bone volume (TBV) was estimated in the proximal tibia by measuring the total 
area of trabecular structures in an area 0-2 mm distal to the capillary invasion front of 
the growth plate. TBV is expressed as percentage of the total area that was covered by 
trabeculae.
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Statistical Analyses
All data are represented as means ± SE. Statistical evaluation was carried out by ANOVA 
using post-hoc of LSD.
RESULTS
Effect of ZOL and Fc-OPG on bone destruction
Compared to vehicle treatment, both treatments inhibited significantly the development of 
radiographically detectable osteolytic lesions (Fig. 1). There was no significant difference 
between the two treatment groups, but Fc-OPG prevented completely the development of 
radiographically evident osteolytic lesions.
 Histological examination of tibiae inoculated with tumor cells corroborated the radio-
graphic findings (Fig. 2A). In vehicle-treated animals trabecular bone was destroyed and 
was replaced by tumor. In contrast, treatment with either ZOL or Fc-OPG preserved the 
integrity of bone trabeculae and prevented bone destruction (Fig. 2). In addition, trabecular 
bone volume (TBV) was similar between the two actively treated groups and significantly 
higher than in animals treated with vehicle alone (Fig. 2B).
 The effect of both ZOL and Fc-OPG on bone destruction was due to their action on bone 
resorption as evidenced by the significant decrease in TRAcP-positive (TRAcP+) osteoclasts 
(Fig. 3). However, whereas practically no TRAcP+ cells were observed in tibiae preparations 
of animals treated with Fc-OPG, such cells were still present in the animals treated with ZOL 
(Fig. 3B). Though, in the ZOL-treated animals, many of the TRAcP+ osteoclasts that are still 
present are not tightly attached to the bone surface and represent non-active osteoclasts not 
capable of resorbing bone (Fig. 3A). This discrepancy between the effects on osteoclasts of 
the two agents is probably due to their different mechanisms of actions. Fc-OPG inhibits the 
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Figure 1 Radiographically evident osteolytic lesions after 42 days of experimental treatment with Fc-OPG or 
ZOL. n.d. = not detected; ** p <0.01, *** p < 0.001 compared to vehicle.








increases their rate of apoptosis. Therefore, the TRAcP+ cells persisting in the ZOL treatment 
group are probably non-functioning osteoclasts, as shown previously 20-22.
Effect of ZOL and Fc-OPG on tumor growth
A. ZOL and Fc-OPG did not decrease the total tumor growth in the hindlimb assessed by 
BLI. Representative examples of animals treated with vehicle, ZOL or Fc-OPG are shown 
in figure 4A and the overall results of treatment are depicted in figure 4B. Although there 
appeared to be a trend for less tumor burden with both active treatments at the end of the 
experiment, this was not significantly different from vehicle-treated animals.
 B. Histologically, the intra-bone tumor burden was significantly decreased with both 
treatments (Fig. 5B), but cancer cells were still present in bone marrow spaces (Figs. 2A, 






























Figure 2 Effects of Fc-OPG and ZOL treatment on bone trabeculae as shown by Goldner staining. A, Fc-OPG and 
ZOL treatment inhibited cancer-induced bone destruction leading to a significant increase in trabecular 
bone area when compared with vehicle treated animals. Scalebars = 100μm; BM = bone marrow; T 
= tumor. B, trabecular bone volume (TBV) was significantly increased by Fc-OPG and ZOL treatment 
to a comparable extent when compared with vehicle treatment as determined by histomorphometric 
analysis. *** p <0.001 compared to vehicle.
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The overall tumor burden (combined intra-bone and extramedullary growth) decreased, 
but not significantly so, which is full agreement with the BLI data.
DISCUSSION
In this study we tested the hypothesis that suppression of bone resorption could reduce the 
growth and progression of breast cancer cells in the bone microenvironment. For this we 
have used a mouse model of intra-tibial injection of cancer cells as a model for late events 

















































Figure 3 TRAcP staining to examine osteoclast numbers. Osteoclasts were stained red with TRAcP staining. A, 
in the ZOL treated animals, many of the TRAcP+ osteoclasts that are still present are not tightly attached 
to the bone surface and represent non-active osteoclasts not capable of resorbing bone. In the Fc-
OPG group the osteoclasts were almost totally eradicated. Selected areas in the figures at the top are 
enlarged in the figures at the bottom. Scalebars are 50μm (figures at the top) and 80μm (figures at the 
bottom). B, both Fc-OPG and ZOL treatment significantly reduced the number of osteoclasts compared 
to vehicle treatment. In addition, Fc-OPG treatment resulted in a superior deletion of osteoclasts when 
compared to ZOL treatment. *** p < 0.001 compared to vehicle; # p < 0.05.
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Figure 4 Tumor growth as detected by bioluminescent imaging. A, representative examples of Fc-OPG and 
ZOL treated mice with intraosseous tumor growth and tumor-induced bone destruction as detected 
by bioluminescent imaging (BLI) and radiography. Scale bars in X-rays: 10 mm. B, tumor burden as 
measured by BLI and quantified in 105 relative light units (RLU).
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in the bone metastatic process. This in vivo model, therefore, does not represent earlier 
stages of bone metastasis (e.g., bone homing), but is ideally suited to monitor the effects of 
bone resorption inhibitors on the growth of cancer cells in the bone microenvironment. Our 
results show that the two very potent agents used, ZOL and Fc-OPG, significantly reduce 
intra-bone tumor burden (as measured by histology). Despite a marked effect on tumor-
induced bone resorption and intra-bone tumor burden, ZOL and Fc-OPG failed to reduce the 
total tumor burden which included extramedullary growth.
 Interference with the microenvironmental growth support has been proposed as an 
attractive strategy for decreasing metastatic tumor growth 23. Bone is a dynamic tissue that 

























Figure 5 Effects of Fc-OPG and ZOL treatment on intra-bone and extramedullary tumor growth in tibiae as 
assessed by histomorhphogical analysis. A, goldner staining showing intra-bone tumor growth (IT), 
extramedullary tumor growth (ET), and muscle tissue (M). Scale bars: 200 μm. B, ** p <0.01 and * p <0.05 
compared to vehicle.








and human studies have shown that high bone remodeling promotes the formation of bone 
metastases 8-10,13 through the release of factors from bone matrix that support metastatic 
growth in the bone marrow 1,25.
 Differently from other tissues, agents that specifically decrease bone resorption and 
remodeling are available and are used clinically or experimentally for the protection of bone 
destruction by metastases from different primary tumors 26-30. The question is whether 
local growth and spread of metastases in bone can also be decreased during this process. 
To provide an answer to this question, in the present proof-of-concept study we aimed to 
suppress bone resorption maximally with doses of agents that specifically and effectively 
inhibit and osteoclast-induced bone resorption.
 Bisphosphonates are used extensively in the management of patients with bone metas-
tases 27,29-31. They suppress bone resorption and reduce significantly the frequency of skel-
etal-related events 31-34. Of the currently available bisphosphonates, ZOL is the most potent 
inhibitor of bone resorption in vitro and in vivo 21,34 and it has also been reported to induce 
apoptosis of tumor cells in vitro 35-37. We, therefore, used high doses of ZOL to examine the 
relation between suppression of bone resorption and local progression of breast cancer cell 
growth. As expected and previously reported 22,38, ZOL reduced markedly tumor-induced 
osteolysis, as shown radiographically and histologically, through its effects on osteoclasts. 
TRAcP+ cells were not totally eradicated but those still persisting were probably inactive 
apoptotic osteoclasts, as has been previously shown in studies with different bisphospho-
nates 20,22. Intraosseous tumor burden was reduced, however, the total tumor burden (intra-
bone and extramedullary) still progressed and although at the end of the experiment this 
appeared less compared to controls, the difference was not significant. It should be noted 
that the dosing regimen we used seems unlikely to be responsible for the observed effects 
as daily and and once-weekly administration of ZOL has been reported to have similar 
effects on tumor growth in a different model of bone metastasis 50.
 ZOL, as all potent nitrogen-containing bisphosphonates, acts primarily on mature osteo-
clasts and decreases their activity and life-span 21,39. To exclude the possibility that for an 
effect on tumor growth all stages of osteoclastogenesis leading to increased bone resorp-
tion need to be optimally suppressed, we also treated animals with Fc-OPG. OPG is the nat-
ural inhibitor of RANK ligand (RANKL) 40-42, an essential factor for the formation and activity 
of osteoclasts 43,44. Fc-OPG has been shown in animal models to strongly inhibit cancer-
induced osteolysis 45-47 and to suppress bone resorption in patients with bone metastases 
from breast cancer 28. In our study, Fc-OPG suppressed markedly bone resorption, pro-
tected the integrity of bone trabeculae and prevented the development of osteolytic lesions. 
These effects were due to its actions on osteoclast formation and activity as evidenced by 
the nearly complete eradication of TRAcP+ cells in bone from treated animals. Further-
more, as was also the case with ZOL, intraosseous tumor burden was significantly reduced. 
Since there was not an effect of Fc-OPG on extramedullary tumor burden, the total tumor 
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burden (sum of intraosseous and extramedullary) still progressed, and although through-
out the entire experiment this appeared less compared to controls, the difference was not 
significant.
 It should be noted that with both ZOL and Fc-OPG the intra-bone tumor burden dimin-
ished considerably as shown in histological sections of the tibiae. This is, at least in part, 
due to the increase in trabecular bone volume and concomitant decrease in bone marrow 
volume where tumor cells could reside. In other words, even if tumor cells completely fill 
bone marrow spaces, the relative intra-bone tumor volume would be less in ZOL and Fc-
OPG-treated animals compared to vehicle-treated animals. In fact, space limitations within 
the bone marrow may direct invasive growth towards the extramedullary.
 If we had, thus, confined our assessment of tumor growth strictly within the bone we 
could have arrived to the wrong conclusion about an effect on tumor growth. This under-
lines the importance of careful dissection of the tumor-containing bones in such a way that 
the invaded surrounding soft tissue is not removed. It is important to note that the growth of 
MDA-231 breast cancer cell outside the bone collar in the surrounding soft tissue was also 
observed in our previous studies with olpadronate 13 and those of Sasaki and co-workers 
with risedronate and other BPs 12,15. In these studies, a bone metastasis model of injection 
of tumor cells into the left heart ventricle was used, rather than direct injection into bone. 
Therefore, tumor cells invading the surrounding soft tissue can not fully be explained by a 
potential artefact of the model of direct injection into bone. In this respect, it is also impor-
tant to note that MDA-231 cancer cells can migrate from the bone marrow to periosteal 
surfaces through vascular channels 13.
 Zheng and co-workers showed that curative OPG treatment significantly inhibited tumor 
growth in the bone environment, as assessed by histology 48. In fact, tumor areas for OPG 
and vehicle treated mice were comparable to our data. Furthermore, OPG treatment inhib-
ited proliferation and stimulated apoptosis of cancer cells in the bones. Another study, 
in which tumor cells were injected into the left heart ventricle, showed that curative low 
and high dose OPG treatment inhibited tumor growth in bone, and that only high dose OPG 
increased tumor cell apoptosis 49.
 So, bone resorption inhibitors could affect tumor progression in bone by decreasing the 
bone marrow volume where tumor cells could reside, and by stimulating apoptosis and 
inhibiting proliferation of cancer cells. However, our data demonstrate that tumor progres-
sion into extramedullary spaces is not affected by those treatments. In addition, ZOL and 
Fc-OPG do not have a major impact on overall tumor burden under the experimental condi-
tions described here. Therefore the results of our experiments do not provide support for 
the notion that suppression of bone resorption in already established metastatic disease 
in bone arrest tumor growth and progression, despite its inhibitory effects on intra-bone 
tumor volume. These data favor the hypothesis that metastatic cancer cells in bone after 
an initial growth phase that depends on their interaction with the bone marrow stroma 








and extracellular bone matrix, become increasingly independent of microenvironmental 
growth factor support and progress autonomously 13. At this stage, for skeletal protection 
and arrest of further tumor growth, anti-resorptive agents should probably be combined 
with compounds with different mechanism of action on the metastatic cascade such as, for 
example, cytostatics or anti-angiogenic factors.
 The important, and clinically relevant question, that still needs to be addressed is 
whether suppression of bone resorption early in the course of metastatic disease and while 
cancer cells are still dormant may prevent the development of macrometastases. Animal 
studies with bone resorption inhibitors given before the colonization of bone by cancer cells 
strongly suggest that this can be feasible 13-15. Therefore, this issue needs to be addressed 
in properly designed clinical studies.
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Bone Morphogenetic Protein 7 (BMP7) counteracts physiologic epithelial-to-mesenchymal 
transition (EMT), a process that is indicative of epithelial plasticity. Since EMT is involved in 
cancer we investigated whether BMP7 plays a role in prostate cancer growth and metas-
tasis.
 In this study we show that decreased BMP7 expression in primary breast cancer is sig-
nificantly associated with the formation of clinically overt bone metastases in patients with 
≥ 10 years follow-up. In line with these clinical observations, BMP7 expression is inversely 
related to tumorigenicity and invasive behavior of human breast cancer cell lines. Moreo-
ver, BMP7 decreased the expression of vimentin, a mesenchymal marker associated with 
invasiveness and poor prognosis, in human MDA-MB-231-B/Luc+ breast cancer cells under 
basal and TGF-β stimulated conditions. In addition, exogenous addition of BMP7 to TGF-β 
stimulated MDA-MB-231 cells inhibited Smad-mediated TGF-β signaling. Furthermore, in a 
well-established bone metastasis model using whole body bioluminescent reporter imag-
ing, stable overexpression of BMP7 in MDA-MB-231 cells inhibited de novo formation and 
progression of osteolytic bone metastases and, hence, their metastatic capability. In line 
with these observations, daily intra-venous administration of BMP7 (100 μg/kg/day) sig-
nificantly inhibited orthotopic and intra-bone growth of MDA-MB-231-B/Luc+ cells in nude 
mice.
 Our data suggest that decreased BMP7 expression during carcinogenesis in the human 
breast contributes to the acquisition of a bone metastatic phenotype. Since exogenous BMP7 
can still counteract the breast cancer growth at the primary site and in bone, BMP7 may 
represent a novel therapeutic molecule for repression of local and bone metastatic growth 
of breast cancer.
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Introduction
Approximately 90% of cancer deaths result from the local invasion and distant metastasis 
of tumor cells 1. Better understanding of the process of metastasis is, therefore, urgently 
needed. Increased motility and invasiveness of breast cancer cells is reminiscent of the 
epithelial-to-mesenchymal transition (EMT) that occurs during embryonic development 2,3. 
This transition to a more mesenchymal, motile cellular phenotype is the result of a complex 
physiological process that includes dissolution of adherens junctions, loss of cell polarity, 
a change to spindle-like cell morphology, cytoskeletal reorganization, increased cell motil-
ity, loss of epithelial markers and induction of mesenchymal marker 2,4. Increased vimentin 
expression and perturbation of E-cadherin-mediated cell adhesion appear as hallmarks 
of this process 4-8. However, in organogenesis ‘mesenchymal’ cells may possess remark-
able plasticity and can eventually, regain a fully differentiated epithelial phenotype via a 
mesenchymal-to-epithelial transition (MET) 9-11.
 Members of the transforming growth factor β (TGF-β) superfamily, which include 
bone morphogenetic proteins (BMPs), are involved in the control of many different bio-
logical processes including cell proliferation, differentiation, apoptosis and regulation of 
invasiveness 12-14. In normal and non-malignant epithelial cells TGF-β is a potent growth 
inhibitor 15,16. However, different types of carcinomas often escape this tumor-suppressing 
activity and become refractile to growth inhibition 15,16. Even more, TGF-β can also potenti-
ate tumorigenesis and contribute to the progression and invasiveness of various carcino-
mas 8,17,18. Accordingly, it has been shown that a blockade of TGF-β (signaling) inhibits tumor 
cell viability, migration, and metastasis 19, including the formation of bone metastases 20,21.
The homodimeric protein bone morphogenetic protein 7 (BMP7) induces MET in normal and 
non-transformed cells 14,22. For instance, during kidney development, BMP7 is essential 
for the condensation and epithelialization of the metanephric mesenchyme in the kidney, 
resulting in the formation of the tubular epithelium 9-11,14. Furthermore, BMP7 appears to be 
involved in the preservation of the epithelial phenotype 23,24, decreases fibrogenesis 23-25, and 
causes repression of inflammation 26,27.
 In this study, we present a crosstalk between BMP7 and TGF-β signaling in the regula-
tion of EMT in breast cancer and identified BMP7 as a potential therapy for metastatic bone 
disease.
Materials and Methods
Cell line and Culture Conditions
The human breast cancer cell lines MDA-MB-231 (MDA-231), T47D and ZR-75-1 (ATCC, Rock-
ville, USA) were cultured in DMEM (Gibco-BRL, Breda, The Netherlands) containing 4.5 g of 
glucose/L for MDA-231 or RPMI (ATCC, Rockville, USA) for T47D and ZR-75-1, supplemented 








with 10% FCS (Gibco-BRL, Breda, The Netherlands), 100 units/ml penicillin and 50 μg/ml 
streptomycin (Life Technologies, Invitrogen, Breda, The Netherlands). Culture medium for 
T47D was supplemented with 6,5 μg/ml insulin (Sigma Chemical Co., St. Louis, MO, USA), 
and in culture medium for MDA-231-B/Luc+, a bone-seeking and luciferase expressing sub-
clone from MDA-231 28, 800 µg/ml geneticin/G418 (Gibco-BRL, Breda, The Netherlands) was 
added. MCF10A 29 and its fully malignant derivate MCF10CA1a 30 (Barbara Ann Karmanos 
Cancer Institute, Detroit, MI, USA) were cultured as described previously 30. All cell lines 
were grown in a humidified incubator at 37°C and 5% CO2. Mycoplasma contamination was 
regularly tested by PCR, but never detected.
 Putative BMP7 effects on luciferase expression by MDA-231-B/Luc+cells have been 
tested and excluded (data not shown).
Generation of isogenic BMP7-overexpressing cell lines using targeted integration
MDA-231 cells that display an unique predilection for bone (MDA-231-BO2 31) were selected 
to generate a stable cell line that overexpresses BMP7. Stable cell lines were generated 
using the Flp-In system (Invitrogen, Breda, The Netherlands) according to manufacturer’s 
protocol 32. In short, a MDA-231-BO2-Flp-in host cell line (MDA-231-BO2-Frt11) was gener-
ated by stable introduction of a single copy of a Flp-Recombinase target (FRT) site as an 
integral part of an antibiotic resistancy gene in the genome of these cells. Subsequently, 
a luciferase expressing subclone (MDA-231-BO2-Frt11/Luc+) was generated as described 
previously 28. This clone was used for the generation of isogenic stable cell lines by transient 
co-transfection of an FRT-targeting vector and a Flp-recombinase expression vector. The 
FRT-targeting vector was either a pcDNA5/FRT vector (Invitrogen, Breda, The Netherlands) 
expressing Green Fluorescent Protein (GFP) (control) or BMP7 (target gene) under the 
control of the CMV promotor. Due to Flp-mediated recombination at the genomic FRT-site, 
this targeting vector was incorporated in the genome. Simultaneously, a shift in antibiotic 
resistancy was introduced allowing positive selection for integrants in the genomic FRT-site 
only and negative selection for random integrants in one single step 32. This method allows 
the generation of isogenic stable cell lines, which only differ in sequence inserted in the 
genomic FRT site, thereby eliminating the need for clonal selection. It is important to note 
that both the MDA-231-BO2-Frt11 and MDA-231-BO2-Frt11/Luc+ cell line were validated for 
in vivo bone metastasis formation.
Patients
We retrospectively analyzed tumor tissue from 67 primary unilateral non-metastatic ductal 
breast carcinomas excised from women treated at Centre René Huguenin, St. Cloud, France 
from 1980 to 1994. The samples were examined histologically for the presence of tumor 
cells. A tumor sample was considered suitable if the proportion of tumor cells was more 
than 70%. Immediately after surgery, the tumor samples were stored in liquid nitrogen until 
RNA extraction.
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 Standard prognostic factors are presented in Table 1. All patients were treated by hor-
mone therapy only after surgery. The patients had physical examinations and routine chest 
radiography every 3 months for the first 2 years, followed by annual examination (mammo-
grams). The median follow-up was 11.2 years (range 1.5-20.3y). 35 Patients were without 
relapse (≥ 10 years of follow-up), 17 patients developed exclusively visceral metastases 
(liver and/or lung) and 15 patients developed exclusively bone metastases. Immunohisto-
chemical validation was performed on fixed, paraffin-embedded tissue sections from pri-
mary breast tumor specimens (8/67).
Table 1 Characteristics of the 67 breast tumors from patients with and without relapse.
Total
population (%)
Number of patients with 
relapse (%)
P-values
Total 67 (100) 32 (47.8)
Histological grade §
     I+II







     Node-negative
     Node-positive 1-3









     ≤30mm







     Negative







     +
     -
32 (15 with bone mets)
35
§ Scarff Bloom Richardson classification, n.s. = not significant.
Enzyme-linked immunosorbent assay (ELISA) for human BMP7
Levels of BMP7 in conditioned media were measured with a commercially available specific 
ELISA kit using sandwich enzyme immunoassay technique (R&D systems, Abingdon, United 
Kingdom). Cells were routinely cultured for 4 days.
Real-Time RT-PCR
Total RNA was extracted with the RNeasy Midi kit (Qiagen, Venlo, The Netherlands) from in 
vitro cultured cells at 70-80% confluence. Reverse transcription was performed with ran-
dom primers in the presence of RNase inhibitor (Roche Diagnostics, Rotkreuz, Switzerland). 
Quantitative real-time RT-PCR (qPCR) was performed using commercially obtained exon-
specific primers for BMP7, E-cadherin, vimentin, and β-actin (primer catalog numbers: 








Hs 002333477 m1, Hs 00170423 m1, Hs 00185584 m1 and Hs 99999903 m1, respectively; 
Applied Biosystems, Rotkreuz, Switzerland) on an ABI Prism 7700 sequence detection sys-
tem (Applied Biosystems, Rotkreuz, Switzerland). All experiments were performed in duplo 
on 4 different samples. For BMP7 mRNA detection in patients, qPCR (incl. thermal cycling 
conditions) was performed as described previously 33. Each sample was normalized on the 
basis of its TATA box-binding protein (TBP) content. Primers used: BMP7 fwd ATG GCC AAC 
GTG GCA GAG AA, BMP7 rev CAG CCC AGG TCT CGG AAG CT, TBP fwd TGC ACA GGA GCC 
AAG AGT GAA and TBP rev CAC ATC ACA GCT CCC CAC CA. All qPCR values were normal-
ized using the comparative method of Livak and Schmittger 34.
Western Blot
Cells were seeded in 6-wells plates at a density of 20.000/cm2 in DMEM with 0.1% Fetal 
Clone II (FCII; HyClone, Perbio Science Nederland B.V., Etten-Leur, The Netherlands) for 
MDA-231-B/Luc+. After 18 hours, cells were stimulated with recombinant human mature 
BMP7 (rhBMP7) 35 (0.5 mg batches, Creative Biomolecules, Hopkinton, MA, USA; rhBMP7 
was freshly dissolved to a stock solution – 1 mg/ml in 20 mM acetate buffer with 5 % man-
nitol, pH 4.5 – and was obtained from Dr. Vukicevic) and/or porcine TGF-β2 (R&D systems, 
Uithoorn, The Netherlands). After an additional 48 hours, cells were lysed and collected 
in 250 μl lysisbuffer (20 nM Tris pH 7.5; 20% glycerol; 400 mM KCl; 1 nM DTT; aprotinin 
(1/1000) and Roche protease inhibitor mix) followed by one or two rounds of freeze/thaw-
ing, and used for Western Blot analysis as described earlier 36. Rabbit polyclonal antibodies 
α-vimentin (diluted 1:500; ab7783, Abcam, Cambridge, UK) and α-E-cadherin (diluted 1:500; 
sc-7870, Santa Cruz Biotechnologies, Tebu-bio, Heerhugowaard, The Netherlands), and a 
mouse monoclonal antibody α-beta-actin (clone AC-15, Sigma–Aldrich, Zwijndrecht, The 
Netherlands) were used as primary antibodies.
Cells Grown on Chamber Slides
MDA-231-B/Luc+cells were seeded at a density 20.000/cm2 in DMEM with 0.1% FCII in 8 
chamber slides (Falcon, Becton Dickinson, Etten-Leur, The Netherlands), and growth fac-
tors were added after 18 hours. After 30 hours, cells were dried for 5 minutes and fixed with 
3.7% paraformaldehyde (pH 6.8) (Merck, VWR, Amsterdam, The Netherlands) in PBS for 10 
minutes and stained for vimentin as described for tissues, with the exception of the antigen 
retrieval step (see section ‘histomorphometry, histochemistry and immunohistochemis-
try’). Images were acquired using a color charged-coupled device (CCD) camera mounted 
on a Nikon Eclips 610 microscope at a twenty-fold magnification. Subsequently, cells were 
scored double-blind for positive vimentin staining from four randomly chosen fields by two 
investigators (J.B. and P.v.O.).
Jeroen_Buijs_18.indd   152 26-11-2008   10:18:44
 BMP7, breast cancer progression and bone metastasis 153
Transient transfections and transcription reporter assays
MDA-231 cells were seeded at a density 7.500 cells /cm2 in DMEM with 10% FCII in 24-well 
plates. On the subsequent day, cells were transiently transfected with 1μg of the indicated 
constructs using FuGENE 6 (Roche, Mannheim, Germany) transfection reagent following 
manufacturer’s protocol. To correct for transfection efficacy, 100 ng of renilla luciferase 
(pRL-CMV; Promega, Madison, WI, USA or pRL-CAGGS, Promega, Madison, WI, USA) was 
co-transfected. On day 3, cells were serum starved for 24 hours before stimulation with 
TGF-β and/or BMP7 for a duration of 30 hours. On day 5, luciferase activities were quantified 
using Dual Luciferase Assay (Promega, Madison, WI, USA) 37. Firefly luciferase activity was 
corrected for renilla luciferase activity. The experiments were performed in four fold and 
repeated at least twice. Values are expressed as means ± s.e.m.
Luciferase Reporter Gene Constructs
For intracellular signaling of TGF-β the CAGA-luciferase construct, consisting of 12 Smad3/
Smad4 binding sequences (CAGA boxes) and the luciferase-coding sequence was used. The 
CAGA boxes confer TGF-β stimulation to a heterologous promoter reporter construct, whose 
activity depends on binding of activated Smad3/Smad4 transcription factor complexes 37.
The BRE-luciferase construct, that is based on the mouse Id1 promoter, was used to study 
the presence and functionality of BMP-receptors 38.
Proliferation Assay
Cells were seeded in 96-wells plates at a density of 4.000/cm2. 18 Hours after MDA-231-B/
Luc+cells were seeded, cells were stimulated with 500 ng/ml BMP7 for 72 hours. Prolifera-
tion was measured with the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay 
(Promega, Madison, WI, USA) according to manufacturer’s protocol.
Animals
Female nude mice (BALB/c nu/nu) were purchased from Charles River (L’Arbresle, France). 
Animals were housed in individual ventilated cages under sterile condition, and sterile food 
and water were provided ad libitum. Animal experiments were approved by the local com-
mittee for animal health, ethics and research of Leiden University and carried out in accord-
ance with European Communities Council Directive 86/609/EEC. For surgical and analytical 
procedures mice were anaesthetized by intra-peritoneal injection of a 50 µl 1:1:1 mixture; 
Ketamine HCl (Stock solution of 100 mg/ml Nimatek; Vetimex Animal Health B.V., Bladel, 
The Netherlands.) + Xylazine (2% Rompun, Bayer AG, Leverkusen, Germany) + PBS (pH 6.8). 
At the end of the experimental period animals were sacrificed by cervical dislocation.









All cells were harvested at 70-80% confluence after changing to geneticin-free medium 24 
hours before inoculation.
For tumor growth in the bone marrow, single cell suspensions 2.5 x 105 MDA-231-B/
Luc+cells/ 10 µl PBS were injected into the right tibiae of 6-week old mice as described 
previously 28,39.
 Three days after intraosseous (i.o.) inoculation of MDA-231-B/Luc+cells the animals 
were equally distributed into three experimental groups based on a comparable tumor bur-
den/mouse, as detected by whole body bioluminescent reporter imaging (BLI). From this 
time point (day 0), and during a subsequent period of 24 days, all animals received vehicle or 
rhBMP7 (10 μg/kg/day or 100 μg/kg/day) treatment by tail vein injection. The progression of 
intraosseous growth was monitored by BLI at day 3, 10, 17 and 24 and by radiography at day 
17 and 2 28,39.
 6-Weeks old mice were also i.o. inoculated (1.0 x 105 cells/ 10 µl PBS) with either MDA-
231-BO2-Frt11(GFP)/Luc+ cells (n=8) or MDA-231-BO2-Frt11(BMP7)/Luc+ cells (n = 5). The 
progression was monitored by BLI weekly and by radiography at the end of the experiment 
(day 28) 28,39.
 For orthotopic tumor growth, single-cell suspensions of 1.0 x 106 MDA-231-B/Luc+cells/ 
10 µl PBS were inoculated via a 0.5 ml U-100 insulin needle (29G ½, BD Micro-Fine, Becton 
Dickinson, Etten-Leur, The Netherlands) into the mammary fat pads of 7-week old mice. 
Animals were equally distributed into two experimental groups based on a comparable 
tumor burden/mouse, as detected by BLI. From this time point (day 0), all animals were 
given vehicle or BMP7 (100 μg/kg/day) treatment by tail vein injection. Subsequently, the 
progression of orthotopically growing tumors was monitored weekly by BLI 28,39.
4.5-Weeks old nude mice were inoculated (5,0 x 105 cells/ 100 µl PBS) in the tail artery 
with either MDA-231-BO2-Frt11(GFP)/Luc+ cells (n=13) or MDA-231-BO2-Frt11(BMP7)/Luc+ 
cells (n=8), as described earlier 31. The progression was monitored by BLI weekly and by 
radiography at the end of the experiment (day 28) 28,39.
 After the experimental periods, mice were sacrificed by cervical dislocation.
 Mammary fat pads and tibiae with tumors were dissected and processed for further his-
tomorphometrical and immunohistochemical analysis (see below).
Whole Body Bioluminescent Reporter Imaging of Isogenic BMP7- and GFP-Overexpressing Cell lines
In animals that were inoculated with either MDA-231-BO2-Frt11(GFP)/Luc+ or MDA-231-
BO2-Frt11(BMP7)/Luc+, the luciferase activity was visualized through imaging of whole 
bodies with an intensified-charge-coupled device (I-CCD) video camera of the in vivo Imag-
ing System (IVIS 100, Xenogen, Alameda, CA, USA). The animals were anesthetized using 
the isofluorane anesthesia system (XGI-8, Xenogen), and injected intra-peritoneally with 
2 mg D-luciferin sodium salt (Synchem OHG, Felsberg/Altenburg, Germany) dissolved in 
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PBS. Animals were kept anesthetized, and measurements were performed 5 min after 
the injection of D-luciferin. Bioluminescence imaging was acquired with a 15-cm FOV, a 
medium binning factor, and exposure times of 10–60 s. Imaging data were analyzed by using 
the program living image (Xenogen, Alameda, CA, USA). Values are expressed as relative 
light units (RLU) in photons/sec.
Radiographical Analysis
Radiographic analyses of osteolytic lesions were assessed by radiography (Kodak X-OMAT 
TL film, Eastman Kodak Company, Rochester NY) using a Hewlett Packard X-ray system 
Faxitron 43805, and quantified using NIH-Image 1.62b7 software as described earlier 39.
Histomorphometry, Histochemistry and Immunohistochemistry
After orthotopic tumors and bone metastasis were fixed in 3.7% paraformaldehyde (pH 6.8) 
in PBS and processed, they were submitted to Goldner staining, staining for tartrate-resist-
ant acid phosphatase (TRAcP), H&E staining or immunohistochemical staining as described 
previously 39,40. Histomorphometric measurements of tumor burden were performed on 
central sections through the tumor (largest tumor area). Tumor growth in bone could be 
readily identified by pancytokeratin staining alone or in combination with H&E staining. 
Total tumor areas, as an estimate of total tumor burden, was measured by image analysis 
using NIH-Image 1.62b7 image analyses software as described previously 39. Subsequently, 
a distinction was made between the total tumor burden and the intraosseous and extraos-
seous tumor burden as described previously 39.
The following rabbit polyclonal antibodies were used at a concentration of 10 µg/ml: 
α-human pan-cytokeratin (DAKO, Heverlee, Belgium), α-human vimentin (ab7783, Abcam, 
Cambridge, UK), α-human BMP7 (2854ab, directed against pro-domain of BMP7, obtained 
from Dr.Vukicevic) 35,41, α-phosphorylated Smad1 (PS1) 42 and normal rabbit IgG (Jackson 
Immuno Research, Cambridgeshire, UK) antibodies as negative control. Goat α-rabbit IgG 
(DAKO, Heverlee, Belgium) was used as secondary antibody. For antigen retrieval, slides 
were treated for 10 minutes at 37°C with 5 µg/ml proteinase K (Gibco-BRL, Breda, The 
Netherlands). To quantify PS1 and TRAcP staining, three histological sections per mouse 
(n=8) were acquired using a color CCD camera mounted on a Nikon Eclipse 610 microscope 
at a twenty-fold magnification. Subsequently, the number of cells that stained positive was 
scored single-blind by two investigators (G.v.d.P. and P.v.O.).
 BMP7 staining on patient material was performed similarly, except that 5% normal goat 
serum (Jackson Immuno Research, Cambridgeshire, UK)/ 0.5% Boehringer Milk Powder 
(Boehringer Mannheim, Mannheim, Germany)/ TTBS was used instead of 0.5% Boehringer 
Milk Powder/ TTBS for incubation and first antibody dilution, and 0.01 M citrate buffer (pH 
6.0) (7 minutes at 98°C) was used as antigen retrieval step, unless stated otherwise.









Survival rates were determined using the log-rank test. Since BMP7 mRNA levels in patients 
did not follow a Gaussian distribution, (a) the mRNA levels in each subgroup of samples 
were characterized by their median values and ranges, rather than their mean values and 
coefficients of variation, and (b) relationships between the molecular markers and clinical 
and histological parameters were tested using the non-parametric Mann-Whitney U test. 
Other data are represented as mean ± s.e.m.. In vivo tumor growth was measured by gen-
eral linear model with repeated measurements using a LSD post-hoc test when applicable. 
Other statistical evaluations were carried out by ANOVA using a LSD post-hoc test when 
applicable.
Results
BMP7 Expression in Human Primary Breast Cancer and Formation of Distant Metastasis
BMP7 mRNA expression levels in primary breast tumors developing bone or visceral metas-
tases were not significantly different from breast cancer patient without relapse (column 2 
vs. 1, Table 2), and there was no significant difference observed that patients with primary 
breast tumors developing bone metastases had lower BMP7 mRNA expression levels (p = 
0.13; column 3 vs. 1, Table 2) than patients without relapse. However, BMP7 mRNA expres-
sion levels in primary breast tumors developing bone metastases were significantly lower 
when compared to primary breast tumors developing visceral (lung and/or liver) metas-
tases (p = 0.027; column 3 vs. 4, Table 2).
Table 2 BMP7 mRNA expression levels in human primary breast carcinomas as detected by qPCR. Median (range) of 
mRNA levels
1 2 3 4
Breast tumor without 
metastasis (n=35)
Breast tumor with 
metastasis (n=32)
Breast tumor with bone 
metastasis (n=15)
Breast tumor with visceral 
metastasis (n=17)
1.0 (0.03 - 85.92) 0.83 (0.01 - 11.43) # 0.48 (0.01 - 3.71) 1.40 (0.17 - 11.43) *
#, n.s. (column 1 vs. 2); *, p = 0.027 (column 3 vs. 4)
In patient matched normal ducts of the breast, apical BMP7 staining could be observed 
(Fig. 1, upper panels). Staining intensity of BMP7 protein in primary breast cancer specimens 
was in accordance with BMP7 mRNA levels (Fig. 1, middle panels). Adult kidney were used 
as positive (Fig. 1, left bottom panel) and negative (Fig. 1, right bottom panel) control.
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Figure 1 BMP7 mRNA expression levels and BMP7 immunolocalization in human primary breast cancer. BMP7 
immunolocalization. Upper panels, normal ducts of the breast (Pronase (0.1% for 10 minutes at 37°C, 
Roche) was used as antigen retrieval step). Immunolocalization of BMP7 in primary breast tumors with 
low (left middle panel) and high (right middle panel) levels of BMP7 mRNA (0.09 and 16.11, respectively). 
Rat kidney: medullary rays were used as a positive (left bottom panel) and glomeruli (as indicated by *) 
as negative control (right bottom panel). Adjacent to the negative glomerulus, convulated tubuli stained 
positive for BMP7. Scale bars in upper left panel 80 µm, scale bars in other panels 50 µm.








Tumorigenicity and BMP7 Expression In Vitro
We investigated whether BMP7 expression in human breast cancer cell lines is associated 
with tumorigenic and metastatic potential. The six cell lines examined in this study have 
progressively greater tumorigenic and metastatic potential when arranged in the following 
order: MCF10A (normal breast epithelial cells), ZR-75-1, T47D, MCF10CA1a, MDA-231 and 
MDA-231-B/Luc+, where MCF10CA1a, MDA-231 and its derivate MDA-231-B/Luc+are highly 
tumorigenic and metastatic. This arrangement of the cell lines inversely correlates with the 
expression of BMP7 (Fig. 2A). E-cadherin/vimentin expression ratios, indicative of epithelial 
phenotype, are also inversely related to BMP7 expression (Fig. 2A), suggesting that acquisi-
tion of an invasive phenotype coincides with decreased BMP7 expression.
 Immunohistochemical staining of MDA-231-B/Luc+cells for vimentin demonstrated a 
heterogeneous population with 22% vimentin positive (Vim+) cells (Fig. 2B). Stimulation with 
BMP7 significantly decreased the percentage of Vim+ cells (5%; p = 0.038 versus control), 
while stimulation with TGF-β significantly increased the percentage of Vim+ cells (49%; p 
= 0.002 versus control). This increase in vimentin expression by TGF-β could be blocked 
completely by co-incubation of BMP7 (12% Vim+ cells; p < 0.001 versus TGF-β treated cells). 
These results were further confirmed by Western Blotting (Fig. 2C).
 Next we tested whether BMP7 acts on MDA-231 cells to inhibit the acquisition of an inva-
sive, mesenchymal phenotype by antagonizing Smad-dependent TGF-β signaling.
 The presence of functionally active TGF-β receptor complexes, particularly ALK5, in 
MDA-231 cells was demonstrated by the dose-dependent activation of the CAGA-luciferase 
reporter, whose activity depends on activated Smad3/4 transcription factor complexes (Fig. 
2D). Addition of BMP7 to TGF-β-stimulated MDA-231 cells significantly inhibited the TGF-β-
driven CAGA-luciferase activity (p < 0.001).
 Addition of BMP7, but not TGF-β, stimulated BRE4-luciferase activity, indicating the pres-
ence of functioning, activated type I BMP-receptor complexes in MDA-231 cells (Fig. 2D). 
TGF-β antagonizes BMP7 induced BRE-luciferase activity (p < 0.001).
It is important to note that BMP7 did not affect proliferation of MDA-231-B/Luc+cells in vitro 
using different cell culture conditions (1% FCS and 10% FCS; Suppl. Fig. 1).
BMP7 overexpression and Experimental Bone Metastasis
As detected with ELISA, overexpression of BMP7 in MDA-231 cells (MDA-231-BO2-
Frt11(BMP7)/Luc+) resulted in substantial secretion of BMP7 protein in the medium, 6.55 
ng BMP7 protein/ 1E6 cells/ day. In contrast, BMP7 protein was not detectable in the control 
cell line (MDA-231-BO2-Frt11(GFP)/Luc+), < 0.03 ng BMP7 protein/ 1E6 cells/ day.
Overexpression of BMP7 in MDA-231 cells (MDA-231-BO2-Frt11(BMP7)/Luc+) significantly 
inhibited both the intra-bone growth (p = 0.034), osteolytic area (p = 0.007), and extraosseous 
extension (p = 0.042) when compared to control (MDA-231-BO2-Frt11(GFP)/Luc+) (Fig. 3A). 
Moreover, in an experimental model of bone metastasis using tail inoculation of breast can-
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Figure 2 E-cadherin and vimentin expression in breast cancer cell lines. A, BMP7, E-cadherin and vimentin mRNA 
expression in human breast cancer cell lines with increasing tumorigenic and metastatic potential (left 
to right) as detected by qPCR. E-cadherin expression in MDA-231 and MDA-231-B/Luc+cells, vimentin 
expression in T47D and ZR-75-1 cells, and BMP7 expression in MCF10CA1a, MDA-231 and MDA-231-B/
Luc+cells were just above detection level. ** p < 0.01 versus BMP7 expression in T47D, MCF10CA1a, MDA-
231 and MDA-231-B/Luc+cell lines. * p < 0.05 versus E-cadherin expression in all other cell lines; # p < 
0.01 MDA-231 cell lines versus the other cell lines; Expression values are normalised to β-actin (BMP7/103 
β-actin). B, vimentin immunolocalization of MDA-231-B/Luc+cells after incubation with 1 µg/ml BMP7 in the 
presence or absence of 10 ng/ml TGF-β. Representative examples are shown. C, expression of vimentin by 
MDA-231-B/Luc+cells after incubation with 1 µg/ml BMP7 in the presence or absence of 10 ng/ml TGF-β 
as detected by Western Blotting. * p < 0.05 and ** p < 0.01 versus control, # p < 0.001 versus TGF-β, n.s. = 
not significant. D, MDA-231 cells were transiently transfected with the CAGA-luciferase reporter (left panel) 
and the BRE-luciferase reporter (right panel) constructs. The presence of functionally active TGF-β receptor 
complexes was demonstrated with stimulation of the CAGA-luc reporter by TGF-β (*** p < 0.001 vs. all other 
conditions). Addition of BMP7 (500 ng/ml) to TGF-β-stimulated MDA-231 cells significantly (# p < 0.01, ## 
p < 0.001) inhibited TGF-β-driven CAGA-luc activity. Values are normalized to renilla (CAGA-luc/105 pRL-
CAGGS). Value vehicle treated is 16.1 ± 1.1. BMP7 (200 ng/ml), but not TGF-β (5 ng/ml), induces BRE-luc 
actvity, indicating the presence and functionality of BMP-receptors in MDA-231 cells. *** p <0.001 vs. all other 
conditions; values are normalized to renilla (BRE4-luc/10-1 pRL-CMV).


















































































































































































Figure 3 Bone metastatic and intra-bone growth of MDA-231 cells expressing BMP7. A, in an experimental model 
of intraosseous implantation of breast cancer cells, stable BMP7 overexpression inhibited osteolysis as 
detected by radiographical analysis, total tumor burden as measured by BLI (RLU: 106 photons/sec), and 
extraosseous tumor volume determined as the percentage of total tumor volume (TTV) that has started 
to grow extramedullary. B, experimental model of bone metastasis formation after tail inoculation of 
breast cancer cells, from which representative examples of radiography, BLI, Goldner staining (scale 
bars 200 μm) and BMP7 immunolocalization (scale bars 50 μm) (from left to right) are shown. Arrows 
indicate osteolytic lesions; T = tumor; B = bone. C, in the experimental bone metastasis model stable 
BMP7 overexpression inhibited de novo formation of osteolytic bone metatases (per mouse) as detected 
by radiographical analysis, and total tumor burden (per mouse) as measured by BLI (RLU: 106 photons/
sec). * p < 0.05 and ** p < 0.01 versus control (GFP).
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Figure 4 Representative examples of BMP7 treatment 
and intra-bone growth of MDA-231-B/
Luc+cells. A, intra-bone growth of tumor cells 
and tumor-induced osteolysis (BLI, radiography 
and histology). In the graphs, BLI is quantified in 
relative light units (RLU) (105 photons/sec). Scale 
bars in X-rays: 10 mm; scale bars in histological 
sections: 1 mm. T = tumor, BM = bone marrow. B, 
expression of vimentin (1-4) and pan-cytokeratin 
(5-8) in MDA-231-B/Luc+cells growing in bone 
marrow after vehicle (1,2,5,6) and 100 μg/kg/d 
BMP7 (3,4,7,8) treatment. Scale bars in 1,2,5,6: 
150 µm, scale bars in 3,4,7,8: 40 µm.
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cer cells, overexpression of BMP7 in MDA-231 cells (MDA-231-BO2-Frt11(BMP7)/Luc+) was 
shown to significantly inhibit the number of osteolytic lesions (p = 0.025; Fig. 3B,C). In line 
with the ELISA data described above, overexpression of BMP7 protein in tumor cells was 
also detected in histological sections in bone metastasis from MDA-231 cells overexpress-
ing BMP7 (MDA-231-BO2-Frt11(BMP7)/Luc+), but not in the GFP-control cell line (Fig. 3B). 
In addition, a trend was noticed for less overall total tumor burden as detected by BLI (p = 
0.10; Fig. 3C). Furthermore, it is important to note that BMP7 overexpression did not affect 
the growth rate in vitro (doubling time MDA-231-BO2-Frt11(BMP7)/Luc+ cells: 21.0hr, vs. 
MDA-231-BO2-Frt11(GFP)/Luc+ cells: 20.9hr).
Experimental BMP7 Treatment
Fig. 4 depicts a representative example from each experimental group (vehicle treatment, 
10 μg/kg/day BMP7 or 100 μg/kg/day BMP7) showing different in vivo imaging methods (BLI, 
radiography, histology) that have been used to detect MDA-231-B/Luc+breast cancer cells 
growing in bone. Breast cancer growth in bone and the formation of osteolytic lesions was 
strongly inhibited, particularly in the high dose BMP7 group (100 μg/kg/day BMP7) (Fig. 4A). 
Markedly, mice receiving 100 μg/kg/day BMP7 had tumors that express higher levels of 
cytokeratins and lower levels of vimentin when compared to vehicle treated mice (Fig. 4B). 
The number of strong cytokeratin-positive cells was increased by 25% upon BMP7 treat-
ment. This indicates that BMP7 treatment provokes a more epithelial-like phenotype.
 In the vehicle treated group, the tumor burden increased strongly over time (Fig. 5A). 
Tumor growth in mice receiving 10 μg/kg/day BMP7 was not significantly different from 
vehicle treated animals, whereas 100 μg/kg/day BMP7 strongly and significantly inhibited 
tumor progression (p = 0.038; Fig. 5A). This result was confirmed by histomorphometric 
analysis of total tumor burden (p = 0.049; Fig. 6A). In addition, no significant difference was 
observed in extraosseous tumor volume upon BMP7 treatment (100 μg/kg/day) (p = 0.15; 
Fig. 5A). Furthermore, radiographic analysis of the tibiae revealed that mice receiving 100 
μg/kg/day BMP7 show significantly smaller bone lesions (p = 0.046), although number of 
osteoclasts per mm bone cortex appeared not to be different at the end of the experiment 
(p = 0.528; Fig. 5B). Systemic administration of BMP7 for the duration of the experiment 
can directly act on MDA-231-B/Luc+bone metastatic cells as visualized by significantly 
enhanced nuclear staining for phospho-Smad1 when compared to vehicle treated animals 
(p = 0.0097; Fig. 5C).
 Next, we studied the effects of BMP7 treatment on the growth of MDA-231-B/Luc+cells 
that were orthotopically implanted into the mammary fat pads of nude mice (Fig. 6A-C). Fig. 
6B depicts a representative example from both experimental groups (vehicle and 100 μg/
kg/day BMP7) as detected by BLI and histomorphometry. Tumor growth of the orthotopi-
cally implanted breast cancer cells in mice receiving 100 μg/kg/day BMP7 was significantly 
inhibited versus vehicle treated animals (p = 0.049; Fig. 6C).
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Figure 5 Effects of BMP7 treatment on intra-bone tumor growth, osteolysis and BMP7 signalling of MDA-
231-B/Luc+cells. A, tumor burden as measured by BLI (RLU: 105 photons/sec) and histomorphometric 
analysis, and the extraosseous tumor volume determined as the percentage of total tumor volume (TTV) 
that has started to grow extramedullary. B, radiographical analysis of tumor-induced osteolysis in tibia 
at the end of the experimental treatment (24 days)(left), and number of osteoclasts (OCs) per mm bone 
cortex (right). C, phospho-Smad1 positive cells in the tumor at the end of the experimental treatment. 
The animals were either vehicle or BMP7 treated 6 hours prior explantation and fixation of the tibiae. 
Scale bars: 80 µm, * p < 0.05 and ** p < 0.01 versus vehicle.
Buijs et al. Figure 5 
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Figure 6 BMP7 treatment and growth of MDA-231-B/Luc+cells in mammary fat pads. A, orthotopically implanted 
MDA-231-B/Luc+cells have formed a tumor located in the mammary fat pad as shown by Hematoxylin 
& Eosin staining. The figure on the right is a magnification from the box in the left figure. Lymphocytic 
infiltrates (indicated by arrows) in tumors could be observed. Scale bar: 80 µm (left figure) and 50 µm 
(right figure); D = mammary duct, T = tumor. B, representative examples for BLI and HE staining are 
shown. BLI is quantified in RLU (105 photons/sec), scale bars: 500 µm. (C) Tumor burden is measured by 
BLI (RLU: 105 photons/sec). * p < 0.05 versus vehicle.
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Discussion
While BMP7 has been proposed as a marker of differentiation in normal and breast cancer 
cells 43, the role of BMP7 in breast cancer progression has remained largely elusive 43-45. In 
this report novel evidence is provided for a role of BMP7 in breast cancer development and 
bone metastases. We describe here that BMP7 expression in patients with primary breast 
tumors exclusively developing bone metastases is significantly lower than in primary breast 
tumors developing exclusively visceral (lung and/or liver) metastases. These clinical find-
ings suggest that decreased BMP7 expression may confer a bone metastatic potential to 
human breast cancer cells. Normal ducts of the breast display strong apical BMP7 protein 
expression. BMP7 protein expression in patient-matched lymph node metastases was low 
or absent, and as a consequence, generally lower than in normal ducts and primary breast 
carcinomas (J.T.Buijs, unpublished observations). Strikingly, BMP7 appears to be expressed 
predominantly in tumor cells in the solid tumor area rather than in migratory tumor cells 
outside this area 43, indicating that low BMP7 expression may support the acquisition of a 
more migratory invasive phenotype.
 It has been well-established that the process of epithelial-to-mesenchymal transition 
(EMT) provides mechanisms for breast epithelial cells to overcome physical constraints 
imposed on them by intercellular junctions and adopt a motile phenotype 3,8,46. It is becoming 
increasingly clear that this local invasive process, representing initial stages of the meta-
static cascade during carcinogenesis, is adapted from the remarkable epithelial plasticity 
(EMT) that occurs during embryonic development and postnatal tissue maintenance 2,47. In 
many cancers, TGF-β is a pro-tumorigenic factor that stimulates ‘oncogenic’ EMT 8,17,18. In 
contrast, BMP7 is a strong inducer of the reverse process (MET) during embryonic develop-
ment 9-11,14 and in renal fibroblasts 22. Moreover, BMP7 can inhibit TGF-β-induced fibrosis 25, 
and counteracts TGF-β-induced EMT in normal renal epithelial cells 24.
 We show here that BMP7 mRNA expression is inversely related to tumorigenicity and 
invasive behavior of human breast cancer cell lines. Functional studies reveal that BMP7 
overexpression by breast cancer cells inhibits de novo formation of osteolytic bone metas-
tases, and hence, the metastatic capability of breast cancer cells in our in vivo bone metasta-
sis model. Furthermore, BMP7 overexpression significantly inhibited tumor growth in bone. 
In keeping with these functional data, daily systemic administration of BMP7 strongly and 
significantly impairs both the orthotopic and intraosseous growth of human MDA-231-B/
Luc+breast cancer cells in nude mice.
 Our in vitro studies reveal for the first time that BMP7 is a potent inhibitor of TGF-β-
induced EMT in MDA-MB-231 cancer cells. In these cells, BMP7 is able of counteracting 
Smad-dependent TGF-β signaling. These actions of BMP7 may be of critical importance and 
could explain the observed beneficial effects of experimental BMP7 treatment on orthotopic 
growth and skeletal metastasis. In this context it is important to note that inactive TGF-β is 








concentrated and stored in high amounts in extracellular bone matrix, and can be released 
and activated by osteoclastic resorption. Activated bone matrix-derived TGF-β may act as 
a paracrine growth factor for neighboring osteolytic cancer cells that may have colonized 
the bone marrow 21,40,48. Our in vivo data further support this notion since BMP7 antagonizes 
TGF-β signaling routes in human breast cancer cells that are metastatic to the skeleton. 
We hypothesize that the activation process of micrometastases in bone marrow may bear 
similarities to EMT that occurs at the primary site in various epithelial cancers and during 
ontogeny 49.
 BMP7, however, could not restore E-cadherin expression in MDA-231-B/Luc+cells. 
Recent observations support the notion that hypermethylation of the E-cadherin promoter 
in MDA-MB-231 cells is involved in E-cadherin expression 6. Apparently, BMP7 can not over-
come this epigenetic effect.
 It is important to note that comparable data have been obtained in clinical samples of 
prostate cancer 50 and uveal melanoma 51. Moreover, in human prostate cancer we recently 
observed that BMP7 antagonizes TGF-β induced EMT concomitant with an induction of 
E-cadherin expression 50.
 Collectively, our data suggest that BMP7 regulates epithelial homeostasis in the human 
mammary gland by preserving the epithelial phenotype. Decreased BMP7 expression dur-
ing breast cancer progression may, therefore, contribute to the acquisition of a bone meta-
static phenotype. Furthermore, exogenous BMP7 can still inhibit breast cancer growth at 
the primary site and in bone marrow. Therefore, BMP7 may represent a novel therapeutic 
molecule for repression of local and bone metastatic growth of human breast cancer.
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Bone Morphogenic Protein 7 (BMP7) counteracts physiologic epithelial-to-mesenchymal 
transition (EMT), a process that is indicative of epithelial plasticity. Since EMT is involved in 
cancer we investigated whether BMP7 plays a role in prostate cancer growth and metastasis.
 BMP7 expression in laser micro-dissected primary human prostate cancer tissue was 
strongly down-regulated compared to normal prostate luminal epithelium. Furthermore, 
BMP7 expression in prostate cancer cell lines was inversely related to their tumorigenic 
and metastatic potential in vivo and significantly correlated to E-cadherin/vimentin ratios. 
Exogenous addition of BMP7 to human prostate cancer cells dose-dependently inhibited 
TGF-β induced activation of nuclear Smad-2/3 via ALK5 and induced E-cadherin expression. 
Moreover, BMP7-induced activation of nuclear Smad1/4/8 signaling transduced via BMPR-
1A receptors was synergistally stimulated in the presence of TGF-β, a growth factor that is 
enriched in the bone microenvironment.
 Daily BMP7 administration to nude mice inhibited the growth of cancer cells in bone. 
In contrast, no significant growth inhibitory effect of BMP7 was observed in intra-pros-
tatic xenografts. Collectively, our observations suggest that BMP7 controls and preserves 
the epithelial phenotype in the human prostate, underscoring a decisive role of the tumor 
microenvironment in mediating the therapeutic response of BMP7. BMP7 can still coun-
teract the EMT process in the metastatic tumor, positioning BMP7 as a novel therapeutic 
molecule for treatment of metastatic bone disease.
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Introduction
The phenotypic changes of increased motility and invasiveness of carcinoma cells are remi-
niscent of the epithelial-to-mesenchymal transition (EMT) that occurs during embryonic 
development and morphogenesis 1-3.
 During EMT epithelial cell layers lose polarity and cell-cell contact, undergo a dramatic 
remodeling of the cytoskeleton, express mesenchymal components and manifest a migratory 
phenotype by resolving cell-matrix contacts and digesting adjacent basal lamina 4,5. Whereas 
in the developing embryo EMT is a prerequisite for the formation of various tissues and organs, 
EMT in postnatal life is required for repair and remodeling of numerous tissues or organs 1,6.
 Plasticity resulting from cells shifting between epithelial and mesenchymal phenotypes 
is discernible either by EMT or the reverse process of mesenchymal-to-epithelial transition 
(MET) 2. Both processes have emerged as a fundamental principle for reprogramming of 
gene transcription and as a major determinant of stem cell fate in development and in adult 
tissue homeostasis. The process of EMT is currently considered a potential mechanism of 
the disease progression in malignant and fibrotic disorders 1.
 An example of the latter is the persistence of a pathogenic insult of the kidney that causes 
disruption of the tubular basement membrane and eventually may lead to renal fibrosis 
due to transition of tubular epithelial cells into a migratory, mesenchymal phenotype (EMT-
derived fibroblasts in the interstitium) 6.
 In epithelial cells TGF-β has been identified as one of the main inducers of EMT during 
development and in fibrotic disorders 5-10, while another member of the TGF-β superfamily, 
bone morphogenetic protein 7 (BMP7) alias osteogenic protein-1 (OP-1), is involved in the 
maintenance of the epithelial phenotype by induction of MET 11-14. Zeisberg and co work-
ers demonstrated that BMP7 was capable of counteracting TGF-β-induced EMT and could 
reverse chronic renal injury 13,14.
 Prostate cancer is the second most frequently diagnosed cancer and the second leading 
cause of cancer death in the Western male population. Evidence is mounting that during car-
cinogenesis developing prostate cancer cells acquire mesenchymal (and even osteoblastic) 
characteristics and migratory features concomitant with a loss of epithelial characteristics 
like E-cadherin expression 15,16. In cancer progression, “oncogenic” EMT refers to clusters of 
malignant cells that loose epithelial characteristics and acquire self-sustained migratory and 
highly invasive phenotypes 5. We hypothesized that the Gleason histological grading of prostate 
cancer parallels EMT starting from “well-differentiated” cells with well-defined boundaries 
that still resemble healthy prostate epithelium (Gleason patterns 1 and 2), via infiltrative can-
cer cells with less-defined boundaries with extensions into adjacent non-neoplastic prostate 
tissue (Gleason pattern 3), towards “poorly-differentiated” highly migratory prostate cancer 
cells that have lost many epithelial characteristics and have acquired an invasive, metastatic 
and mesenchymal phenotype (Gleason patterns 4 and 5).








 Several defects in the canonical TGF-β signaling pathway have been reported in prostate 
cancer 17,18 and may contribute to the development and progression of prostate cancer as 
alterations in TGF-β and TGF-β-receptor II expression are associated with poor clinical out-
come 19. A growing number of in vivo studies demonstrate that inhibitors of TGF-β or TGF-β-
receptors may reduce the metastatic and/or invasive properties of a variety of experimental 
cancers by preventing EMT pathways 5,20,21, thus underscoring the importance of TGF-β in 
oncogenic EMT associated with cancer progression.
 This study was designed to investigate whether tumorigenicity and invasive behavior is 
associated with modulated BMP7 expression in clinical prostate cancer specimens and in 
human prostate cancer cell lines with different tumorigenic potential. Furthermore, we 
studied if systemic administration of BMP7 affects the growth of human prostate cancer 
cells in orthotopic tumor and bone metastasis models by whole body bioluminescent imag-
ing (BLI). We present evidence for cross talk between BMP7 and TGF-β signalling in the 




Radical prostatectomy specimens were obtained at the department of Urology of the Uni-
versity of Bern, Switzerland. Written informed consent was obtained from all patients and 
tissue sampling was approved by the local ethical committee. Within 15 minutes from sur-
gical excision, samples of prostate cancer tissue or non-cancerous tissue of the prostate 
were taken and either snap-frozen or immersed in RNAlater (Qiagen, Basel, Switzerland) 
22. Tissue adjacent to the respective samples was processed for paraffin embedding and 
served as histological control. Histological diagnosis and grading were performed by a 
pathologist (R.M.).
Laser Capture Microdissection (LCM)
Six μm cryo-sections were treated according to the HistoGene LCM Frozen Section staining 
Kit (Arcturus, Bucher Biotech, Basel, Switzerland) 22,23. The P.A.L.M. Micro-Beam system 
(P.A.L.M. Microlaser Technologies, Bernried, Germany) was used to excise approximately 
thousand pure epithelial cells of non-cancerous prostate (NP) and prostate cancer (PC) 
tissue in each prostate. Total RNA was extracted with the Pico Pure RNA Isolation Kit 
( Arcturus).
Real-Time PCR Analysis
Total RNA (see above) was reverse transcribed using random primers in presence of RNase 
inhibitor (Roche Diagnostics, Rotkreuz, Switzerland). Real-time PCR was performed with 
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exon specific primers for human BMP7 (Hs_002333477_m1), GAPDH (Hs_99999905_m1) 
E-cadherin (Hs 00170423 m1), Vimentin (Hs_00185584_m1), and β-actin (Hs_99999903_
m1) (primer catalogue Applied Biosystems, Rotkreuz, Switzerland) on an ABI Prism 7700 
Sequence Detection System (Applied Biosystems). The resulting values were normalized to 
GAPDH or β-actin. Semi-quantitative PCR was performed on samples of experimentally-
induced bone metastases from PC-3M-Pro4 after intracardiac inoculation into nude mice 
using the following exon-specific and human-specific BMP primers 22,24.
Cell lines and culture conditions
The human prostate cancer cell lines PC-3 (ATCC Number CRL-1435, ATCC-LGC Promo-
chem, Molsheim Cedex, France) and PC-3M-Pro4 were grown in DMEM+ 10% FCS (Bio-
Wittaker, Verviers, Belgium). The PC-3M-Pro4 cells were generated from PC-3M cells, by 
injecting PC-3M cells into athymic mouse prostates and selecting for variants with increas-
ing metastatic potential by several rounds of re-injecting cells from xenograft tumors back 
into the mouse prostate 25,26. The human prostate cancer cell line LNCaP and LNCaP-derived 
cell lines C4-2 and C4-2B4 27,28 were grown in T-Medium.
 Cells at 70%-80% confluence were used for RNA extraction using an RNeasy Midi RNA 
extraction kit (Qiagen). Quantitative real-time PCR analysis was performed as described 
above.
 Human PC-3M-Pro4 prostate cancer cells were stably transfected with a CMV-promoter 
driven mammalian expression vector for luciferase, CMV-luc, and one clone with the high-
est expression of luciferase expression (PC-3M-Pro4/Luc+) was successfully used for in 
vivo whole body bioluminescent reporter imaging (BLI) 29,30,32. PC-3M-Pro4/Luc+ were cul-
tured in DMEM+10% FCS and 800 µg/ml geneticyne/G418 (Gibco-BRL, Breda, the Nether-
lands). Cells were regularly certified free of mycoplasma contamination.
 For intraosseous or orthotopic inoculation cell suspensions of PC-3M-Pro4/Luc+ (1 x 105 
cells /10 µl PBS) were prepared 29-32.
Animals
Male nude (BALB/c nu/nu) mice were purchased from Charles River (L’Arbresle, France). 
Mice were housed in individual ventilated cages under sterile condition according to the 
Dutch guidelines for the care and use of laboratory animals (DEC 4077). For surgical and 
analytical procedures were performed mice were anaesthetized 29,31,32.
Intraosseous inoculation of PC-3M-Pro4/Luc+ cells
A single cell suspension of PC-3M-Pro4/Luc+ cells was injected into the right tibiae 29-32. 
The progression of cancer cell growth was monitored weekly by BLI. After the experimental 
period the animals were sacrificed, the tibia dissected and processed for further histomor-
phometrical and immunohistochemical analysis (see below).








Inoculation of PC-3M-Pro4/Luc+ into the mouse prostate (orthotopic implantation)
A single cell suspension of 1 x 105 PC-3M-Pro4/Luc+ cells/10 µl PBS was surgically inocu-
lated into the prostate of anaesthesized 6-week-old male nude mice. The cutaneous wound 
was sutured. The progression of cancer cell growth was monitored weekly by BLI. Subse-
quently the animals were treated daily with 100 µg/kg/d BMP7 or vehicle solution. After the 
experimental period the animals were sacrificed. Directly after removal of the mouse pros-
tate, BLI images were taken of the animals to establish the number of locoregional lymph 
node metastases. Tissues dissected and processed for further histomorphometrical and 
immunohistochemical analysis (see below).
Induction of systemic metastases by intracardiac injection of PC-3M-Pro4/Luc+ cells
A single cell suspension of 1 x 105 PC-3M-Pro4/Luc+ cells /100 µl PBS was injected into the left 
cardiac ventricle and cancer cell growth was monitored weekly by BLI and radiography 29-32. 
Daily BMP7 treatment started 2 days prior to inoculation of the cancer cells until the end of 
the experiment.
BMP7 treatment and prostate cancer growth in vivo
Human BMP7 was obtained from Dr. Vukicevic. BMP7 was expressed, purified and lyophilized 
33. When used, BMP7 was freshly dissolved to a stock solution containing 1 mg/ml in 20 mM 
acetate buffer with 5 % mannitol, pH 4.5. BMP7 (20 µl) or vehicle solution (20 µl, 20 mM acetate 
buffer with 5 % mannitol) was administered daily into the tail veins of mice for 21-23 days (100 
µg/kg/d human BMP7).
Whole body bioluminescent reporter imaging (BLI) and quantification of the bioluminescent signal
BLI of tumors induced by the luciferase-expressing human prostate cancer cell lines was 
performed 29,32. Analyses for each metastatic site were performed after definition of the 
region of interest and quantified 32. Values are expressed as relative light units (RLU).
Histomorphometry, Histochemistry and Immunohistochemistry (IHC)
Five micrometer paraffin sections of patient-matched normal prostate and prostate cancer 
tissue were rehydrated, and a rabbit polyclonal antibody against BMP7 pro-domain was 
applied at a dilution of 1:100. Rabbit IgG (Jackson ImmunoResearch, La Roche, Switzer-
land) served as negative control. A species-specific biotinylated anti-IgG antibody followed 
by streptavidin/alkaline phosphatase conjugate (Amersham Biosciences) were used as the 
detection system. 3-Amino-9-ethyl-carbazole (AEC, Sigma, Buchs, Switzerland) served as 
chromogen (Sigma, Buchs, Switzerland).
Dissected tissues from animal studies were fixed in 4 % paraformaldehyde (pH 6.8), decal-
cified (only bones) as described previously and processed for paraffin embedding, section-
ing and staining 31 with PS1 antibodies directed against phosphorylated-Smad1 34,35.
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Immuno-blotting
Crude cell lysates (10 µg/lane) loaded were separated on SDS-polyacrylamide gels and 
blotted on Hybond-P membranes (Amersham Biosciences). E-Cadherin mAb (5µg/ml) and 
a monoclonal mouse anti-actin antibody (1:5000) were used as primary antibodies. Bind-
ing was detected with a peroxidase-labeled anti-mouse secondary antibody (Amersham 
Biosciences) and the ECL Advanced chemiluminescence substrate (Amersham) using the 
VersaDoc imaging system and QuantityOne imaging software (Bio-Rad).
Human BMP7 ELISA
PC-3M-Pro4 cells, and a clone stably transfected to overexpress rhBMP7, were seeded in 
a 6-wells plate (120.000 cells/ml) and conditioned medium was harvested and analysed for 
BMP7 protein synthesis by ELISA after 4 days of culture according to the manufacturer’s 
protocol (R&D systems).
Transient transfections and transcription reporter assays
Transient transfections and transcription reporter assays were performed and values 
expressed as luciferase intensities (relative light units or RLU) 36. The experiments were 
performed in four fold and repeated at least twice. Values are expressed as means ± s.e.m. 
Incubation time with TGF-β or BMP7 was performed for 30 hours.
Luciferase Reporter Gene Constructs
For intracellular signaling of TGF-β the CAGA-luciferase construct, consisting of 12 Smad3/
Smad4 binding sequences (CAGA boxes) and the luciferase-coding sequence was used. The 
CAGA boxes confer TGF-β, but not BMP-stimulation to a heterologous promoter reporter 
construct 37.
 The BRE4-luciferase construct, that is based on the mouse Id1 promoter, was used to 
study the presence and functionality of BMP-receptors 37. Signaling of BMP to stimulate the 
expression of BRE4-luciferase is transduced by BMPR-IA and mediated by Smad1, Smad4 
and Smad5, which form a complex with this reporter construct 38.
 The SBE4 construct consists of 4 Smad Binding Elements (SBEs) in the promoter of the 
JunB gene, an immediate early gene that is potently induced by TGF-β, activin, and bone 
morphogenetic proteins 39.
 The E-cadherin promoter-luciferase construct is based on the upstream fragment (posi-
tions -178 to +92). The pGL3-E-cadherin promoter plasmid 40 was a kind gift from Dr. Antonio 
Garcia de Herreros.
Statistical Analysis
The paired t-test was performed for statistical evaluation of patient matched mRNA expression 
and the unpaired t-test for comparison of mRNA expression in bulk and laser captured tissue 








using GraphPad Prism Version 3 (GraphPad Software Inc., USA). Data are presented as mean 
± s.e.m. ANOVA was performed for statistical evaluation of whole body BLI data and reporter-
luciferase assays. A p-value equal or superior to 0.05 was considered as non-significant.
Results
BMP7 mRNA Expression in Radical Prostatectomy Specimens
Samples of prostate cancer tissue (PC) and internal controls from the same patient (non-
cancerous tissues of the prostate, NP) were obtained after radical prostatectomy and BMP7 
mRNA was measured by real-time PCR.
 In bulk tissue BMP7 mRNA expression was generally lower than in whole tissue speci-
mens of non-cancerous prostate (11/16, mean decrease 26 %), a non significant difference 
(Fig. 1A,C; P=0.1). However, the multi-focal nature of prostate cancer and the coexistence of 
epithelial and stromal tissues may cross-contaminate and dilute cell-specific gene expres-
sion analyzed in bulk tissue specimens. Therefore, we next collected pure populations of 
>1000 prostate cancer cells and patient-matched non-cancerous prostate epithelial cells 
by laser capture microdissection (LCM) from 14 patients. In 93% of those cancer cell sam-
ples BMP7 mRNA was strongly under-expressed when compared to patient-matched non-
cancerous epithelial cells (13/14, mean decrease 70%, P=0.0019; Fig. 1B,D). Comparison 
of the BMP7 mRNA expression in non-cancerous prostate either derived from bulk tissue 
or from laser captured epithelial cells revealed a 9.4 x higher expression in the epithelial 
compartment alone than in bulk tissue. BMP7 expression in laser captured prostate cancer 
was also (2.8 x) higher when compared to bulk prostate cancer tissue, but these differences 
were less pronounced. These data strongly suggest that BMP7 is expressed mainly in the 
epithelial compartment of the prostate gland, particularly in the glandular epithelium.
 Immunohistochemical analyses were performed for BMP7 on primary prostate cancer 
specimens and non-cancerous tissue adjacent to the respective samples which served as 
a histological control. Histological diagnosis and grading were performed by a certified 
pathologist (R.M.). BMP7 immunoreactivity was present in the cytoplasm of the luminal 
cell layer of the normal acinar epithelium in samples of non-cancerous prostate tissue, 
while hardly any BMP7 could be detected in basal cells (Fig. 1E,F). In addition, BMP7 protein 
expression was also found in the prostate stromal compartment and blood vessels. In con-
trast, prostate cancer cells showed lack of BMP7 immunoreactivity (Fig. 1G,H).
 Our LCM and IHC data reveal that BMP7 expression is enriched in non-cancerous prostate 
epithelium compared to prostate cancer cells in the same patients, suggesting that BMP7 
down-regulation may facilitate prostate carcinogenesis, dissemination and/or metastasis. 
Moreover, BMP7 expression (ratio PC/NP) appeared inversely correlated to Gleason pat-
terns but the distribution of patients for each pattern were too small to reach statistical 
significance (results not shown).
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Figure 1 BMP7 mRNA expression in non-cancerous prostate epithelium (NP) and prostate cancer cells (PC) of 
radical prostatectomy specimens. A, BMP7 mRNA expression in patient matched specimens consisting 
predominantly of NP and PC tissue (n=16, P=0.1, paired t-test). B, BMP7 mRNA expression in NP and neoplastic 
epithelial cells isolated by LCM (PC) (n=14, P=0.0019, paired t-test). C, mean BMP7 mRNA expression values 
± s.e.m. in bulk tissue in NP and PC both normalized to GAPDH (P=0.1, paired t-test). D, mean BMP7 mRNA 
expression values ± s.e.m. in microdissected non cancerous epithelium (NP) and neoplastic epithelium (PC) 
both normalized to GAPDH (P=0.0019, paired t-test). BMP7 mAb immuno-reactivity and in clinical specimens 
of NP (E,F) and PC (G,H). E, boxed area is magnified in F, BMP7 immuno-reactivity was detected in the apical 
cytoplasm of the luminal cell layer of the normal acinar epithelium and parts of stroma (arrowhead), but 
weak or no staining of the basal cells was found. G, H, prostate cancer cells lack BMP7 immuno-reactivity, 
whereas BMP7 was still detectable in parts of the stroma (arrowhead). Bars = 100 µm.








BMP7 mRNA Expression in Prostate Cancer Cell Lines
 We further investigated whether BMP7 expression in prostate cancer cell lines was asso-
ciated with tumorigenicity, metastatic potential and EMT degree. The prostate cell lines 
examined have progressively greater tumorigenic and metastatic potential in the following 
order: LNCaP, C4-2, C4-2B4, PC-3, PC-3M-Pro4. This arrangement of cell lines also paral-
lels the gradual loss of expression of epithelial markers (E-cadherin epithelial marker) and 
acquisition of mesenchymal characteristics (Fig. 2A). Vimentin is a characteristic marker 
for the mesenchymal phenotype of cancer cells and enhanced vimentin expression was 
previously found in motile prostate cell lines and in poorly differentiated and metastatic 
prostate carcinoma 41. In line with these observations we found that vimentin expression 
increased with tumorigenicity and that E-cadherin/vimentin ratios decreased with aug-
mented invasiveness and aggressiveness (Fig. 2A).
 BMP7 mRNA levels in prostate cancer cell lines strongly correlated to E-cadherin/
vimentin ratio (Fig. 2A,B) whereas no association was observed for other BMPs (results not 
shown) 24. The highly tumorigenic and metastatic human prostate cancer cell line PC-3 and 
its derivative PC-3M-Pro4 did not show detectable BMP7 mRNA expression (Fig. 2B) and 
protein synthesis in vitro (human specific BMP7 ELISA; all < 10 pg/ml hBMP7, n=4). The lack 
of BMP7 expression by PC-3M-Pro4 cells in vitro was confirmed in vivo in bone metastases 
(Fig. 2D), suggesting that the bone microenvironment is unable to induce BMP7 expression 
in the metastatic cancer cells. In contrast, the LNCaP, C4-2, and C4-2B4 cell lines, charac-
terized by a much lower tumorigenic and metastatic potential, showed substantial expres-
sion of BMP7 mRNA (Fig. 2B). E-cadherin/vimentin ratio together with BMP7 expression, 
therefore, decreased with increasing tumorigenic potential and a strong correlation exists 
between BMP7 expression and E-cadherin/vimentin ratio (R2=0.98, p=0.0015, Fig. 2C).
BMP7 Treatment of Bone Metastasis and Orthotopic Prostate Cancer Growth In Vivo
 To test whether the observed decrease of BMP7 expression during prostate cancer pro-
gression may contribute to the acquisition of an invasive metastatic phenotype, we investi-
gated if systemic administration of rhBMP7 affected the growth of human prostate cancer 
cells in orthotopic tumor and bone metastasis animal models by whole body bioluminescent 
reporter imaging (BLI) of human PC-3M-Pro4/Luc+ cells.
 Three days after intra-bone inoculation of PC-3M-Pro4/Luc+ cells into the tibiae 
of BALB/c nu/nu mice, the animals were treated daily via tail i.v. injections of 100 µg/kg 
rhBMP7 or a vehicle solution and growth of prostate cancer cells was monitored weekly by 
BLI and  radiography. Administration of BMP7 for the duration of the experiment resulted in 
a significant and sustained inhibition of tumor cell growth and tumor-induced osteolysis in 
bone marrow (Fig. 3A-C). Systemic administration of BMP7 directly acts on bone-residing 
PC-3M-Pro4/Luc+ tumor cells as visualized by nuclear staining for Phospho-Smad1 while 
this is significantly lower in vehicle–treated animals (Fig. 3D). Inoculation of PC-3M-Pro4/
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Figure 2 mRNA expression levels of E-cadherin, vimentin and BMPs in prostate cancer cell lines with different 
tumorigenic potential in vitro and in experimentally-induced bone metastases. A, E-cadherin/
vimentin ratios in prostate cancer cell lines. B, BMP7 mRNA expression in prostate cancer cell lines. 
C, correlation between E-cadherin/vimentin ratio and BMP7 mRNA expression in prostate cancer cell 
lines with different tumorigenic potential (R2=0.98, P=0.0015). D, Relative BMP mRNA expression levels 
in an experimentally-induced bone metastasis from PC-3M-Pro4 cells in nude mice (β2-µglobulin was 
used for normalization as described previously 31). All panels: mRNA levels (± SEM) were quantified by 
real-time RT-PCR.
Luc+ cells into the left cardiac ventricle of nude mice resulted in the formation of multiple 
bone metastases 29-32. Continuous daily treatment with BMP7 did not significantly inhibited 
the number of bone metastases, despite a tendency toward a decrease. However, the aver-
age tumor burden per bone lesion was significantly decreased upon BMP7 treatment (Fig. 
3E).
 Our data therefore suggest that BMP7 inhibits the growth of bone metastases by human 
prostate cancer cells in nude mice. In contrast to its inhibitory effect on bone metastases, 
BMP7 treatment of orthotopically implanted PC-3M-Pro4/Luc+ cells did not alter tumor 
growth (Fig. 4A). After removal of the prostate containing the orthotopically growing tumor, 
multiple loco-regional lymph nodes harbored bioluminescent PC-3M-Pro4/Luc+ cells (Fig. 
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Figure 3 Effects of systemic administration of 100 µg/kg/d rhBMP7 on the growth of human prostate cancer cells in 
bone marrow and bone metastasis in vivo after intraosseous transplantation or intracardiac inoculation of 
human PC-3M-Pro4/Luc+ cells using whole body bioluminescent reporter imaging. A, BMP7 treatment of PC-
3M-Pro4/Luc+ cells growing in bone marrow of nude mice as monitored by BLI. B, representative examples of 
bioluminescent photon emission in a vehicle and BMP7 treated animal at day 21. C, representative radiographs 
at day 21 after intraosseous transplantion of PC-3M-Pro4/Luc+ cells growing in bone marrow (arrows indicate 
bone lesions in tibiae of nude mice). D, immunohistochemical analyses of phosho-Smad1localization at 
day 21 after intraosseous transplantation of PC-3M-Pro4/Luc+ cells growing in bone marrow. The animals 
were either vehicle treated (upper left panel) or treated with rhBMP7 (upper right panel) 6 hours prior to 
explantation and fixation of the tibiae. The number of phosphoSmad1 positive cells in the BMP7 treated group 
are increased significantly. E, effect of BMP7 treatment on the formation and growth of bone metastases by PC-
3M-Pro4/Luc+ in nude mice as monitored by BLI (tumor burden, number of bone metastases, representative 
examples of BLI at day 19). BLI was performed once weekly starting at day 0 after intraosseous implantation or 
intracardiac inoculation of the prostate cancer cells and quantified in relative light units (RLU) ± s.e.m. n=8 for 
each experimental group for intraosseous transplantation experiment (A-D); n=10 for intracardiac inoculation 
(E). Values are expressed as means ± s.e.m. *p<0.05, **p<0.001 (ANOVA)
Jeroen_Buijs_18.indd   182 26-11-2008   10:19:02

























Figure 4 Effects of systemic administration of 100 µg/kg/d rhBMP7 on intra-prostatic growth of human PC-3M-
Pro4/Luc+ cells and formation of loco-regional lymph node metastases nude mice. A, tumor take of 
PC-3M-Pro4/Luc+ cells growing in prostate upon treatment with vehicle solution or 100 µg/kg/d rhBMP7 
as monitored by BLI. B, number of affected lymph nodes in nude mice after 21 days as detected by BLI. 
C, representative example of bioluminescent photon emission of a mouse with multiple loco-regional 
lymph node metastases 21 days after intra-prostatic inoculation of PC-3M-Pro4/Luc+ cells. The mouse 
prostate was removed prior to bioluminescent reporter imaging to obtain sensitive measurements 
of affected lymph nodes (panel B). The presence of micrometastatic deposits in lymph nodes was 
confirmed by HE-staining. BLI was performed at least once weekly starting at day 0 after intra-prostatic 
implantation of the prostate cancer cells and quantified in Relative light units (RLU) ± s.e.m. n=8 for each 
experimental group. Values are expressed as means ± s.e.m. (ANOVA).








4B). Administration of BMP7, however, did not result in decreased formation of locoregional 
lymph node metastases (Fig. 4C).
BMP7 and Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells
Next we tested whether BMP7 acts on human PC-3M-Pro4 prostate cancer cells to inhibit 
the acquistion of an invasive, mesenchymal phenotype by antagonizing Smad-dependent 
TGF-β signaling. For this, we first studied the functionality of both TGF-β and BMP receptors 
in PC-3M-Pro4 prostate cancer cells. Challenging PC-3M-Pro4/Luc+ cells by both BMP7 
and TGF-β, that were transiently transfected with SBE4-luciferase, resulted in a significant 
induction of reporter expression (Fig. 5A). This indicates that functional TGF-β and BMP 
receptors are present in these cells, thus confirming our earlier observations 22,24. Exog-
enous addition of BMP7, but not of TGF-β, strongly stimulated BRE4-luciferase activity in 
PC-3M-Pro4 cells and indicated the presence of functioning, activated type I BMP-receptor 
complexes in these prostate cancer cells (Fig. 5B). Strikingly, when BMP7 and TGF-β were 
given simultaneously, BRE4-luciferase activity was significantly stimulated in a synergistic 
manner (Fig. 5B).
 The presence of functionally active TGF-β receptor complexes, particularly ALK5 (TGF-β 
type I receptor), in PC-3M-Pro4 cells was demonstrated by the CAGA-luciferase reporter. 
The CAGA boxes confer TGF-β, but not BMP, stimulation to the promoter reporter constructs 
in PC-3M-Pro4 cells in a dose-dependent manner (Fig. 5 C,D). Addition of BMP7 to TGF-β-
stimulated PC-3M-Pro4 cells dose-dependently inhibited TGF-β-driven CAGA-luciferase 
activity. This suggests that BMP7 counteracts TGF-β-induced nuclear activation of Smad3/4 
(Fig. 5C,D) in human prostate cancer cells, whereas TGF-β can stimulate BRE4-luciferase 
only in the presence of BMP7 (Fig. 5B).
The observed anti-tumor effects of BMP7 in vivo may, therefore, be caused by inhibition of 
TGF-β mediated growth stimulatory responses in bone metastasis. This may be particu-
larly true for the bone microenvironment since bone is a storehouse for TGF-β and it has 
been shown that activated TGF-β is released from bone matrix by bone-resorbing osteo-
clasts 29,31,32,42,43.
 The expression level of E-cadherin appears to be inversely related with prostate cancer 
grade and its loss considered a hall mark of EMT 23,44,45. Recombinant human BMP7 dose-
dependently induced E-cadherin promoter activity (> 150% at 1 µg/ml BMP7, p<0.01) while 
TGF-β had no effect (Fig. 6A). Strikingly, E-cadherin promoter activity was stimulated in a syn-
ergistic, dose-dependent and significant manner by BMP7 in the presence of TGF-β (Fig. 6B, 
350%). In line with this observation, Western blot analysis revealed that E-cadherin/vimentin 
ratio at the protein level was strongly up-regulated under these circumstances (Fig. 6C). These 
data, therefore, suggest that BMP7 can counteract the acquisition of an invasive, metastatic 
phenotype by re-expressing the key epithelial marker E-cadherin, that is an absolute require-
ment for epithelial integrity by decreasing cell motility, invasion and migration.
Jeroen_Buijs_18.indd   184 26-11-2008   10:19:02
 BMP7 and prostate cancer progression 185
 When TGF-β was added to PC-3M-Pro4/Luc+ cells the intermediate filament and mes-
enchymal marker vimentin was redistributed in the prostate cancer cells (Fig. 6D). This 
TGF-β-induced vimentin expression and cellular redistribution was completely abolished 
by BMP7 (Fig. 6D).
Discussion
In this report novel evidence is provided for the importance of BMP7 (and TGF-β) in the 
development of an epithelial cancer and metastastic behavior with prostate cancer as 














































































Figure 5 The effects of BMP7 on gene promoter luciferase constructs in human PC-3M-Pro4 prostate cancer cells. 
A, challenge of the SBE4 construct, demonstrates the presence of functional BMP7 and TGF-β receptors 
(Smad-mediated signaling). B, BMP7, but not TGF-β, induces BRE4-luciferase actvity, indicating the presence 
and functionality of BMP-receptors. Signaling of BMP to stimulate the expression of BRE4-luciferase is 
transduced by BMPR-IA and mediated by Smad1, Smad4 and Smad5, both of which form a complex with this 
reporter construct. Strikingly signaling of BMP7 to stimulate BRE4-luciferase is significantly enhanced when 
co-incubated in the presence of TGF-β. C,D, the presence of functionally active TGF-β receptor complexes, 
particularly ALK5 (TGF-β type I receptor), in PC-3M-Pro4 cells was demonstrated by the CAGA-luciferase 
reporter, whose activity depends on binding of activated Smad3/Smad4 transcription factor complexes. The 
CAGA boxes confer TGF-β, but not BMP, stimulation to the promoter reporter constructs. Addition of BMP7 to 
TGF-β-stimulated PC-3M-Pro4 cells dose-dependently inhibited TGF-β-driven CAGA-luciferase activity. All 
panels: * p < 0,01 vs. Co; # p < 0,01 vs. TGF-β 
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Figure 6 The effects of BMP7 on E-cadherin promoter luciferase constructs,and protein expression of E-cadherin/
vimentin in human PC-3M-Pro4 prostate cancer cells. A,B, BMP7 induces a dose-dependent and significant 
increase in E-cadherin promoter-luciferase construct activity (* p<0.05 vs. Co; # p<0.01 vs. BMP7 aloneCo). 
E-cadherin promoter activity is significantly and synergistically enhanced when BMP7 and TGF-β were 
coincubated (P<0.05 vs BMP7 alone). C, E-cadherin and vimentin protein expression in PC-3M-Pro4 cells 
in the presence or absence of rhBMP7 and/or TGF-β for 48 hours as determined by immuno-blotting. 
Treatment of PC-3M-Pro4 cells with 0.5 µg/ml rhBMP7 in the presence of TGF-β induces protein expression 
of E-cadherin. Values are expressed as E-cadherin/Vimentin ratio. D, vimentin mAb immuno-reactivity of 
cultured PC-3M-Pro4 cells. In the presence of BMP7 the TGF-β−induced vimentin expression and cellular 
redistribution was completely abolished. Values are expressed as means ± s.d. (n=4, ANOVA).
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human prostate cancer and we postulate a role for BMP7 in controlling epithelial home-
ostasis of the prostate gland. In line with these clinical findings experimental treatment of 
bone metastases from human prostate cancer in vivo position BMP7 as a good candidate for 
the treatment of skeletal metastasis from prostate cancer.
 Members of the TGF-β superfamily play crucial roles in embryonic development, cer-
tain fibrotic diseases, inflammation and cancer. Although TGF-β inhibits the proliferation of 
normal prostate cells and functions as a tumor suppressor in early tumorigenesis, it acts 
as a tumor promoter in later stages of tumor progression and mediates oncogenic EMT 
2,5,10,17,46-49,63. Prostate cancers often grow in a variety of growth patterns, that are classi-
fied by Gleason histological grading. Prostate cancer classification according to this “gold 
standard” is predictive of disease status and also seems to parallel EMT. Laser capture 
micro-dissection of prostate epithelium/cancer was used because the epithelial compart-
ment in the normal prostate represents only a small percentage (~5%) of the entire organ. 
Furthermore, infiltrative prostate cancer patterns vary among individual cases. The latter 
can lead to misinterpretation of epithelium-specific gene expression among the various 
clinical specimens. By comparing pure populations of laser-captured cancer cells and non-
cancerous epithelial cells from the same patient we observed significant and consistent 
BMP7 mRNA under-expression in invasive primary prostate carcinoma. In contrast, BMP7 
mRNA expression in bulk tissue specimens of non-cancerous prostate and prostate cancer 
tissue showed only a tendency toward under-expression in prostate cancer. Our observa-
tions support concerns that high throughput RNA expression analysis performed on bulk 
tissue samples, either on primary tumors or its metastases, may not detect differences 
in relevant gene expression restricted to the epithelial or mesenchymal compartment 22. 
Clearly, LCM is preferred to establish putative changes in gene expression repertories in 
both epithelial and stromal compartments.
 Emerging evidence from a variety of tumors suggests that the effects of BMPs (and TGF-
β) are cell specific and could be either pro-tumorigenic or anti-tumorigenic 48. For instance, 
BMP7 was shown to either counteract EMT by inducing MET, to induce EMT or to have no 
effect 2,4,10,49,50. In the non-cancerous human prostate, expression of BMP7 protein was 
restricted mainly to the glandular epithelium, whereas primary prostate cancers show low 
or undetectable BMP7 protein expression. It also appeared that BMP7 expression is nega-
tively correlated to Gleason score (data not shown) but the number of patients per Gleason 
pattern were too small for statistical analysis. Clearly more LCM and real-time PCR analy-
sis are warranted to address this issue.
 In line with these clinical observations, the level of BMP7 expression in tested prostate 
cancer cell lines correlated with an epithelial phenotype and appears, therefore, inversely 
related to their tumorigenic and metastatic potential in vivo.
 Daily systemic administration of recombinant BMP7 did not affect the growth of orthopi-
cally implanted PC-3M-Pro4/Luc+ prostate cancer cells and subsequent formation of 








lymph node metastasis in nude mice. However, the growth of micrometastatic deposits 
from human PC-3M-Pro4/Luc+ prostate cancer cells in bone marrow was inhibited signifi-
cantly, whereas the process of bone marrow colonization per sé appeared unaffected. Our 
findings suggest, therefore, that the tumor microenvironment is an important determinant 
of the therapeutic response to BMP7.
 Our in vitro studies reveal for the first time that BMP7 is a potent inhibitor of TGF-β-
induced EMT in PC-3M-Pro4 prostate cancer cells. In these cells, BMP7 counteracts TGF-
ß-induced activation of Smad3/4 signaling. BMP7 induced a dose-dependent expression of 
E-cadherin that led to an overall increase in E-cadherin/vimentin ratio as an established 
indicator of less-malignant and more epithelial phenotype. Surprisingly, we observed that 
these BMP7-mediated effects were synergistically enhanced by co-incubation with TGF-β 
at both transcriptional and protein levels. These actions of BMP7 may be of critical impor-
tance for explaining the successful experimental treatment of skeletal metastasis and 
intra-bone growth. In this context it is important to note that TGF-β, which is concentrated in 
high inactive amounts in bone matrix, can be released and activated by osteoclastic resorp-
tion. TGF-β may act as paracrine growth factors for neighboring cancer cells that may have 
colonized the bone marrow 31,32,42,43. Compelling evidence suggests that the formation of 
micrometastatic deposits in bone marrow and subsequent development into clinically overt 
(macro)metastasis are critically dependent on the tumor-bone (marrow) interactions, in 
particular bone remodeling 32,43,51. Although little is known regarding the impact of bone 
(marrow) stromal cells in prostate cancer bone metastasis, it can be argued that the pro-
duction and release of specific growth factors, CSFs and cytokines like Wnts, that are criti-
cally important for the maintenance of the hematopoietic stem cells niche (and that regulate 
hematopoiesis), may also be essential for colonization, survival and growth of cancer cells. 
Interestingly, TGF-β/BMPs and other pathways like wingless/Wnt, Notch, Hedgehog, appear 
not only to be involved in bone development/homeostasis and hematopoiesis but also in 
prostate cancer initiation and progression 2,8,52-55. Our in vitro and in vivo data further support 
the notion BMP7 can antagonize TGF-β signaling routes in human prostate cancer cells that 
are metastatic to the skeleton.
 EMT provides mechanisms for prostate epithelial cells to overcome physical constraints 
imposed on them by intercellular junctions and adopt a motile phenotype. We hypothesize 
that the activation process of micrometastases in bone marrow may bear similarities to EMT 
that occurs at the primary site in various epithelial cancers and during ontogeny. TGF-β/
BMPs and their signaling molecules, have been implicated in the cellular plasticity that 
occurs during organogenesis, tissue repair/remodeling and carcinogenesis where cells can 
shift between epithelial and mesenchymal phenotypes 1,2. EMT/MET can thus be viewed as 
a prime example of such cell plasticity. Considering the importance of TGF-β superfamily in 
bone metastasis 42, our findings suggest that the efficacy of BMP7 in the experimental treat-
ment of bone metastases is interfering with recapitulation of such cell plasticity of bone 
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marrow micrometastatic cancer cells, particularly the acquisition of an invasive phenotype 
by (TGF-β-driven?) EMT. Clinical studies also seem to underline the cellular plasticity of 
prostate cancer during dissemination and bone metastasis 56,57. The transition from a well-
differentiated epithelial phenotype to an invasive mesenchymal phenotype may, of course, 
involve molecular mechanisms other than those described here (reviewed in 58). Other stud-
ies have provided evidence that motility and invasiveness can be enhanced without inducing 
a complete conversion of cellular identity 58. After migrating to new organ or tissue territo-
ries, metastatic prostate cancer cells can regain epithelial morphology by a phenomenon 
known as MET and re-establish E-cadherin expression and epithelial junctions 56-58. The 
observed reversion to an epithelial morphology in prostate cancer seems possible even at 
bone metastatic sites 56-58 and is in full agreement with our in vitro and in vivo data presented 
here. Furthermore, previous studies demonstrated cellular plasticity of human prostate 
cancer cells (PC-3 cells), particularly the EMT/MET interconversion induced by different 
culture conditions (monolayer vs. 3D cultures) 59.
 In many prostate cancer patients, micrometastatic deposits may already exist in bone 
marrow after removal of the primary tumor that cannot be identified at the time of diagno-
sis (minimal residual disease). Whole body BLI of luciferase-expressing human prostate 
cancer cells revealed that growth of micrometastatic deposits in bone marrow are sig-
nificantly inhibited by systemic administration of BMP7. Similar observations were made 
by us for other epithelial cancers, including breast cancer 62,63. Interestingly, recent data 
suggest that BMPs can inhibit the tumorigenic potential of human brain tumor-initiating 
cells, mediated via a significant reduction in the stem-like, tumor-initiating precursors 60. 
Accumulating evidence suggests that cancer stem cells with tumor-initiating potential exist 
in human prostate cancer 61. Although speculative at present, the observed therapeutic 
effects of BMP7 described here may be mediated, at least in part, by prostate cancer cells 
with tumor-initiating (and metastastic) potential. Studies are currently on-going to address 
these important issues.
 In conclusion, our data suggest that BMP7 controls the epithelial homeostasis in the 
human prostate gland by preserving the epithelial phenotype. Loss of BMP7 expression 
during prostate cancer progression could stimulate the TGF-β stimulated EMT and, thus, 
contribute to the acquisition of an invasive phenotype. However, exogenous BMP7 can still 
counteract the EMT process in the metastatic tumor, thus underscoring tumor plastic-
ity, but its therapeutic response may be determined by the microenvironment. Therefore, 
BMP7 may represent a novel therapeutic molecule for repression of systemic prostate can-
cer progression.
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The skeleton is one of the most commonly affected organs in metastatic disease, and it is 
a major cause of morbidity, characterized by severe pain and high incidence of fractures, 
spinal cord compression and bone marrow aplasia requiring hospitalization. However, 
only a restricted number of solid cancers, especially those of the breast and prostate, are 
responsible for the majority of the bone metastases 1-4. Despite the high frequency of skel-
etal metastases, the molecular mechanisms underlying the predisposition for tumors to 
colonize bone are poorly understood and treatment options are often unsatisfactory. There-
fore, the focus of this thesis is to better understand the processes that contribute to the 
formation of distant metastasis (chapter 2), particularly to bone (chapter 4–7), as well as to 
explore new treatment strategies with conventional (chapter 4 and 5) and novel therapeutic 
molecules (chapter 6 and 7) using new and better animal models (chapter 3–7).
PAS+ Structures as Predictor of Clinical Outcome in Breast Cancer Patients
Although current clinicopathologic parameters are widely used to predict outcome, the clin-
ical behavior of prostate and breast cancer can still be quite different 5. In order to improve 
breast and prostate cancer management, better and reliable markers are needed that can 
distinguish patients with good and poor prognosis.
 In chapter 2, we demonstrate that, in addition to the tumor blood vessels, different thin 
periodic acid-Schiff-positive (PAS+) meshworks may exist in invasive ductal carcinoma (IDC) 
of the breast and their lymph node metastases. More importantly, the complexity of the PAS+ 
meshwork in the lymph node metastases was related to poor prognosis. Moreover, we found 
that the presence of the most complex thin PAS+ pattern — the PAS+ network — in lymph node 
metastases and stage classification of the tumor were the only two independent risk factors 
associated with the occurrence of a distant metastasis. Additionally, the presence of a PAS+ 
network in a positive lymph node is the factor most strongly associated with poor prognosis.
 Immunohistochemically, these PAS+ meshworks showed continuous expression of 
SMA and patchy expression of CD31. The presence of lumina in the PAS+ meshwork might 
be indicative for septa that may facilitate perfusion and/or dissemination of cancer cells. 
Indeed, tumor cells were frequently present in the lumina, whereas, erythrocytes were only 
occasionally found in these structures.
 In 63 % of the patients, thin PAS+ patterns were present in both the primary tumors and 
in their respective lymph node metastases. Some tumors may, therefore, have the capabil-
ity to form such PAS+ patterns; however, none of the thin PAS+ patterns scored in primary 
tumors appeared to be of prognostic significance. The non-prognostic value of these pat-
terns in primary tumors can be explained by the coexistence of other PAS+/SMA+ structures 
in primary tumors or normal breast tissue, that hamper the interpretation. Most probably, 
myoepithelial cells and myofibroblasts interfere with scoring of the PAS+ patterns in the 
primary breast cancer.







 Foss and co-workers provided evidence that PAS+ extracellular septa could be partic-
ularly favorable substrates for the in-growth of angiogenic, and possibly lymphatic, ves-
sels 6. Consequently, tumors that contain these PAS+ structures might be more aggressive, 
as these structures provide better means for (blood) vessel in-growth than tumors lack-
ing these structures. The lack of continuous flt-4 (alias VEGFR-3) expression in the PAS+ 
networks of breast cancer patients may, therefore, indicate that these structures do not 
entirely represent lymphatic vasculature. Indeed, the differences in distribution of flt-4+ 
and CD31+ patterns within the PAS+ networks in our tissue specimens from the patients, 
support the notion that PAS+ meshworks are complex and consist of multiple types of vas-
culature (blood vessels, and possibly lymphatics). If the septa consist of two layers of ECM 
elaborated by opposing layers of tumor cells, the layers could separate, forming channels 
and laminar openings. Such openings could particularly lead to capillary growth. The patchy 
expression of the endothelial marker, CD31, is in agreement with this hypothesis. Finally, it 
has been suggested that the open ends of the growing capillaries could feed blood into the 
channels. This may explain the presence of erythrocytes in the channels, reconciling differ-
ent hypotheses 7.
 In both uveal and cutaneous melanoma the presence of networks that stain positive with 
PAS has also been described 8-11 and was shown to be of prognostic significance as well 11-13. 
These cancers could also generate such PAS+ networks in vitro without participation of 
endothelial cells and thus independent of angiogenesis. This was termed ‘vasculogenic 
mimicry’ (VM) to emphasize their de novo generation 6,14-19. In VM, the PAS+ interconnected 
loops are the tumor-lined vessels that might be perfused indicated by the presence of 
erythrocytes. Tumor cells that form the PAS+ loops express a variety of endothelial mark-
ers, such as VE-cadherin. It was reported that vasculogenic mimicry may also exist in ovar-
ian 20, prostate 21 and inflammatory breast cancer 14,22. It is tempting to speculate that tumor 
cells that align hollow tubular structures are phenotypically distinct from other tumor cells 
due to epithelial cell plasticity. Accordingly, epithelial cell plasticity might be a prerequi-
site for a tumor to form such a network 21. The absence of expression of VE-cadherin, an 
endothelial marker that was shown to be a crucial molecule for melanoma VM 23, in both 
the MDA-MB-231 (MDA-231) and PC-3M-Pro4 cell lines (unpublished results), makes it less 
likely that VM is also present in our models.
 Although the exact nature and origin of the PAS+ network in different carcinomas remains 
to be elucidated, the presence of PAS+ patterns, at least in breast cancer (chapter 2), uveal 
and cutaneous melanoma 11-13, is a strong and independent risk factor for the occurrence of 
a distant metastasis. Therefore, by examining IDC patients for the presence of PAS+ net-
works in their lymph node metastases, the clinical behavior of this heterogeneous group 
of breast cancer patients can be better predicted, which may ultimately lead to improved 
management of the disease.
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A Mouse Model of Bone Metastasis using Bioluminescent Imaging
Animal models have become important tools to study the molecular mechanisms that are 
involved in the formation of bone metastases, and have adequately served as pre-clinical 
models to test new drug compounds and strategies. The formation of bone metastases after 
injection of breast cancer cells into the left cardiac ventricle of immunodeficient (nu/nu) 
mice, has been one of the most widely used model of bone metastasis 24-26. This experimen-
tal setting closely resembles the clinical situation of minimal residual disease (MRD) after 
removal of the primary tumor. However, radiographic analysis for detection of experimen-
tally-induced bone metastases is far from ideal. Firstly, radiologically evident osteolytic/
osteosclerotic metastases are a late and macroscopic event in the evolution of metastatic 
bone disease. Thus, radiography lacks the sensitivity that would be necessary to investigate 
initial processes, such as the ‘angiogenic switch’, which may be critical for tumor progres-
sion 27. Secondly, radiography does not detect actual tumor burden but reveals only changes 
in bone mineral density, which is an indirect, late, and inconsistent sign of the presence of a 
tumor. In fact, determination of an osteolytic area depends on the ability of the cancer cells 
to secrete bone-resorbing cytokines rather than on tumor mass itself. Furthermore, the 
determination of the osteolytic area does not take into account the extension of the tumor 
burden in the surrounding soft tissues. Therefore, more sensitive and direct methods of 
detecting bone metastatic growth in experimental animals are needed.
 As described in chapter 3, we are now able to directly monitor the distribution and growth 
of luciferase-transfected cancer cells in intact animals using whole-body bioluminescent 
reporter imaging (BLI). BLI is based upon photon signals emitted by luciferase-express-
ing cancer cells after addition of the substrate luciferin, and provides a direct indication of 
tumor viability and growth. In comparison with the indirect detection using radiography, 
the BLI method yields higher sensitivity, reliability, and statistical power. The remarkable 
sensitivity of the optical imaging in detecting microscopic bone marrow (BM) metastases 
allows the detection of bone micrometastatic deposits of 0.5 mm3 volume, preceding the 
appearance of radiological evident osteolysis by ~2 weeks. In fact, newer optical imaging 
modalities with even better resolution have already been developed. In chapters 4–7, BLI 
was used both to study the molecular mechanisms in bone metastasis, as well as to develop 
and evaluate conventional and novel treatments.
Treatment of Bone Metastases with Bone Resorption Inhibitors
Interference with the microenvironmental growth support has been proposed as an attrac-
tive strategy for decreasing metastatic tumor growth 28. Bone is a dynamic tissue that is 
continuously remodeled by bone resorption and subsequent bone formation 29. Animal and 
human studies have shown that increased bone remodeling promotes the formation of bone 







metastases through the release of factors from bone matrix that support metastatic growth 
in the BM 30,31. Differently from other tissues, agents that specifically interfere with the tumor 
microenvironment are available for bone and bisphosphonates (BPs) are used clinically for 
the protection of bone destruction by metastases from different primary tumors 32-36.
 In chapter 4, we have shown that treatment with clinically relevant doses of BPs before 
the establishment of micrometastases (preventive protocol) reduced the number of devel-
oping bone metastases by ~70%. This level of inhibition is consistent with the observation 
that in the experimental animal not more than 70% of the bone resorption can be inhibited 
by high doses of BPs 37. Possibly, this persistently low level of bone resorption is sufficient 
to provide growth support to a minimal number of micrometastatic foci. BP treatment also 
inhibited the early progression of tumor growth in the small number of still developing 
metastases. However, at later stages, when bone metastases have already developed, BP 
treatment did not inhibit tumor growth.
 So, when BPs were given to animals with established bone metastases they did not 
inhibit the growth of breast cancer cells in the bone microenvironment, despite a substan-
tial anti-osteolytic effect. There are at least three hypotheses to explain these data, the lack 
of tumor growth response was due 1) to the magnitude of suppression of bone resorption 
and, hence, the potency of the BPs given, 2) to the mechanism of inhibition of bone resorp-
tion by the BPs, or 3) that the initial growth phase of cancer cells in bone is dependent upon 
the interaction with the bone microenvironment, but eventually becomes independent of the 
bone microenvironment and can progress autonomously.
 To address these issues, we used an experimental model of intraosseous growth and 
compared the effects of very high doses of the most potent BP currently available 38,39, 
zoledronic acid (ZOL), with the effects of osteoprotegerin (Fc-OPG), which inhibits bone 
resorption by a different mechanism of action (chapter 5). As expected, both Fc-OPG and 
ZOL treatment markedly suppressed bone resorption, protected the integrity of bone 
trabeculae and prevented the development of osteolytic lesions. Intraosseous tumor bur-
den was reduced, however, the total tumor burden (intra-bone and extramedullary) still 
progressed. Although at the end of the experiment the total tumor burden in treated groups 
appeared less compared to controls, this difference was not significant.
 Previous studies of the effects of BPs on bone metastatic breast cancer growth in animal 
models have shown contradictory results. BPs were reported to reduce the tumor burden 
in established bone metastases but not in soft tissue and visceral metastases. This effect 
seemed to be mediated by induction of apoptosis of the cancer cells 25,40. Treatment with BP, 
given before the development of evident metastasis, resulted in a marked reduction of the 
number of bone metastases 25,41,42. However, another preventive study showed that BP treat-
ment resulted in an increased tumor burden in the developing bone metastases but not in 
visceral metastases 43. In these investigations tumor burden has been quantified by indirect 
measurements of the tumor-induced osteolytic area on bone radiographs and end-stage 
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histology. In contrast, BLI allowed us to detect the total tumor burden directly and more 
sensitive, yielding more reliable data. Our BLI data favor the hypothesis that metastatic 
cancer cells in bone — after an initial growth phase that depends on their interaction with 
the BM stroma and extracellular bone matrix — become increasingly independent of micro-
environmental growth factor support and is self-maintained by autocrine mechanisms.
 How can the therapeutic effect of inhibition of bone resorption/turnover on early stages 
of bone metastasis development be explained? Bone remodeling does not occur through-
out the entire bone surface but takes place at microscopic patches of bone resorption 
and subsequent bone formation. The number and activity of so-called basic multicellular 
units (BMUs) determine the rate of bone turnover. We hypothesize that the probability that 
a micrometastasis becomes a clinically evident bone metastasis should be related to the 
chance that metastasis-initiating cells (MICs) are in close proximity with an active BMU. 
MICs may extravasate near active BMUs, or dormant MICs may encounter active BMUs. In 
either case, a higher number of active BMUs (high bone turnover rate) increases the prob-
ability that MICs come in close proximity of active BMUs. This hypothesis is substantiated 
by clinical data demonstrating that high bone turnover in cancer patients with metastatic 
bone disease is associated with skeletal-related events, disease progression and death 
44-47, and by experimental evidence showing that high bone turnover is causally associated 
with establishment and progression of bone metastases 31,48. Accordingly, inhibition of bone 
turnover before the generation of a self-maintaining, autocrine cancer cell growth may 
arrest the vicious cycle underlying the initial growth support by the BMU and ultimately 
prevent the outgrowth of a micrometastasis into an overt bone metastasis.
 Based on our preclinical data (chapter 4) and that of others, one may predict that BP 
therapy as adjuvant treatment in breast cancer patients decreases the risk of formation 
of new bone metastases. However, clinical studies have shown mixed results with regard 
to the development of new bone metastases. Clodronate as adjuvant therapy significantly 
reduced 49, non-significantly reduced 50, or did not reduce 51,52 the development of new bone 
metastases. Nevertheless, the largest reported randomized controlled study to date of BP 
use in patients with breast cancer demonstrated that clodronate significantly improved 
bone relapse-free survival 52,53. Results from the National Surgical Adjuvant Breast and 
Bowel Project B34 trial, an even larger randomized placebo-controlled trial of clodronate 
versus placebo in women with early-stage breast cancer who have received standard adju-
vant systemic therapy, are awaited.
 Although current clinicopathologic parameters are widely used to predict clinical out-
come, the clinical behavior of breast (and prostate) cancer can still be quite different. There-
fore, more specific and more reliable markers that can distinguish between patients with 
high and low risk for bone metastasis formation are needed, and may become the rationale 
to start adjuvant BP treatment even before the onset of bone metastatic disease.







 At present, the most promising approaches that may lead to a better identification and 
stratification of the cancer patients at risk to develop bone metastases are the 1) assess-
ment of bone turnover status, 2) use of microarray technology, and 3) detection of dissemi-
nating tumor cells (DTCs) in BM (and blood).
 Although high bone turnover rate in bone metastatic cancer patients is associated with 
bone disease progression 45-47, to date, it has not been specifically addressed whether high 
bone turnover in non-metastatic cancer patients is associated with subsequent formation of 
new bone metastases. Interestingly, many cancer patients with a resected primary tumor dis-
play a high bone turnover rate, which is either induced at a basal level (e.g., induced by men-
opause) or induced after surgical or chemical gender steroid deprivation. Especially these 
patients — who probably harbor micrometastatic MICs in the BM at the moment of diagnosis 
and/or surgery — may benefit from prophylactic bone resorption inhibition by BPs.
 Microarray analysis is a new and promising technique that may also identify which 
patients are at increased risk for developing bone metastases. Using this technology, 
Kang and co-workers generated a 122-gene bone metastasis signature by comparing gene 
expression among sublines of the human breast cancer cell line, MDA-231, that are highly 
vs. weakly metastatic to bone in nude mice 54. Moreover, Woelfle and co-workers reported a 
73–gene signature capable of identifying lymph node-negative patients with or without BM 
micrometastasis 55. Furthermore, Smid and co-workers have studied lymph node-negative 
primary breast cancer and reported a putative molecular signature capable of predicting 
metastatic recurrence to bone vs. recurrence elsewhere in the body 56. A 31-gene signature 
was selected to predict which patients developed bone metastases with 100% sensitivity 
and 50% specificity. The low specificity may reflect that microarray analysis only describes 
global mRNA obtained from the tumor, whereas all genes that are necessary to metas-
tasize to bone have to be coordinately expressed in an individual tumor cell. Surprisingly, 
genes that were previously identified to promote bone metastasis such as IL-8 57, PTHrP 
58 and αvβ3 59, were not members within any of these bone signatures. Although the bone 
signatures from Kang and Smid display a common increase in the FGFR-p42/44 MAPK 
pathway, it is still disappointing that just one single gene (BENE) is shared between any 
two of the three signatures. Besides differences in experimental approaches and patient 
population selected, the lack of overlap may also be reflected by the low reproducibility 
between studies using microarray technology. This was demonstrated by the comparison 
of two studies which both generated a gene signature capable to predict distant metastasis 
in lymph node negative breast cancer patients 60,61. Although both studies included a simi-
lar number and type of patients, had comparable experimental design, and used similar 
statistical methods of validation, the resulting 70 and 76 gene predictors overlapped only 
by three genes.
 Another approach to predict which patients are at high risk to develop a bone metastasis 
is to screen BM for the presence of DTCs. Although not only true MICs might be identified, 
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the presence of DTCs in BM at time of diagnosis is significantly associated with the forma-
tion of distant metastases, particularly to bone 62,63.
 In conclusion, these different approaches are very promising and may lead to a better 
stratification of patients at high risk for the de novo formation of bone metastasis, and there-
fore, may become the rationale to start adjuvant BP treatment even before the onset of 
bone metastatic disease. However, these approaches need first to be extensively validated 
in large confirmatory studies by independent groups.
BMP7 in Progression and Metastasis in Osteotropic Cancers
The increased motility and invasiveness of cancer cells are reminiscent of the epithelial-
to-mesenchymal transition (EMT) that occurs during embryonic development 64. The EMT 
is associated with decreased expression of epithelial markers such as E-cadherin, and 
increased expression of mesenchymal markers such as vimentin. By signaling through the 
Smad mediators, transforming growth factor (TGF)-β is a well-known inducer of EMT in 
both embryogenesis and its’ counterpart in cancer progression. However, in organogen-
esis, ‘mesenchymal’ cells may possess remarkable plasticity and may regain a fully dif-
ferentiated phenotype via a mesenchymal-to-epithelial transition (MET) under the influence 
of bone morphogenetic protein (BMP) 7 65-67. Under pathologic conditions, particularly in 
malignant disease, the role of BMP7 has remained largely elusive.
Expression of BMPs during Cancer Progression
In chapter 6 and 7, we described that BMP7 expression in breast and prostate cancer 
cell lines in vitro correlated with expression of E-cadherin, and inversely correlated with 
aggressiveness and expression of vimentin. In addition, human prostate cancer cells from 
the primary tumor had a decreased BMP7 expression when compared with matched non-
carcinogenic prostate epithelium as assessed by laser-microdissection and immunohis-
tochemical staining. Overall, BMP6 is overexpressed in aggressive prostate cancer when 
compared with normal prostate tissue 68-70, and BMP2, BMP4, 70 and BMP7 (chapter 7) are 
expressed predominantly in normal prostate tissue, and their expression tends to be lower 
or absent during progression of prostate cancer (reviewed in 71). In this regard, it should be 
mentioned that it seems to have become a general misconception that BMP7 was found to 
be significantly increased in prostate cancer bone metastases. This is probably due to the 
misleading title “Increased expression of BMP7 in bone metastatic prostate cancer” of an 
article 72, in which BMP7 mRNA expression levels in bone metastatic prostate cancer from 
autopsies were only found to be significantly increased when compared to non-tumor bear-
ing bone, not when compared to primary tumor. Therefore, this first needs to be further 
investigated, including immunohistochemical staining for BMP7 on autopsy material.







 BMP7 expression in prostate cells is regulated by androgens because orchidectomy 
decreased BMP7 expression 73, while testosterone and dihydrotestosterone increased 
it 74 (Fig. 1). These observations are in line with our data, showing that BMP7 expression 
is reduced in prostate cancer cell lines that are androgen-insensitive. These data, conse-
quently, raise the question that evolution of prostate cancer to metastatic dissemination 
after hormonal therapy may be linked to the loss of androgen-induced BMP7 expression 
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Figure 1 Role of BMP7 in cancer progression. Top: In breast cancer, TGF-β and BMP7 exert opposing effects. 
Whereas TGF-β induces epithelial-to-mesenchymal (EMT), BMP7 induces the opposite process of 
mesenchymal-to-epithelial transition (MET). Bottem: Similarly, BMP7 induces MET, and TGF-β induces 
EMT in prostate cancer cells. Remarkably, BMP7 induces MET more prominently in the presence of TGF-β 
in prostate cancer cells. In the prostate gland, androgens stimulate the production of BMP7 by prostate 
epithelial cells. In the later stage of the disease, BMP7 ceases to act on cancer cells, potentially because 
of the loss of androgen-induced production of BMP7 after anti-androgen therapy. Subsequently, TGF-β 
alone induces EMT, including repression of E-cadherin expression and stimulation of the acquisition 
of an invasive phenotype. Consequently, the cancer cells with an acquired metastatic potential can 
disseminate through the bloodstream to other organs, including bones.
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and loss of epithelial phenotype maintenance. In other words, androgen deprivation therapy 
may directly result in perturbation of the epithelial homeostasis.
 The expression of different BMPs in breast cancer progression is less well-studied, and 
only a very limited number of studies have explored the consequences of BMP signaling 
on patient outcome. In ductal breast cancer patients, BMP2 expression did not affect the 
overall or relapse-free survival 75, whereas overexpression of BMP receptor IB associated 
with poor prognosis in estrogen receptor (ER)-positive breast cancer 76. In 170 breast cancer 
patients with IDC, Schwalbe and co-workers observed that expression of BMP7 protein was 
highly associated with ER and progesterone receptor (PR) levels. Using a tissue microar-
ray (TMA), we confirmed indeed that expression of BMP7 in 520 breast cancer patients was 
associated with ER + PR levels (manuscript in preparation). To follow up on these findings, 
we are currently investigating whether treatment with the hormones estrogen and proges-
terone regulates BMP7 gene expression in breast cancer as well (manuscript in prepara-
tion). Furthermore, our TMA data did not show an association between BMP7 expression in 
primary tumor and (disease free) survival or metastatic pattern. This seeming discrepancy 
with the data that BMP7 mRNA was associated with formation of bone metastasis (chap-
ter 6), may be explained by the findings from Alarmo and co-workers who showed that there 
is no significant correlation between BMP7 copy number, BMP7 mRNA and BMP7 protein 
levels 77. This is substantiated by the fact that invasive lobular carcinoma (ILC) of the breast 
expressed elevated levels of BMP7 protein when compared to IDC, even though an increase 
in BMP7 gene copy number was found in IDC, but not in ILC 77. The observation that regulat-
ing the recruitment of histone deacetylase HDAC2 to the BMP7 promoter region acts as a 
regulatory mechanism to control BMP7 expression 78, suggests that the lack of association 
between BMP7 copy number and BMP7 mRNA may be due to epigenetic regulation. Moreo-
ver, the lack of correlation between BMP7 mRNA and protein expression levels could be a 
result of the stability of mRNA or protein. The 3’UTR of BMP7 mRNA is very long, which is 
a characteristic that has been linked to mRNA stability 79. Subsequently, translation could 
occur from very few copies of mRNA. The involvement of microRNAs — non-coding small 
RNAs that primarily function as gene regulators 80 — on regulating BMP7 mRNA has not 
been addressed to date, but the presence of such microRNAs may greatly influence BMP7 
mRNA stability. In addition, BMPs are synthesized as pre-proteins, which are modified to 
mature BMPs by pro-domain cleavage, and are subsequently secreted. Pro-domains are 
known to affect the stability of the BMP protein 81. Taken together, it is likely that both mRNA 
and protein processing are involved in the regulation of BMP7 expression levels.
 Although the finding from Alarmo and co-workers that BMP7 expression was lost from 
most of the local recurrences as compared with the corresponding primary tumor 82 is in 
agreement with our data, the observation that BMP7 protein levels in primary breast cancer 
are associated with the formation of bone metastases 82, is not. In contrast to Schwalbe and 
our findings, Alarmo and co-workers did not find an association between BMP7 and ER or 







PR 82. They explained this discrepancy by differences in tumor materials and classification 
of immunohistochemical staining results. Surprisingly, only 37% of primary IDC and 57% of 
primary ILC were classified as being positive for BMP7, while in an earlier study the same 
authors showed that the majority (71.4%) of 91 breast cancer patients (IDC+ILC) showed 
strong BMP7 staining, whereas moderate staining was observed in the rest of the cases 77. 
Even though they performed an additional antigen retrieval step, one would not expect that 
BMP7 staining was detected exclusively in the cytoplasm, when an earlier study showed 
exclusive nuclear staining in primary breast cancer cells using the same antibody (sc-9305; 
D.Bobinac, personal communication).
 Using tissue micro arrays containing malignant primary skin melanomas 83 or primary 
renal carcinomas 84, BMP7 was associated with poor and good prognosis, respectively. This 
apparent contradiction underlines once more the heterogeneous effects that specific BMPs 
can exert on different cell types.
BMP7, Cellular Function and Signaling
BMPs have a well-known role in osteogenesis by inducing differentiation of cells from the 
osteoblast lineage and enhancing osteoblast activity 85,86. For example, BMP7 has the abil-
ity to enhance osteoblast activity, partly by inducing VEGF expression 87. Therefore, BMPs 
have also been implicated in the sclerotic phenotype of bone metastases. Noggin is a BMP 
antagonist and inhibits BMP2, -4, -6, -7 signaling by binding BMP ligands 88. Indeed, over-
expression of Noggin in osteosclerotic prostate cancer cell lines significantly decreased 
the osteoblastic response in vivo, but tumor burden was not affected 89,90. In contrast, over-
expression of Noggin in the osteolytic prostate cancer cell line PC-3 significantly inhibited 
the expansion of the lesion in vivo 91. In this and other studies, particularly BMP2 and BMP6 
stimulated migration and invasion of prostate cancer cells, while BMP4 and BMP7 had no 
or almost no effect 89,91,92. Direct experimental evidence that a specific BMP could affect the 
osteoblastic response was provided when neutralizing BMP6 antibodies inhibited, besides 
intra-bone tumor growth, the blastic response 92. Taken together, the inhibitory effects of 
Noggin on cancer progression are most probably mediated by antagonizing the pro-tumor-
igenic effects of BMP2 and BMP6, rather than antagonizing BMP4 or BMP7.
 Many different BMP7-induced biological effects are known, but they are mostly cell type-
dependent as well as dose-dependent. In prostate cancer, addition of BMP7 to in vitro cul-
tured cells has resulted, so far, in at least three different kinds of responses, affecting 1) 
proliferation, 2) apoptosis, and 3) cellular plasticity (Fig. 2A)93-97.
 Although under normal culture conditions — 10% fetal calf serum (FCS) in culture medium 
— BMP7 did not affect proliferation of PC-3 cells, BMP7 could inhibit the proliferation of the 
LNCaP, PC-3 and DU 145 cells under culture conditions of 1% FCS 94. The observed G1-arrest 
was most likely caused by BMP7 induced up-regulation of the cyclin-dependent kinase inhibi-
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Figure 2 BMP7-induced intracellular signaling cascades described in prostate (A) and breast (B) cancer cells, 
regulating cellular processes, such as proliferation, apoptosis and epithelial plasticity. In addition, a 
very limited scheme for intracellular TGF-β signaling is depicted . *, signaling pathway described in this 
thesis; §, described for BMP signaling; based on data from 93-96(A) and 115,116(B).







tor (CDKI) p21CIP1/WAF1 94, as was also demonstrated for BMP2 and BMP4 in LNCaP cells 98. 
Interestingly, BMP7 induced a concentration-dependent biphasic effect on the proliferation of 
LNCaP in the absence of exogenous androgen. While higher concentrations of BMP7 inhibited 
proliferation of LNCaP cells, lower concentrations of BMP7 stimulated the proliferation in the 
absence of androgen 94. At yet another FCS concentration (0.5% FCS), the anti-proliferative 
effect of BMP7 was only detected in the cell line representing a benign prostatic epithelial 
hyperplasia (BPH-1), but not in the invasive PC-3 and DU 145 cells 97.
 In keeping with the findings that BMP signaling can exert anti-proliferative effects, Kim 
and co-workers demonstrated that transfection of a dominant negative type II BMP receptor 
(BMPRII) into PC-3M cells (a PC-3 subclone), resulted in a growth rate 10 times higher than 
that of control cells in the murine tumor model 99. In addition, the introduction of the consti-
tutively active ALK6 (BMPRIB) in PC-3 cells resulted in the inhibition of cell proliferation in 
vitro as well as inhibition of tumor growth after subcutaneous injection 94.
 In the second type of response, BMP7 protected prostate cancer cells from stress-
induced apoptosis. Yang and co-workers have shown that BMP7 inhibited serum starved-
induced apoptosis in LNCaP and C4-2B cells 96. In the C4-2B cells, this was mediated via 
both Smad5-dependent upregulation of Survivin and Smad-independent activation of the 
JNK pathway.
 Finally, the third type of described responses to BMP7 is related to cell plasticity. It has 
long been recognized that TGF-β can induce morphologic conversion, invasiveness, and 
migration in epithelial cells, collectively referred to as an EMT 64. BMP7, however, was 
shown to induce the opposite process, the mesenchymal-to-epithelial transition (MET) in 
renal epithelial cells 100,101. In chapter 7, we demonstrate that BMP7 induce MET in prostate 
cancer cells, as demonstrated by induced E-cadherin promoter activity and E-cadherin pro-
tein expression, and concomitant inhibition of vimentin expression. Therefore, we hypoth-
esize that BMP7 expressed in normal epithelial cells induces E-cadherin expression and 
contributes to maintenance of an epithelial state, whereas loss of BMP7 during cancer pro-
gression may result in EMT and metastasis (Fig. 1). In prostate cancer cells, the effects of 
BMP7 could be further potentiated by addition of TGF-β (Fig. 3). The synergistic actions of 
BMP7 and TGF-β were not detected in any other epithelial cell line studied so far and may 
be cell-specific for reasons that remain to be explained.
 In contrast, Yang and co-workers showed that BMP7, but not TGF-β, stimulated EMT in 
PC-3 cells 97. However, in addition to our in vitro, in vivo, and clinical data, a protective role 
for BMP7 is substantiated by data obtained in numerous studies that showed that 1) loss of 
BMP7 increases the invasive and migratory properties of prostate cancer cells 102, 2) BMP7 
is downregulated in recurrent prostate cancer 74, and 3) that BMP receptors are frequently 
lost during prostate cancer progression 99,103. Interestingly, the accessory type III receptor 
endoglin was shown to decrease prostate cancer cell migration and invasion through activa-
tion of ALK2–Smad1 pathway 104. This is in total agreement with earlier data, which showed 
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that endoglin inhibits TGF-β1-induced ALK5–Smad3 signaling and promotes BMP7–Smad1/
Smad5 signaling 105,106. Therefore, we suggest that the inhibitory effects of BMP7 on prostate 
cancer cell migration and invasion are most likely mediated via its type I receptor ALK2 and 
is Smad-dependent.
 Similarly, expression of BMP receptors was reduced, and BMP signaling was diminished 
in colorectal cancer, indicating that loss of BMP signaling also correlates tightly with pro-
gression of adenomas to colorectal cancer occuring relatively early during cancer progres-
sion 107,108.
 Compared to prostate cancer, even less is known about the BMP effects in breast cancer 
cells. A dominant negative truncated BMPRII inhibited proliferation of T47D breast cancer 
cells suggesting a stimulatory role for BMPs 109. In contrast, a dominant negative mutated 
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Figure 3 Interactions between TGF-β and BMP7 signaling. The biological distinct effects of TGF-β and BMP7 can 
be explained at the level of intracellular signaling. A, in breast cancer cells, BMP7 can inhibit Smad-
dependent TGF-β-signaling, and vice versa, TGF-β can inhibit Smad-dependent BMP7-signaling. B. In 
prostate cancer cells, TGF-β has an stimulatory rather than an inhibitory effect on BMP7-signaling. 
Consequently, BMP7 alone or in combination with TGF-β, results in epithelial maintenance. However, 
when BMP7 expression is lost, TGF-β may still trigger the TGF-β-induced EMT and acquisition of a 
metastatic phenotype. So, whereas in breast cancer prevailed TGF-β-signaling might already result in 
induction of an EMT, in prostate cancer, loss of BMP7 is a prerequisite for EMT to occur.







BMPRII — inhibiting BMP–Smad signaling, but not p38MAPK signaling — stimulated prolifera-
tion of NMuMG breast cancer cells suggesting a stimulatory role for BMPs via p38MAPK 110. In 
breast cancer, BMP7 has not yet been studied in many functional studies. BMP2, however, 
is one the the most investigated BMPs in breast cancer. BMP2 can inhibit proliferation 111,112, 
inhibit hypoxia-induced apoptosis 75, stimulate migration of cancer cells, and induce tumor 
formation in vivo after subcutaneous implantation in nude mice 113. In chapter 6, we describe 
that BMP7 does not affect proliferation, induces MET, and inhibits TGF-β induced EMT in 
MDA-231 breast cancer cells. In line with its inhibitory role in cancer progression, we show 
that stable overexpression of BMP7 in MDA-231 breast cancer cells inhibits de novo forma-
tion and progression of osteolytic bone metastases.
 In mammary (and other) epithelial cells, members of TGF-β superfamily strongly regu-
late the expression of Inhibitor of DNA binding (Id) proteins in normal and cancerous cells in 
a Smad-dependent manner. Id proteins antagonize basic helix-loop-helix transcription fac-
tors by inhibiting them from DNA binding and transactivation of their target genes, thereby 
playing critical roles in animal development and cancer 114. Kowanetz and co-workers have 
shown that Id2 and Id3 showed long-term repression by TGF-β and sustained induction by 
BMP7 in NMe mammary, lens and other epithelial cells (Fig. 2B) 115,116. Moreover, overex-
pression of Id2, and to a lesser extent Id3, blocked TGF-β-induced EMT in these cells. Fur-
thermore, BMP7 could counteract TGF-β-induced EMT by overriding the downregulation of 
Id2 and Id3 by TGF-β in lens epithelial cells. Surprisingly, Id2 knockdown in these cells not 
only enhanced TGF-β-induced EMT, but also permitted EMT by BMP7. Thus, during tumor 
progression, misregulation of epithelial Id2 and Id3 expression could possibly allow even 
BMP pathways to cause EMT and enhance tumor invasiveness. Accordingly, Id2 was found 
to play an important role in the preservation and maintenance of the differentiated and non-
invasive phenotype of breast cancer cells 117. However, the role of Id proteins in our models 
has not yet been addressed. If regulation of Id proteins is also critically involved in biologi-
cal responses in other carcinomas, such as prostate, the absence or very low basal level of 
Id2 and Id3 proteins in the PC-3 cells used by Yang might explain that BMP7 was capable to 
induce EMT 97.
 Recently, it was demonstrated that BMP7 is a novel target of the p53 family in breast 
cancer 116. In fact, Id2 is also regulated by p53, and whereas a functional BMP7 or an active 
p53 pathway was sufficient to maintain basal levels of Id2, loss of both pathways abrogated 
Id2 expression. Subsequently, loss of Id2 resulted in inhibition of cell proliferation 116. 
Interestingly, p53 is the most frequently mutated gene found in human cancers, including 
breast cancer. For this reason, it is tempting to speculate that loss of both p53 and BMP7, 
which is the case for MDA-231 cells, may be a prerequisite for EMT in cancer cells that have 
already escaped from the anti-proliferative effects exerted by restrained Id2 signaling.
 Although much remains to be understood about the complexity of signaling from BMPs 
in cancer, there is emerging evidence from a variety of tumor systems that the observed 
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effects are cell specific and could be either pro- or anti-tumorigenic. Consequently, results 
derived from the study of one cell system frequently could not be applied to other systems 
of the same cancer type. While the BMPs themselves may hold some of the answers, BMP 
receptors are probably also determining factors in distinguishing between the pro- or anti-
tumorigenic effects seen in cancer cells. There is a good possibility that further under-
standing of the expression pattern of the type I and type II receptors and their relationship 
to the development and progression of cancer may provide much more information on this 
phenomenon. In addition, the physiological response of many different types of cancer cells 
might also very well be explained by the basal level and regulation of sensitive gene targets, 
such as Id2 and Id3.
 It is important to note that analogous to its protective role in breast and prostate cancer 
progression (chapter 6 + 7), we have recently demonstrated that decreased BMP7 expres-
sion also contributes to progression of uveal melanoma 118.
BMP7 Treatment in Experimental Models
It has never been specifically addressed whether systemic treatment with (any) BMP might 
influence the progression of (breast and prostate) cancer. In line with our earlier observations 
that BMP7 inhibits tumorigenicity in breast cancer, we describe in chapter 6 that daily intra 
venous administration of BMP7 (100 μg/kg/d) significantly inhibited orthotopic and intra-bone 
growth of MDA-231-B/Luc+cells in nude mice. In addition, we describe in chapter 7 that BMP7 
treatment also inhibits PC-3M-Pro4/Luc+ prostate cancer bone metastatic growth. However, 
prostate cancer growth was not inhibited after orthotopic implantation. Clearly, the tumor 
microenvironment is an important determinant of the therapeutic response to BMP7 in pros-
tate cancer. In fact, it cannot be excluded that the successful treatment may also be explained 
by direct effects of BMP7 on tumor stroma. This question may, for example, be adequately 
addressed in an experiment in which cancer cells are transfected with a constitutively active 
form of ALK2, excluding the direct BMP7 effects on the stroma.
 Interestingly, the effects of BMP7 can be further potentiated in prostate cancer cells by 
an environment rich in TGF-β, such as in bone, because the combination of BMP7 and TGF-β 
increased E-cadherin and decreased vimentin expression to greater extent than BMP7 alone 
(Fig. 1-3). In prostate cancer, these synergistic actions of BMP7 and TGF-β may explain the 
successful experimental treatment of skeletal metastases and intra-bone growth, but not 
of orthotopic growth. For the full beneficial effects of BMP7 in prostate (cancer) cells, para-
doxically, the presence TGF-β may be needed for BMP7 to fully function as a growth factor 
that maintains the epithelial homeostasis. Taken together, the tumor microenvironment is 
an important determinant of the therapeutic response to BMP7 in prostate cancer.
 In the bone matrix, TGF-β is highly concentrated in an inactive form that can be released 
and activated by osteoclastic resorption 119. Upon activation, TGF-β may act as a paracrine 







growth factor for neighboring cancer cells that may have colonized the BM 120. In this con-
text, our observation that BMP7 could counteract TGF-β signaling in both breast and pros-
tate cancer cells (Fig. 1-3), may be very important in explaining the successful treatment of 
osteolytic bone metastases from breast and prostate cancer (Fig. 4). The important role of 
TGF-β in the progression of bone metastasis was established in experiments that showed 
that interference with TGF-β signaling by either small-molecule inhibitors of ALK5 (TβRI) 
kinase 121,122, overexpression of the inhibitory Smad7 123, or introduction of a dominant nega-
tive TβRII 58 could reduce osteolytic tumor burden. Nevertheless, we did not provide direct 
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Figure 4 Potential mechanisms to inhibit bone metastatic growth. Osteoclastic bone resorption results in 
release of growth factors, such as TGF-β, from the bone matrix that may stimulate (cancer) cell growth. 
Therefore, inhibition of bone resorption provide a potential mechanism for treatment and prevention of 
bone metastasis. Either treatment with OPG, inhibiting the formation of osteoclasts, or treatment with 
a bisphosphonate (BP), reducing the number of active osteoclasts, may not only inhibit osteolysis but 
also the development and growth of bone metastases. It is important to note that in both blastic and lytic 
lesions the osteoclastic bone resorption is increased and plays an important role in the pathophysiology 
of the bone metastasis. BMP7, either endogenously expressed or given as a therapeutic agent, can inhibit 
TGF-β signaling in cancer cells. Therefore, BMP7 may also represent a novel therapeutic molecule that 
may also halt or slow down the progression and development of bone metastases.
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of addressing this using an in vivo model in which cancer cell line lines stably expressing the 
TGF-β-specific reporter construct CAGA-luciferase are monitored (manuscript in prepara-
tion). Using this enhancement of our in vivo models, the effects of various compounds, such 
as BMP7, on TGF-β signaling in cancer cells will be elegantly monitored.
 In conclusion, we provide a role for BMP7 expression in the maintenance of epithelial 
cell behavior in the breast and prostate. We propose a model wherein BMP7 can induce the 
expression of E-cadherin, repress vimentin synthesis, and prevent EMT in normal epithelial 
cells. In later stages of tumorigenesis, cancer cells lose BMP7 expression or become resist-
ant to the BMP7 secreted by surrounding normal epithelial cells. Consequently, malignant 
cells may lose their expression of E-cadherin under the influence of TGF-β, resulting in EMT 
and subsequent metastatic spread. In prostate cancer, TGF-β may even contribute to the 
epithelial homeostasis as long as BMP7 remains present as well. This model re-empha-
sizes the double-edged-sword properties and the complexity of members of the TGF-β 
superfamily in cancer biology. It also provides a rationale for further investigation of BMP7 
in the prevention of osteolytic bone metastases from breast and prostate cancer. Overall, 
we provide novel and possibly clinically relevant perspectives for the therapeutic use of 
BMP7, but also raise numerous questions regarding the molecular mechanisms involved, 
and its role at different stages of cancer that exemplify the promises but also the versatility 
of the members of the TGF-β superfamily.
BMP7, Future Perspectives
Since we position BMP7 as a promising novel therapeutic molecule for repression of sys-
temic breast and prostate cancer progression, it is of utmost interest to unravel the molec-
ular and biological roles of BMP7 in cancer progression and bone metastasis formation that 
have not yet been addressed. Given the correlation between BMP7 and androgens — BMP7 
expression is associated with androgen receptor status, and stimulated by androgens — it 
is of great interest to study the effects of BMP7 treatment on androgen-positive cell lines in 
experimental models as well. In addition, the effect of BMP7 on the initial phases of metas-
tasis and on osteosclerotic lesions also remains to be investigated.
 In our animal models, orthotopic breast and prostate cancer growth does not lead to 
distant metastases. Hence, studying the role of BMP7 in inhibiting EMT in the process of 
metastasis requires investigation in animal models in which tumor cells metastasize from 
the primary site to distant sites, such as bone. For this, very few models are available that 
recapitulate the events of the entire metastatic cascade attributable to prostate or breast 
cancer. A relevant model that fulfills this requirement, and shows enhanced metastasis with 
increased TGF-β signaling uses a genetically engineered expression of the proto-oncogene 
Her2/Neu (erBB2), a receptor tyrosine kinase under the control of the mouse mammary 
tumor virus in mouse mammary gland 124. In this system, mammary tumors spontaneously 







developed and metastasized to lung. Overexpression of either active TGF-β 125 or a consti-
tutively active form of ALK5 126 increased metastasis formation, whereas impairment of the 
TGF-β pathway in mammary cells with a dominant negative form of the TβRII 126, or adminis-
tering a soluble form of TβRII 125, decreased the frequency of metastasis to the lungs. Analy-
sis of endogenous expression of BMP7 and EMT markers, as well as testing the effects of 
a BMP7 treatment could answer questions about BMP7 antagonism of TGF-β-induced EMT 
and the early steps of metastasis. However, bone metastases do not develop in this model.
 Particularly, transgenic mice that spontaneously develop primary breast or prostate 
tumors may very well be used to further elucidate the role of BMP7 in development and 
progression of these carcinomas 128. For example, in these transgenic mice the BMP7 gene 
could be knocked-out using the Cre/loxP system in a prostate or breast specific manner.
 In another model, inoculation of the 4T1 murine breast cancer cells into the mammary 
gland results in formation of a primary tumor that disseminates to lung, adrenal glands, 
and bone. Using this model, Muraoka and co-workers showed that inhibition of TGF-β sign-
aling with a soluble type II receptor significantly reduced metastases 127. Unfortunately, EMT 
or bone metastases have not been studied in this model.
 Most patients with prostate cancer metastases manifest with radiologically osteoblastic 
lesions. However, enhanced osteoclastic bone resorption is also clearly evident and con-
tributes to the pathophysiology of bone metastasis in this setting. In fact, the bone resorp-
tion marker N-telopeptide is increased in prostate cancer patients with bone metastases 
and is a stronger predictor of death than prostate specific antigen 46. Furthermore, BPs also 
improve skeletal morbidity in patients with osteoblastic disease 129. Although our animal 
model lacks a strong osteoblastic component that is often evident in humans with prostate 
cancer bone metastases, important information can be gleaned regarding the role of BMP7 
in osteolytic prostate (and breast) cancer bone metastases. Nonetheless, the effect of BMP7 
on bone metastases with a sclerotic phenotype has not yet been established, and should, 
therefore, also be evaluated in osteoblastic models such as those induced by the breast 
cancer cell line ZR-75-1 130, and prostate cancer cell lines LuCap 23.1 131 or C4-2B 132.
Cancer Stem Cells and the Bone Metastatic Process
It is becoming increasingly clear that tumor cell populations arising in breast and prostate 
are organized much like normal tissues, in which self-renewing stem cell populations are 
responsible for spawning the bulk of the cells 133. The bulk populations (>>95%) of tumor 
cells behave much like the transit-amplifying cells found in a normal tissue 134,135. While the 
cancer stem cells are tumorigenic, in that they can seed a new tumor mass when implanted 
into the host, the non-stem cells (i.e., the transit-amplifying cells) in the tumor mass are 
unable to do so, because they are endowed with only a limited replicative potential. Strik-
ingly, TGF-β and BMPs affect stem cell renewal and induction of differentiation into spe-
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cialized-epithelial structures (reviewed in 136-139). These observations may have important 
implications for the process of metastasis. If the non-stem cells in a primary tumor mass 
are truly non-tumorigenic, then these cells may well succeed in leaving the primary tumor 
and lodging in distant sites, but they will be unable to colonize these sites because of their 
limited proliferative potential. Accordingly, the ability to create macroscopic metastases 
may be limited to the relatively small number of tumor stem cells that escape from the pri-
mary tumor. These MICs may possess the ability to replicate to an unlimited extent and are 
therefore ideally suited to found new metastatic colonies that eventually expand to a life-
threatening size. Such dynamics may well contribute to metastatic inefficiency — the failure 
of the vast majority of DTCs to colonize the tissue sites in which they have landed 140-143.
 In addition to the TGF-β and BMP pathways, the Notch, hedgehog and Wnt pathway are 
critically involved in normal and cancer stem cell proliferation (reviewed in 134). Interest-
ingly, multiple interactions between these pathways and different BMPs have been estab-
lished. BMP7 could inhibit Notch signaling in normal prostate gland development 144, and 
BMP signaling can inhibit intestinal stem cell-renewal through suppression of Wnt/β-
catenin signaling 145. For instance, we have found that BMP7 is able to inhibit Wnt signaling 
in PC-3M-Pro4 prostate cancer cells (unpublished data). Furthermore, recent data suggest 
that BMP(4)-induced Smad-signaling can inhibit the tumorigenic potential of human brain-
tumor initiating cells, mediated via a significant reduction in the stem-like, tumor-initiating 
precursors 146. Accumulating evidence suggests that cancer stem cells with tumor-initiating 
potential exist in human breast 147 and prostate cancer 141. Although speculative at present, 
some of the observed effects of BMP7 described in this thesis may be mediated, at least in 
part, by osteotropic cancer cells with tumor-initiating (and metastatic) potential.
 Further research is certainly warranted to address the role of BMP7 and other members 
of the TGF-β superfamily in these pathways that are crucially important in developmental 
processes as well as in cancer progression. Furthermore, identification and characteriza-
tion of MICs may provide new strategies for the treatment of patients with (as yet) incurable 
metastatic bone disease.
Summary and Conclusion
In this thesis, several processes have been unraveled that are critically important in the for-
mation of metastases, particularly to bone. The presence of PAS+ networks in lymph node 
metastases from breast cancer is a prognostic factor for the formation of distant metas-
tases. In addition, low BMP7 mRNA expression levels in primary breast cancer may be 
used as a prognostic indicator for the formation of bone metastases. After validation, these 
markers may be used to predict which patients are at high risk for distant metastases and 
become the rationale to offer patients a more adequate treatment, e.g., prophylactic BP 
treatment for patients that have low BMP7 levels.







 Furthermore, we propose a model in which DTCs from osteotropic cancers are spread 
throughout the body, but with a modestly higher propensity for bone. Only DTCs with stem-
cell like characteristics, i.e., MICs, which end up in a suitable environment can ultimately 
develop into a metastasis. In the bone environment, MICs can stay dormant for many years 
until a BMU comes into close proximity. When this happens the BMU may induce high local 
concentrations of growth factors such as TGF-β, which can stimulate the outgrowth of a 
micrometastatic deposit to an overt bone metastasis. So, only MICs that are in the close 
proximity of a BMU may be activated to form a bone metastasis. Also, therapies that may 
reduce the actual number of BMUs, like OPG and BP, may inhibit the formation of bone 
metastases (Fig. 4). This may also be true for treatments that antagonize the pro-tumori-
genic effects of TGF-β. In addition, BMP7 may not only inhibit TGF-β-induced EMT, but also 
induce epithelial homeostasis in normal breast and prostate epithelium, representing a 
putative novel therapeutic molecule for breast and prostate cancer.
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Summary
The skeleton is one of the most common organs to be affected by metastatic disease. 
However, only a restricted number of solid cancers, especially those of the breast and 
prostate, are responsible for the majority of the bone metastases. Bone metastases are 
a major cause of morbidity, characterized by severe pain and high incidence of fractures, 
spinal cord compression and bone marrow aplasia requiring hospitalization. Despite 
the high frequency of skeletal metastases, the molecular mechanisms underlying the 
predisposition for tumors to colonize bone are poorly understood and treatment options 
are often unsatisfactory. The focus of this thesis was to better understand the processes 
that contribute to the formation of distant metastasis (chapter 2), particularly to bone 
(chapter 4–7), as well as to explore new treatment strategies with conventional (chapter 
4 and 5) and novel therapeutic molecules (chapter 6 and 7) using optical imaging to 
sensitively monitor growth, dissemination and metastasis in mouse models (chapter 3–7).
 Although current clinicopathologic parameters are widely used to predict clinical 
outcome, the clinical behavior of prostate and breast cancer can still be quite different. In 
order to improve breast and prostate cancer management, better and reliable markers 
are needed to distinguish patients with good and poor prognosis.
In chapter 2 we demonstrated that, in addition to the tumor blood vessels, thin periodic 
acid-Schiff-positive (PAS+) patterns may exist in invasive ductal carcinoma (IDC) of the 
breast and their lymph node metastases. More importantly, the complexity of the PAS+ 
patterns in lymph node metastases was related to poor prognosis. Moreover, we found 
that the presence of the most complex thin PAS+ pattern — the PAS+ network — in lymph 
node metastases and stage classification of the tumor were the only two independent risk 
factors associated with the occurrence of a distant metastasis. Additionally, the presence 
of a PAS+ network in a positive lymph node is the factor most strongly associated with 
poor prognosis. Therefore, by examining IDC patients for the presence of PAS+ networks 
in their lymph node metastases, the clinical behavior of this heterogeneous group of 
breast cancer patients can be better predicted. This may ultimately lead to improved 
management of the disease.
Animal models have become important tools to study the molecular mechanisms that are 
involved in the formation of bone metastases and have adequately served as pre-clinical 
models to test new drug compounds and strategies. The formation of bone metastases 
after injection of MDA-MB-231 breast cancer cells into the left cardiac ventricle of 
immunodeficient (nu/nu) mice has been one of the most widely used bone metastasis 
models. The subsequent formation of cancer-induced osteolysis can be monitored by 







radiographic detection. However, radiographic detection is an indirect and insensitive 
method to analyze bone metastases. Therefore, we described in chapter 3 a technique 
that is able to directly monitor and quantify the distribution and growth of luciferase-
transfected (luc+) cancer cells in intact animals using whole-body bioluminescent reporter 
imaging (BLI). In comparison with indirect detection using radiography, the BLI method 
yields higher sensitivity, reliability, and statistical power. The remarkable sensitivity of the 
optical imaging in detecting microscopic bone marrow metastases allowed us to detect 
bone micrometastatic deposits of 0.5 mm3 volume, preceding the appearance of radiological 
evident osteolysis by 2 weeks. At present, the use of new CCD cameras and better luciferase 
expression have yielded even higher sensitivity. In the subsequent chapters (4–7), BLI was 
used to study the molecular mechanisms in bone metastasis, as well as to develop new 
treatment strategies with novel and conventional compounds.
Interference with the microenvironmental growth support has been proposed as an 
attractive strategy for decreasing metastatic tumor growth. Agents that specifically 
decrease bone resorption and remodeling, such as bisphosphonates, are available and are 
used clinically for the protection of bone destruction by metastases from different primary 
tumors. In chapter 4, we have shown that clinically relevant doses of bisphosphonates, 
administered before the establishment of micrometastases (preventive protocol), reduced 
the number of developing bone metastases by 70%. Bisphosphonate treatment also 
inhibited the early progression of tumor growth in the small number of still developing 
metastases. However, when bisphosphonates were given to animals with established bone 
metastases (curative protocol) they did not inhibit the growth of breast cancer cells in the 
bone microenvironment, despite a substantial anti-osteolytic effect.
The lack of tumor growth response may be due to the magnitude of suppression of 
bone resorption and hence the potency or dose of bisphosphonates given, or due to the 
mechanism of bone resorption inhibition by bisphosphonates. In chapter 5 we investigated 
these mechanisms in more detail in an experimental model of intra-tibial injection of 
human breast cancer cells. We assessed the effects of very high doses of the most 
potent bisphosphonate currently available, zoledronic acid, and we compared these to 
the effects of osteoprotegerin, which inhibits bone resorption by a different mechanism 
of action. As expected, both zoledronic acid and osteoprotegerin treatment markedly 
suppressed bone resorption, protected the integrity of bone trabeculae and prevented 
the development of osteolytic lesions. At the end of the experiment intraosseous tumor 
burden was reduced, but extramedullary growth was not affected. Although total (intra-
bone and extramedullary) tumor burden in treated groups appeared less compared to 
controls, this difference was not significant. Taken together, using BLI for monitoring and 
quantifying tumor burden, our data favor the hypothesis that metastatic cancer cells in 
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bone, after an initial growth phase that depends on their interaction with the BM stroma 
and extracellular bone matrix, become increasingly independent of microenvironmental 
growth factor support and are self-maintained by autocrine mechanisms.
In order to become invasive, cancer cells have to lose epithelial characteristics, such as 
expression of E-cadherin. The acquisition of an invasive phenotype is reminiscent of the 
epithelial-to-mesenchymal transition (EMT) that occurs during embryonic development. It 
has long been recognized that transforming growth factor-β (TGF-β), by signaling via the 
Smad pathway, can induce EMT in many different cell types in different settings, including 
embryogenesis, wound healing, and carcinogenesis. In contrast, bone morphogenetic 
protein 7 (BMP7) was shown to counteract TGF-β–induced EMT and induce the opposite 
process, a mesenchymal-to-epithelial transition (MET), in renal epithelial cells.
In chapter 6 and 7, we described that BMP7 expression in breast and prostate cancer 
cell lines in vitro correlated with E-cadherin expression, and inversely correlated with 
aggressiveness and expression of the mesenchymal marker vimentin. Furthermore, we 
demonstrated that BMP7 induced MET and inhibited TGF-β–induced EMT in breast and 
prostate cancer cells. In clinical samples, decreased BMP7 expression was observed 
in prostate cancer cells when compared to normal epithelial prostatic cells. In addition, 
decreased BMP7 mRNA expression levels in primary tumor were correlated with 
formation of bone metastases in breast cancer patients. In line with its inhibitory role in 
cancer progression, we show that stable overexpression of BMP7 in MDA-MB-231-BO2/
luc+ breast cancer cells inhibited de novo formation and progression of osteolytic bone 
metastases. In Chapter 6, we examined the effects of daily intra-venous administration 
of BMP7 (100 μg/kg/d) and observed significant inhibition of orthotopic and intra-bone 
growth of luciferase transfected MDA-MB-231-B/luc+ cells in nude mice. BMP7 treatment 
also inhibited PC-3M-Pro4/Luc+ prostate cancer bone metastatic growth, but not 
orthotopic growth. Clearly, the tumor microenvironment is an important determinant of 
the therapeutic response to BMP7 in prostate cancer.
 To summarize our data described in chapter 6 and 7, we propose a role for BMP7 
expression in the maintenance of epithelial cell behavior in the breast and prostate. In 
normal epithelial cells BMP7 can induce the E-cadherin expression, repress vimentin 
synthesis, and prevent EMT. In later stages of tumorigenesis, because of loss of BMP7 
expression by cancer cells and/or resistance of these cells to the BMP7 secreted by 
surrounding normal epithelial cells, malignant cells may lose their expression of 
E-cadherin under the influence of TGF-β leading to EMT and subsequent metastatic 
spread. In prostate cancer, TGF-β may even contribute to the epithelial homeostasis as 
long as BMP7 remains present as well.







In this thesis, several processes have been unraveled that are critically important in the 
formation of metastases, particularly to bone. The presence of PAS+ networks in lymph 
node metastases from breast cancer is a prognostic factor for the formation of distant 
metastases. In addition, low BMP7 mRNA expression levels in primary breast cancer 
may be used as a prognostic indicator for the formation of bone metastases. Both these 
markers may be used to predict which patients are at high risk for distant metastases 
and become the rationale to offer patients a more adequate treatment, e.g., prophylactic 
bisphosphonate treatment for patients that have low BMP7 levels.
Altogether, we propose a model in which disseminating tumor cells (DTCs) from 
osteotropic cancers are spread throughout the body with a modest higher propensity for 
bone. Only DTCs with stem-cell like characteristics such as an indefinite capacity of self-
renewal, which end up in a suitable environment, can ultimately develop into a metastasis. 
In the bone environment cancer cells can stay dormant for many years until a bone 
remodeling unit (or basic multicellular unit, BMU) comes into close proximity. Osteoclastic 
bone resorption within the BMU induces high local concentrations of growth factors 
such as TGF-β, which may stimulate the outgrowth of a micrometastatic deposit into an 
overt bone metastasis. Also, therapies that can reduce the actual number of BMUs, like 
treatment with osteoprotegerin and bisphosphonates, may inhibit the formation of bone 
metastases. This may also be true for compounds that antagonize the pro-tumorigenic 
effects of TGF-β, such as BMP7. In addition, BMP7 may not only inhibit TGF-β–induced 
EMT, but also be involved in the homeostasis of normal breast and prostate epithelium, 
representing thus a putative novel therapeutic molecule for breast and prostate cancer.
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Samenvatting
Van een tumor kunnen cellen losraken, die via het bloed en de lymfe op andere plekken 
in het lichaam terechtkomen en daar ook een tumor kunnen vormen. Dit proces heet uit-
zaaien. Al sinds de 19e eeuw is bekend dat bepaalde type tumoren, zoals borst- en pros-
taatkanker, vaker naar bot uitzaaien (‘metastaseren’) dan andere tumoren. In de Westerse 
wereld komen borst- en prostaatkanker bovendien het vaakst, bij respectievelijk vrouwen 
en mannen, voor. Uitzaaiingen in het bot veroorzaken grote morbiditeit, gekenmerkt door 
botpijnen, botbreuken en verzakkingen van de wervelkolom. Volgens welke exacte molecu-
laire mechanismen bepaalde tumoren naar bot uitzaaien is echter nog niet bekend. Daar-
naast is er nog geen genezende behandeling voor handen.
 Het onderzoek dat beschreven is in dit proefschrift was erop gericht om de processen 
die betrokken zijn bij (bot)metastasering te ontrafelen (hoofdstuk 2, 4–7), en tevens nieuwe 
behandelstrategieën te ontwikkelen met conventionele (hoofdstuk 4 en 5) én nieuwe (hoofd-
stuk 6 en 7) potentiële medicijnen, gebruikmakend van een techniek waarmee je tumorgroei 
direct en gevoelig kunt meten (hoofdstuk 3–7).
 Ondanks dat in de kliniek verscheidene prognostische factoren worden gebruikt om het 
verloop van borst- en prostaatkanker te voorspellen, is het ziekteverloop nog heel divers. 
Betere prognostische factoren zijn dan ook hard nodig om een beter passende behandeling 
te kunnen aanbieden aan deze patiënten.
In hoofdstuk 2 werd beschreven dat met een histologische “periodic acid-Schiff” (PAS)-
kleuring in borstkanker naast aankleuring van de basaalmembraan van tumorbloedvaten 
ook andere structuren worden aangekleurd. De complexiteit van deze dunne PAS-positieve 
(PAS+) structuren bleek geassocieerd met een slechte prognose voor de patiënt. Bovendien 
waren de aanwezigheid van de meest complexe structuur, een PAS+ netwerk, in lymfek-
liermetastasen en de classificatie van het stadium van de kwaadaardige tumor (‘stagering’) 
de enige twee onafhankelijke risicofactoren voor de vorming van een metastase op afstand. 
De aanwezigheid van een PAS+ netwerk in een lymfekliermetastase bleek zelfs de sterkste 
indicatie voor een slechte prognose. De waarneming van een PAS+ netwerk in een lymfek-
liermetastase zou in de kliniek dus kunnen worden gebruikt om het ziekteverloop van een 
heterogene groep borstkankerpatiënten beter te kunnen voorspellen, zodat de behandeling 
daarop aangepast kan worden.
Diermodellen zijn van essentieel belang bij zowel het ontrafelen van moleculaire mechanis-
men betrokken bij botmetastasering als bij het preklinisch testen van nieuwe behandelingen 
gericht tegen de vorming en verdere groei van botmetastasen. Het meest bekende model 
dat gebruik wordt voor botmetastasering is de injectie van MDA-MB-231 borstkankercellen 







in het linker hartventrikel van naakte imuundeficiënte muizen. Deze tumorcellen metas-
taseren via de bloedbaan naar bot, waar ze botafbrekende cellen (‘osteoclasten’) stimul-
eren tot botafbraak (‘osteolyse’). De tumor-geïnduceerde osteolytische plekken zijn dan na 
drie á vier weken te meten met behulp van röntgenapparatuur. Deze vorm van detectie is 
echter een indirecte en relatief onnauwkeurig methode om botmetastasen te meten. Een 
nieuwe techniek, bioluminescentie, werd beschreven in hoofdstuk 3. Deze techniek maakt 
gebruik van het luciferase-gen, dat wanneer het in de tumorcellen is gezet het enzym luci-
ferase maakt. Na toediening van het substraat luciferine oxideert dit enzym de luciferine, 
waarbij er licht vrijkomt in de tumorcellen. Vervolgens kunnen deze lichtgevende tumor-
cellen in een diermodel met een lichtgevoelige CCD camera worden gevolgd en gemeten. 
In vergelijking met detectie met behulp van röntgenapparatuur kan met bioluminescen-
tie botmetastasen in een eerder stadium gedetecteerd worden, vaak al na 2 weken. In de 
volgende hoofdstukken (4–7) werd bioluminescentie gebruikt als techniek om tumorgroei 
nauwkeuriger te meten.
Bisfosfonaten zijn botresorptieremmers die in de kliniek worden gegeven als behandeling 
tegen tumor-geïnduceerde botafbraak. Tijdens botafbraak komen veel groeifactoren zoals 
transforming growth factor-β (TGF-β) vrij, die mogelijk kunnen bijdrage aan tumorgroei. In 
hoofdstuk 4 en 5 werd onderzocht of botresorptieremming naast remming van tumor-geïn-
duceerde botafbraak ook de groei en ontwikkeling van borstkanker in het bot kon remmen. In 
hoofdstuk 4 werd beschreven dat een preventieve behandeling met klinisch relevante doser-
ingen van bisfosfonaten de vorming van botmetastasen remde. Ondanks een grote remming 
van tumor-geïnduceerde botafbraak, kon een behandeling met bisfosfonaten nadat botme-
tastasen al ontwikkeld waren de tumorgroei niet meer remmen (curatieve behandeling).
Het is echter niet uit te sluiten dat een potenter of hogere dosering van een bisfosfonaat, of 
een botresorptieremmer met een ander werkingsmechanisme verdere groei van borstkanker 
in de bot wel zou kunnen remmen. Daarom hebben we in een model van borstkankergroei 
in de tibia (scheenbeen) in hoofdstuk 5 zowel de effecten bestudeerd van een hoge doser-
ing zoledronine zuur (Zometa®), het nu meest krachtige bisfosfonaat beschikbaar, als het 
effect van osteoprotegerine, dat botresorptie via een ander mechanisme remt. Zoals verwacht 
remden behandeling met zoledronine zuur of osteoprotegerine de vorming van tumor-geïn-
duceerde osteolytische plekken en voorkwamen ze de afbraak van bottrabekels, die in het bot 
onder andere voor extra stevigheid zorgen. De hoeveelheid tumor binnen-bot was na behan-
deling met zoledronine zuur of osteoprotegerine minder groot, echter een gedeelte van de 
tumor groeide buiten-bot en deze hoeveelheid tumor was even groot in vergelijking met de 
controlebehandeling. De totale tumor grootte (binnen-bot + buiten-bot) leek bij de behandelde 
groepen iets minder groot, maar gaf geen significant verschil in vergelijking met de controle-
behandeling. De data beschreven in dit proefschrift wijzen er op dat de initiële tumorgroei in 
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het bot afhankelijk is van de interacties met het botmilieu, maar dat tijdens verdere progressie 
de tumorgroei steeds onafhankelijker wordt van het botmilieu.
Zoals de meeste kankers ontstaan borst- en prostaatkanker uit epitheelcellen: cellen met 
een duidelijke onder- en bovenkant, die de eigenschap hebben dat ze aan elkaar vastzit-
ten en die het oppervlak bekleden van onder andere huid, slijmvliezen, luchtwegen, maag-
darmkanaal, en borst- en prostaatklieren. De ondergrond van een laag epitheel bestaat 
uit bindweefsel, ook wel mesenchym genoemd. Echter, tijdens het ontstaan en de groei 
van kanker (‘carcinogenese’) kunnen tumorcellen bepaalde epitheliale eigenschappen ver-
liezen. Kwaadaardige tumorcellen aan de rand van de primaire tumor kunnen doordat ze 
niet meer goed aan elkaar hechten, losraken van de primaire tumor, binnendringen in het 
omliggende gezonde (bind)weefsel en uiteindelijk uitzaaien naar andere organen. De kanker 
is dan invasief geworden. Het verkrijgen van een invasief fenotype lijkt veel op een epi-
theliale-mesenchymale transitie (EMT), een proces dat van essentieel belang is tijdens de 
embryonale ontwikkeling van verscheidene organen zoals de nier. TGF-β (transformerende 
groeifactor-beta) is een van de belangrijkste factoren die via intracellulaire Smad eiwit-
ten EMT kan stimuleren in verschillende processen zoals bij wondgenezing, embryogenese 
en carcinogenese. BMP7 (bot morfogenese proteïne-7) kan daarentegen EMT remmen en 
het tegenovergestelde proces, een mesenchymale-epitheliale transitie (MET), induceren in 
nierepitheelcellen.
In Hoofdstuk 6 en 7 werd de hypothese getest of BMP7 ook MET kon induceren in borst- en 
prostaatkanker. De hoeveelheid BMP7-eiwit (‘de expressie’) in borst- en prostaatkanker-
cellijnen was gecorreleerd met de expressie van de epitheliale factor E-cadherine, en 
omgekeerd evenredig gecorreleerd met de mesenchymale marker vimentine, en de mate 
van kwaadaardigheid. BMP7 remde TGF-β geïnduceerde EMT en stimuleerde MET in borst- 
en prostaatkankercellijnen. In klinische monsters van prostaatkankerpatiënten was BMP7 
expressie verlaagd in tumorcellen ten opzichte van gezonde prostaatcellen. Bij borstkank-
erpatiënten was verlaagde BMP7 mRNA expressie in de primaire tumor bovendien gecor-
releerd met de vorming van nieuwe botmetastasen. Wanneer BMP7 tot overexpessie werd 
gebracht in een borstkankercellijn, waardoor er meer BMP7 eiwit werd aangemaakt, 
remde dit het ontstaan van het aantal tumor-geïnduceerde osteolytische plekken. Groei 
van borstkanker in de borst en in het bot werd bovendien geremd door dagelijkse behan-
deling met BMP7. Behandeling met BMP7 bleek tevens de groei van prostaatkanker in het 
bot, maar niet in de prostaat te remmen. De omgeving van de tumor bepaalt dus mede de 
therapeutische respons van BMP7 op prostaatkanker.
 De data beschreven in hoofdstuk 6 en 7 suggereren dat er een belangrijke rol voor BMP7 
is weggelegd in het behoud van epitheliale homeostase in de gezonde borst en prostaat. 
Hier stimuleert BMP7 de expressie van epitheliale eiwitten zoals E-cadherine, remt het 







de synthese van het mesenchymale eiwit vimentine, en voorkomt het EMT. Tijdens tumor-
progressie kan verlies van BMP7 expressie mogelijk leiden tot verlies van E-cadherine en 
leiden tot EMT en metastasering. In de prostaat zou in aanwezigheid van BMP7, TGF-β zelfs 
kunnen bijdrage aan de epitheliale homeostase.
In dit proefschrift zijn verschillende processen beschreven die betrokken zijn bij metasta-
sering, in het bijzonder botmetastasering. De aanwezigheid van PAS+ netwerken in lym-
fekliermetastasen van borstkanker is een prognostische factor voor de ontwikkeling van 
metastasen op afstand, en lage BMP7 mRNA expressie in primair borstkanker is een goede 
indicator voor de ontwikkeling van botmetastasen. Deze factoren kunnen worden gebruikt 
om te bepalen welke patiënten een verhoogd risico hebben op metastasering, zodat sneller 
en adequater met bv. een bisfosfonaatbehandeling gestart kan worden.
Op basis van de bevindingen beschreven in dit proefschrift en in de literatuur stellen wij een 
model voor waarbij tumorcellen van borst- en prostaatkanker via de bloedbaan door heel 
het lichaam verspreid worden met een voorkeur om naar bepaalde organen, zoals bot, uit te 
zaaien. Van de uitgezaaide tumorcellen kunnen alleen die cellen met bepaalde stamcelei-
genschappen, zoals de mogelijkheid tot oneindig delen, in staat zijn uiteindelijk uit te groe-
ien tot een macrometastase. Tumorcellen kunnen in het bot jarenlang in ruste zijn en pas bij 
een locale hoge concentratie van groeifactoren van bv. TGF-β en IGF, veroorzaakt door een 
normale botresorptie unit (‘basic multicellular unit’, BMU), worden gestimuleerd tot groei 
en vorming van een macrometastase. Behandelstrategiën die erop gericht zijn het aantal 
botresorptie units te verminderen, zoals bisfosfonaten en osteoprotegerine, zouden dus de 
vorming van nieuwe botmetastasen kunnen remmen. Dit geldt ook voor behandelingen die 
de pro-tumorigene effecten van TGF-β kunnen remmen, zoals BMP7. BMP7 zou bovendien 
kunnen zorgen voor epitheliale homeostase in de borst en prostaat, waardoor dit een goede 
nieuwe behandeling kan worden in strijd tegen borst- en prostaatkanker.
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List of Abbreviatons
ActRII activin type II receptor
ActRIIB activin type IIB receptor
ALK activin receptor-like kinase
AMHRII Anti-Müllerian hormone type II receptor
bFGF basic fibroblast growth factor
BLI bioluminescent imaging
BMP bone morphogenetic protein
BMPRI BMP type I receptor
BMPRII BMP type II receptor
BM bone marrow 




CDKI cyclin-dependent kinase inhibitor (CDKI)
CMV cytomegalovirus
CSC cancer stem cell
CT connective tissue
DFS disease free survival
DKK-1 dickkopf
DTC disseminating tumor cell
ECM extracellular matrix
EGF epidermal growth factor
EMT epithelial-to-mesenchymal transition
ER estrogen receptor
ERK extracellular signal-related kinase
ET-1 endothelin-1
FCS fetal calf serum
FGF fibroblast growth factor
GFP green fluorescent protein
GM-CSF granulocyte-macrophage colony stimulating factor (alias CSF2)
HGF hepatocyte growth factor (alias scatter factor)
Hh hedgehog
HRPC hormone refractory prostate cancer





IBC inflammatory breast cancer 
Id Inhibitor of DNA binding
IDC invasive ductal carcinoma
IGF insulin growth factor
IGFBP insulin-like growth factor binding protein
IHC immunohistochemistry
IL interleukin
ILC invasive lobular carcinoma
JNK JunN-terminal kinase
LAP latency-associated peptide
LCM laser capture microdissection
LLC large latent complex
LSD least significant difference
LTBP large latent TGF-β-binding protein
Luc luciferase







M-CSF macrophage colony stimulating factor (alias CSF1)
MAPK mitogen-activated protein kinase
MET mesenchymal-to-epithelial transition
MIC metastasis-initiating cell
MRD minimal residual disease
MSC (cell) migrating cancer stem (cell)
n.s. not significant




PCR polymerase chain reaction




PTHrP parathyroid hormone-related protein
qPCR quantitative real-time reverse transcription PCR
R-Smads receptor-regulated Smads
RANK receptor activator of nuclear factor κB
RANKL receptor activator of nuclear factor κB ligand
RLU relative light unit
Runx2 runt-related transcription factor 2 (alias core-binding factor α1)
s.c. subcutaneous
s.e.m. standard error of the mean SBE smad-binding element
SCID severely compromised immunodeficient
SCS (cell) stationary cancer stem (cell)
SDF-1 stromal derived growth factor-1
SLC small latent complex
SMA smooth muscle actin
Smad Sma-Mad related proteins
Smurf Smad ubiquitin regulatory factor
SNO (cells) spindle-shaped N-cadherin+ CD45- osteoblastic (cells)
SRE skeletal-related events
sALP serum alkaline phosphatase
TβRII transforming growth factor-β type II receptor 
TBV trabecular bone volume
TGF-β transforming growth factor-β
TGIF TGF-β-induced factor
TMA tissue microarray
TNF tumor necrosis factor
Tob transducer of ErbB-2
TRAcP tartrate-resistant acid phosphatase
uPA urokinase-type plasminogen activator
VCAM vascular cell adhesion molecule
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
VM vasculogenic mimicry
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